<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006649.pub7" GROUP_ID="GYNAECA" ID="513007011012231627" MERGED_FROM="" MODIFIED="2018-01-22 10:30:37 +0000" MODIFIED_BY="Gail Quinn" REVIEW_NO="L001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0"><COVER_SHEET MODIFIED="2018-01-22 10:30:36 +0000" MODIFIED_BY="Gail Quinn"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">Anticoagulation for the initial treatment of venous thromboembolism in people with cancer</TITLE><CONTACT MODIFIED="2018-01-22 10:30:36 +0000" MODIFIED_BY="Gail Quinn"><PERSON ID="18055" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akl</LAST_NAME><POSITION>Director of Clinical Epidemiology Unit</POSITION><EMAIL_1>ea32@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut Medical Center</ORGANISATION><ADDRESS_1>Riad El Solh St</ADDRESS_1><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON></CONTACT><CREATORS MODIFIED="2018-01-22 10:30:36 +0000" MODIFIED_BY="Gail Quinn"><PERSON ID="z1708031320446796169356042339079" ROLE="AUTHOR"><FIRST_NAME>Maram</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Hakoum</LAST_NAME><POSITION>Postgraduate Year 1 Resident</POSITION><EMAIL_1>maram.hakoum@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Family Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><CITY>Beirut</CITY><ZIP>1107 2020</ZIP><COUNTRY CODE="LB">Lebanon</COUNTRY><PHONE_1>+961 (70) 877-152</PHONE_1></ADDRESS></PERSON><PERSON ID="z1404081114197651019260336524884" ROLE="AUTHOR"><FIRST_NAME>Lara</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Kahale</LAST_NAME><POSITION>Clinical Epidemiology Unit</POSITION><EMAIL_1>lk45@aub.edu.lb</EMAIL_1><EMAIL_2>lara.kahale@gmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="z1710020929408427356747479700732" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ibrahim</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Tsolakian</LAST_NAME><POSITION>Research Fellow</POSITION><EMAIL_1>Ibrahim.tsolakian@outlook.com</EMAIL_1><ADDRESS><DEPARTMENT>Faculty of Medicine</DEPARTMENT><ORGANISATION>American University of Beirut</ORGANISATION><ADDRESS_1>Riad El-Solh/ Beirut 1107 2020</ADDRESS_1><ADDRESS_2>P.O.Box 11-0236</ADDRESS_2><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY><PHONE_1>0096171136843</PHONE_1></ADDRESS></PERSON><PERSON ID="z1708031326261660126939984253766" ROLE="AUTHOR"><FIRST_NAME>Charbel</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Matar</LAST_NAME><POSITION>Post-Graduate Year 3 / Resident</POSITION><EMAIL_1>cm46@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut Medical Center</ORGANISATION><ADDRESS_1>Riad El Solh</ADDRESS_1><CITY>Beirut</CITY><ZIP>1107 2020</ZIP><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON><PERSON ID="05F9CC5082E26AA201A256C7CCA7DD21" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Victor</FIRST_NAME><MIDDLE_INITIALS>ED</MIDDLE_INITIALS><LAST_NAME>Yosuico</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><POSITION>Resident</POSITION><EMAIL_1>VYosuico@buffalomedicalgroup.com</EMAIL_1><ADDRESS><ORGANISATION>Buffalo Medical Group</ORGANISATION><ADDRESS_1>85 High Street</ADDRESS_1><CITY>Buffalo</CITY><ZIP>14203-1149</ZIP><REGION>New York</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 (716) 997 7061</PHONE_1></ADDRESS></PERSON><PERSON ID="1047AF4182E26AA2005EBC6E53216EA1" ROLE="AUTHOR"><FIRST_NAME>Irene</FIRST_NAME><LAST_NAME>Terrenato</LAST_NAME><EMAIL_1>irene.terrenato@ifo.gov.it</EMAIL_1><ADDRESS><DEPARTMENT>Biostatistics-Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0652 66 6090</PHONE_1></ADDRESS></PERSON><PERSON ID="10402FB382E26AA2005EBC6E34E65A73" ROLE="AUTHOR"><FIRST_NAME>Francesca</FIRST_NAME><LAST_NAME>Sperati</LAST_NAME><POSITION>Biostatistician</POSITION><EMAIL_1>francesca.sperati@ifo.gov.it</EMAIL_1><ADDRESS><DEPARTMENT>Biostatistics-Scientific Direction</DEPARTMENT><ORGANISATION>Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 0652 66 6249</PHONE_1></ADDRESS></PERSON><PERSON ID="02168E4582E26AA201A256C7D0473398" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maddalena</FIRST_NAME><LAST_NAME>Barba</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>maddalena.barba@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Division of Medical Oncology 2 - Scientific Direction</DEPARTMENT><ORGANISATION>IRCCS Regina Elena National Cancer Institute</ORGANISATION><ADDRESS_1>Via Elio Chianesi 53</ADDRESS_1><CITY>Rome</CITY><ZIP>00144</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 (06) 52665419</PHONE_1></ADDRESS></PERSON><PERSON ID="18105" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Holger</FIRST_NAME><LAST_NAME>Schünemann</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Professor and Chair</POSITION><EMAIL_1>schuneh@mcmaster.ca</EMAIL_1><URL>http://www.fhs.mcmaster.ca/ceb/inside_intro.htm</URL><MOBILE_PHONE>+19055375599</MOBILE_PHONE><ADDRESS><DEPARTMENT>Departments of Health Research Methods, Evidence, and Impact and of Medicine</DEPARTMENT><ORGANISATION>McMaster University</ORGANISATION><ADDRESS_1>1280 Main Street West</ADDRESS_1><CITY>Hamilton</CITY><ZIP>L8N 4K1</ZIP><REGION>ON</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 905 525 9140 Ext: 24931 (assistant)</PHONE_1></ADDRESS></PERSON><PERSON ID="18055" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elie</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Akl</LAST_NAME><POSITION>Director of Clinical Epidemiology Unit</POSITION><EMAIL_1>ea32@aub.edu.lb</EMAIL_1><ADDRESS><DEPARTMENT>Department of Internal Medicine</DEPARTMENT><ORGANISATION>American University of Beirut Medical Center</ORGANISATION><ADDRESS_1>Riad El Solh St</ADDRESS_1><CITY>Beirut</CITY><COUNTRY CODE="LB">Lebanon</COUNTRY></ADDRESS></PERSON></CREATORS><DATES MODIFIED="2018-01-17 12:18:01 +0000" MODIFIED_BY="Gail Quinn"><UP_TO_DATE><DATE DAY="14" MONTH="1" YEAR="2018"/></UP_TO_DATE><LAST_SEARCH><DATE DAY="14" MONTH="1" YEAR="2018"/></LAST_SEARCH><NEXT_STAGE><DATE DAY="14" MONTH="1" YEAR="2021"/></NEXT_STAGE><PROTOCOL_PUBLISHED ISSUE="3" YEAR="2007"/><REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/><LAST_CITATION_ISSUE ISSUE="1" YEAR="2018"/></DATES><WHATS_NEW MODIFIED="2018-01-22 10:27:08 +0000" MODIFIED_BY="Gail Quinn"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2018-01-22 10:27:08 +0000" MODIFIED_BY="Gail Quinn"><DATE DAY="14" MONTH="1" YEAR="2018"/><DESCRIPTION><P>Author list amended.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2018-01-18 15:37:33 +0000" MODIFIED_BY="Gail Quinn"><DATE DAY="14" MONTH="1" YEAR="2018"/><DESCRIPTION><P>Search updated 14 January 2018 (no new studies found). </P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW><HISTORY MODIFIED="2017-11-30 13:34:11 +0000" MODIFIED_BY="Gail Quinn"/><SOURCES_OF_SUPPORT MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><INTERNAL_SOURCES/><EXTERNAL_SOURCES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><SOURCE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><NAME>NIHR Cochrane Review Incentive Scheme 2016. Award reference Number 16/72/24</NAME><COUNTRY CODE="GB">UK</COUNTRY><DESCRIPTION><P>This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group</P></DESCRIPTION></SOURCE><SOURCE MODIFIED="2017-10-02 07:05:43 +0100" MODIFIED_BY="[Empty name]"><NAME>American Society of Hematology</NAME><COUNTRY CODE="US">USA</COUNTRY><DESCRIPTION><P>This project was supported by the American Society of Hematology</P></DESCRIPTION></SOURCE></EXTERNAL_SOURCES></SOURCES_OF_SUPPORT><MESH_TERMS VERIFIED="NO"/><KEYWORDS/></COVER_SHEET><MAIN_TEXT MODIFIED="2018-01-22 10:17:52 +0000" MODIFIED_BY="Gail Quinn"><SUMMARY MODIFIED="2018-01-22 10:17:52 +0000" MODIFIED_BY="Gail Quinn"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">Blood thinners for the initial treatment of blood clots in people with cancer</TITLE><SUMMARY_BODY MODIFIED="2018-01-22 10:17:52 +0000" MODIFIED_BY="Gail Quinn"><P><B>Background</B><BR/>People with cancer are at increased risk of blood clots. The blood thinner (anticoagulant) administered in the first few days after identifying a blood clot can consist of unfractionated heparin (infused through a vein),low molecular weight heparin (injected under the skin once or twice per day; dalteparin, and tinzaparin are two different types of low molecular weight heparin), or fondparinux (injected under the skin once daily). These blood thinners may have different effectiveness and safety profiles.</P><P><B>Study characteristics</B><BR/>We searched scientific databases for clinical trials comparing different blood thinners in people with cancer with a confirmed diagnosis of deep vein thrombosis (a blood clot in the limbs) or pulmonary thrombosis (a blood clot in the lungs). We included trials of adults and children with either solid tumors or blood cancer irrespective of the type of cancer treatment. The trials looked at death, recurrent blood clots, and bleeding. The evidence is current to January 2018. We included 15 trials.</P><P><B>Key results</B><BR/>In this systematic review, data from five studies with 422 participants suggested that the effect of low molecular weight heparin on death compared with unfractionated heparin was uncertain, but if anything of small size. There was not enough evidence to prove superiority in reducing recurrence of blood clots or risk of bleeding. We found no data to compare the safety profile of these two medications. Also, fondaparinux did not prove or exclude any important effect compared to heparins, on death, blood clots, or bleeding. Similarly,the available evidence did not show any difference between dalteparin and tinzaparin for all tested outcomes.</P><P><B>Certainty of the evidence</B><BR/>We judged the certainty of evidence for low molecular weight heparin versus unfractionated heparin to be moderate for all assessed outcomes.</P><P>We judged the certainty of evidence for fondaparinux versus heparin to be moderate for all tested outcomes.</P><P>We judged the certainty of evidence for tinzaparin versus dalteparin to be low for all tested outcomes.</P></SUMMARY_BODY></SUMMARY><ABSTRACT MODIFIED="2018-01-22 10:15:54 +0000" MODIFIED_BY="Gail Quinn"><ABS_BACKGROUND MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE.</P></ABS_BACKGROUND><ABS_OBJECTIVES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixed-dose low molecular weight heparin (LMWH), adjusted-dose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people with cancer.</P></ABS_OBJECTIVES><ABS_SEARCH_STRATEGY MODIFIED="2018-01-22 10:08:25 +0000" MODIFIED_BY="Gail Quinn"><P>A comprehensive search included a major electronic search of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) (2018, Issue 1), MEDLINE (via Ovid) and Embase (via Ovid); handsearching of conference proceedings; checking of references of included studies; use of the 'related citation' feature in PubMed; and a search for ongoing studies. This update of the systematic review was based on the findings of a literature search conducted on 14 January 2018.</P></ABS_SEARCH_STRATEGY><ABS_SELECTION_CRITERIA MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trials (RCTs) assessing the benefits and harms of LMWH, UFH, and fondaparinux in people with cancer and objectively confirmed VTE.</P></ABS_SELECTION_CRITERIA><ABS_DATA_COLLECTION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Using a standardized form, we extracted data in duplicate on study design, participants, interventions outcomes of interest, and risk of bias. Outcomes of interested included all-cause mortality, symptomatic VTE, major bleeding, minor bleeding, postphlebitic syndrome, quality of life, and thrombocytopenia. We assessed the certainty of evidence for each outcome using the GRADE approach.</P></ABS_DATA_COLLECTION><ABS_RESULTS MODIFIED="2018-01-22 10:15:54 +0000" MODIFIED_BY="Gail Quinn"><P>Of 15440 identified citations, 7387 unique citations, 15 RCTs fulfilled the eligibility criteria. These trials enrolled 1615 participants with cancer and VTE: 13 compared LMWH with UFH enrolling 1025 participants, one compared fondaparinux with UFH and LMWH enrolling 477 participants, and one compared dalteparin with tinzaparin enrolling 113 participants. The meta-analysis of mortality at three months included 418 participants from five studies and that of recurrent VTE included 422 participants from 3 studies. The findings showed that LMWH likely decreases mortality at three months compared to UFH (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.40 to 1.10; risk difference (RD) 57 fewer per 1000, 95% CI 101 fewer to 17 more; moderate certainty evidence), but did not rule out a clinically significant increase or decrease in VTE recurrence (RR 0.69, 95% CI 0.27 to 1.76; RD 30 fewer per 1000, 95% CI 70 fewer to 73 more; moderate certainty evidence).</P><P>The study comparing fondaparinux with heparin (UFH or LMWH) did not exclude a beneficial or detrimental effect of fondaparinux on mortality at three months (RR 1.25, 95% CI 0.86 to 1.81; RD 43 more per 1000, 95% CI 24 fewer to 139 more; moderate certainty evidence), recurrent VTE (RR 0.93, 95% CI 0.56 to 1.54; RD 8 fewer per 1000, 95% CI 52 fewer to 63 more; moderate certainty evidence), major bleeding (RR 0.82, 95% CI 0.40 to 1.66; RD 12 fewer per 1000, 95% CI 40 fewer to 44 more; moderate certainty evidence), or minor bleeding (RR 1.53, 95% CI 0.88 to 2.66; RD 42 more per 1000, 95% CI 10 fewer to 132 more; moderate certainty evidence)</P><P>The study comparing dalteparin with tinzaparin did not exclude a beneficial or detrimental effect of dalteparin on mortality (RR 0.86, 95% CI 0.43 to 1.73; RD 33 fewer per 1000, 95% CI 135 fewer to 173 more; low certainty evidence), recurrent VTE (RR 0.44, 95% CI 0.09 to 2.16; RD 47 fewer per 1000, 95% CI 77 fewer to 98 more; low certainty evidence), major bleeding (RR 2.19, 95% CI 0.20 to 23.42; RD 20 more per 1000, 95% CI 14 fewer to 380 more; low certainty evidence), or minor bleeding (RR 0.82, 95% CI 0.30 to 2.21; RD 24 fewer per 1000, 95% CI 95 fewer to 164 more; low certainty evidence).</P></ABS_RESULTS><ABS_CONCLUSIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>LMWH is possibly superior to UFH in the initial treatment of VTE in people with cancer. Additional trials focusing on patient-important outcomes will further inform the questions addressed in this review. The decision for a person with cancer to start LMWH therapy should balance the benefits and harms and consider the person's values and preferences.</P></ABS_CONCLUSIONS></ABSTRACT><BODY MODIFIED="2018-01-22 10:14:02 +0000" MODIFIED_BY="Gail Quinn"><BACKGROUND MODIFIED="2018-01-22 10:08:25 +0000" MODIFIED_BY="Gail Quinn"><P> Please refer to the glossary for the definitions of technical terms (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</P><CONDITION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Cancer status by itself increases the risk of venous thromboembolism (VTE) by four- to six-fold (<LINK REF="REF-Heit-2000" TYPE="REFERENCE">Heit 2000</LINK>). In addition, therapeutic interventions such as chemotherapy, hormonal therapy, and indwelling central venous catheters increase the risk of VTE (<LINK REF="REF-Heit-2000" TYPE="REFERENCE">Heit 2000</LINK>). Similarly, people undergoing surgery for cancer have a higher risk of VTE than people undergoing surgery for diseases other than cancer (<LINK REF="REF-Gallus-1997" TYPE="REFERENCE">Gallus 1997</LINK>; <LINK REF="REF-Kakkar-1970" TYPE="REFERENCE">Kakkar 1970</LINK>). People with cancer and VTE have a higher risk of death than people with cancer alone or VTE alone (<LINK REF="REF-Levitan-1999" TYPE="REFERENCE">Levitan 1999</LINK>; <LINK REF="REF-Sorensen-2000" TYPE="REFERENCE">Sorensen 2000</LINK>).</P><P>This heightened hypercoagulable state might alter the response to anticoagulant treatment and the risk of bleeding. Compared with people without cancer, people with cancer who receive anticoagulant treatment for VTE are more likely to develop recurrent VTE with an annual risk of 21% to 27%, a two- to three-fold risk increase (<LINK REF="REF-Hutten-2000" TYPE="REFERENCE">Hutten 2000</LINK>; <LINK REF="REF-Prandoni-2002" TYPE="REFERENCE">Prandoni 2002</LINK>). These people are also more likely to develop major bleeding with an annual risk of 12% to 13%, a two- to six-fold risk increase (<LINK REF="REF-Hutten-2000" TYPE="REFERENCE">Hutten 2000</LINK>; <LINK REF="REF-Prandoni-2002" TYPE="REFERENCE">Prandoni 2002</LINK>).</P></CONDITION><INTERVENTION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Heparin, low molecular weight heparins (LMWHs), fondaparinux, and danaparoid do not have intrinsic anticoagulant activity but potentiate the activity of antithrombin III in inhibiting activated coagulation factors. These agents constitute indirect anticoagulants as their activity is mediated by plasma cofactors. Recombinant hirudin, bivalirudin, and argatroban directly inhibit thrombin and are classified as direct anticoagulants (<LINK REF="REF-Hirsh-2008" TYPE="REFERENCE">Hirsh 2008</LINK>). Heparin and its low molecular weight derivatives are not absorbed orally and must be administered parenterally by intravenous (IV) infusion or subcutaneous (SC) injection (<LINK REF="REF-Hirsh-1993" TYPE="REFERENCE">Hirsh 1993</LINK>).</P></INTERVENTION><THEORY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>In the initial treatment of VTE, LMWHs and unfractionated heparin (UFH) might have a different comparative efficacy in people with cancer than in people without cancer. Subgroup analyses of one Cochrane systematic review showed that in people without cancer there was no statistically significant difference between the effects of LMWH and UFH on overall mortality (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.61 to 1.56). However, in people with cancer, LMWH resulted in a lower overall mortality compared with UFH (OR 0.53, 95% CI 0.33 to 0.85) (<LINK REF="REF-Robertson-2017" TYPE="REFERENCE">Robertson 2017</LINK>).</P></THEORY><IMPORTANCE MODIFIED="2018-01-22 10:08:25 +0000" MODIFIED_BY="Gail Quinn"><P>We initially conducted and updated this and other reviews on this topic to directly and better inform clinical practice guidelines. The last update of this systematic review, published in 2014, identified 16 trials enrolling 1606 participants (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>; <LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>; <LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>; <LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>). The review found statistically significant reduction in mortality at three months of follow-up with LMWH compared with UFH. No new reviews were identified since then.</P></IMPORTANCE></BACKGROUND><OBJECTIVES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixed-dose low molecular weight heparin (LMWH), adjusted-dose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people with cancer.</P></OBJECTIVES><METHODS MODIFIED="2018-01-22 10:14:02 +0000" MODIFIED_BY="Gail Quinn"><SELECTION_CRITERIA MODIFIED="2018-01-22 10:14:02 +0000" MODIFIED_BY="Gail Quinn"><CRIT_STUDIES MODIFIED="2010-11-15 20:33:05 +0000" MODIFIED_BY="[Empty name]"><P>Randomized controlled trials (RCTs).</P></CRIT_STUDIES><CRIT_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Participants with cancer and a confirmed diagnosis of VTE (acute deep venous thrombosis (DVT) or pulmonary embolism (PE)). Participants could have been of any age group (including children) with either solid or hematologic cancer and at any stage of their cancer irrespective of the type of cancer therapy.</P></CRIT_PARTICIPANTS><CRIT_INTERVENTIONS MODIFIED="2018-01-22 10:14:02 +0000" MODIFIED_BY="Gail Quinn"><P>Experimental arms consisted of initial parenteral anticoagulation (typically the first five to 10 days) with:</P><UL><LI>LMWHs (e.g., dalteparin, tinzaparin, fragmin);</LI><LI>UFHs (e.g., calciparine, multiparin, novoheparin);</LI><LI>fondaparinux (e.g., arixtra).</LI></UL><P>We were interested in comparisons of any combination of the three management options listed above.</P><P>We excluded studies in which thrombolytic therapy (e.g. streptokinase) was part of the intervention. The protocol should have planned to provide evidence concerning all other co interventions (e.g. chemotherapy) similarly.</P></CRIT_INTERVENTIONS><CRIT_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><CRIT_OUTCOMES_PRIMARY MODIFIED="2017-09-27 11:45:45 +0100" MODIFIED_BY="[Empty name]"><UL><LI>All-cause mortality.</LI></UL></CRIT_OUTCOMES_PRIMARY><CRIT_OUTCOMES_SECONDARY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Symptomatic recurrent DVT; events had to be diagnosed using one of the following objective diagnostic tests: venography, <SUP>125</SUP>I-fibrinogen uptake test, impedance plethysmography, or Doppler ultrasound.</LI><LI>Symptomatic recurrent PE; events had to be diagnosed using one of the following objective diagnostic tests: pulmonary perfusion or ventilation scans, computed tomography, pulmonary angiography, or autopsy.</LI><LI>Major bleeding: we accepted the authors' definitions of major bleeding.</LI><LI>Minor bleeding: we accepted the authors' definitions of minor bleeding.</LI><LI>Postphlebitic syndrome.</LI><LI>Quality of life.</LI><LI>Thrombocytopenia.</LI></UL></CRIT_OUTCOMES_SECONDARY></CRIT_OUTCOMES></SELECTION_CRITERIA><SEARCH_METHODS MODIFIED="2018-01-22 10:00:11 +0000" MODIFIED_BY="Joanne Platt"><P> </P><ELECTRONIC_SEARCHES MODIFIED="2018-01-22 10:00:11 +0000" MODIFIED_BY="Joanne Platt"><P>The search was part of a comprehensive search for studies of anticoagulation in people with cancer. We used no language restrictions. We conducted comprehensive searches on 14 January 2018, following the original electronic searches performed in January 2007, February 2010, February 2013. We electronically searched the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (via Ovid, starting 1946ID), and Embase (starting 1980; accessed via Ovid). The search strategies combined terms for anticoagulants, terms for cancer, and a search filter for RCTs. We used no language restrictions. We list the full search strategies for each of the electronic databases in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P></ELECTRONIC_SEARCHES><OTHER_SEARCHES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>We handsearched the conference proceedings of the American Society of Clinical Oncology (ASCO, 1982 up to September 2017) and the American Society of Hematology (ASH, starting with its 2003 issue up to September 2017). We also searched <A HREF="http://www.ClinicalTrials.gov">ClinicalTrials.gov</A> and <A HREF="http://www.who.int/ictrp/search/en/">World Health Organization (WHO) International Clinical Trials Registry Platform</A> for ongoing studies. We reviewed the reference lists of papers included in this review and of other relevant systematic reviews. We used the 'related citation' feature in PubMed to identify additional articles and 'citation tracking' of included studies in Web of Science Core Collection. In addition, we contacted experts in the field to check for unpublished and ongoing trials.</P></OTHER_SEARCHES></SEARCH_METHODS><DATA_COLLECTION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><STUDY_SELECTION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Two review authors independently screened the title and abstract of identified article citations for potential eligibility. We retrieved the full texts of articles judged potentially eligible by at least one review author. Two review authors then independently screened the full-text articles for eligibility using a standardized form with explicit inclusion and exclusion criteria. The two review authors resolved any disagreements concerning eligibility by discussion or by consulting a third review author.</P></STUDY_SELECTION><DATA_EXTRACTION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Two review authors independently extracted data from each included study and resolved their disagreements by discussion. We aimed to collect data related to the following.</P><SUBSECTION><HEADING LEVEL="4">Participants</HEADING><UL><LI>Demographic characteristics (e.g. age, sex).</LI><LI>Cancer characteristics (e.g. type, site of origin, stage at diagnosis, time since diagnosis, estimated life expectancy, current cancer treatments, performance status).</LI><LI>Whether participants had DVT, PE, or both.</LI><LI>Number of participants in each treatment arm.</LI><LI>Number of participants randomized to each study arm.</LI><LI>Number of participants followed up in each study arm.</LI><LI>Number of participants who discontinued intervention in each arm.</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Interventions</HEADING><UL><LI>Type, dosage, and administration schedule of LMWH.</LI><LI>Dosage and administration schedule of UFH.</LI><LI>Dosage schedule of fondaparinux.</LI><LI>Duration of initial parenteral therapy.</LI><LI>Type (oral anticoagulant versus LMWH) and duration of long-term anticoagulation.</LI><LI>Cointerventions including radiation therapy or systemic therapy (type and duration).</LI></UL></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Outcomes</HEADING><P>We attempted to extract both time to event data (for survival outcome) and categorical data (for all outcomes). However, none of the studies reported time to event data for participants with cancer.</P><P>For dichotomous data, we extracted data necessary to conduct a complete case analysis as the primary analysis. We collected all-cause mortality at three months. For studies where VTE was not reported as a separate outcome, we added the number of events of DVT and PE.</P><P>We attempted to contact study authors for incompletely reported data. We decided a priori to consider abstracts in the main analysis only if study authors supplied us with full reports of their methods and results; otherwise abstracts were included only in the sensitivity analysis.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Other</HEADING><P>We extracted from each included trial any information on the following points:</P><UL><LI>source of funding;</LI><LI>ethical approval;</LI><LI>conflict of interest.</LI></UL></SUBSECTION></DATA_EXTRACTION><QUALITY_ASSESSMENT MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>We assessed risk of bias at the study level using Cochrane's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Two review authors independently assessed the methodologic quality of each included study and resolved their disagreements by discussion. 'Risk of bias' criteria included the following.<BR/></P><UL><LI>Adequate sequence generation.</LI><LI>Allocation concealment.</LI><LI>Blinding of participants and personnel.</LI><LI>Blinding of outcome assessment.</LI><LI>Percentage of follow-up and whether incomplete outcome data were addressed.</LI><LI>Whether the study was free of selective outcome reporting.</LI><LI>Whether the study was stopped early for benefit (other bias).</LI></UL><P>See section on <LINK TAG="MISSING_DATA" TYPE="SECTION">Dealing with missing data</LINK> about assessing risk of bias associated with participants with missing data per outcome and across studies.</P></QUALITY_ASSESSMENT><EFFECT_MEASURES MODIFIED="2011-01-04 10:42:19 +0000" MODIFIED_BY="[Empty name]"><P>We collected and analyzed risk ratios (RRs) for dichotomous data. None of the outcomes of interest were meta-analyzed as a continuous variable.</P></EFFECT_MEASURES><UNIT_OF_ANALYSIS MODIFIED="2010-11-15 20:46:41 +0000" MODIFIED_BY="[Empty name]"><P>The unit of analysis was the individual participant.</P></UNIT_OF_ANALYSIS><MISSING_DATA MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>It was unclear whether certain participant categories (e.g. those described as 'withdrew consent' or 'experienced adverse events') were actually followed up by the trial authors (versus had missing participant data) (<LINK REF="REF-Akl-2016" TYPE="REFERENCE">Akl 2016</LINK>). To deal with this issue, we made the following considerations:</P><UL><LI>'ineligible participants' and 'did not receive the first dose' participant categories, which were defined prior to the initiation of the study intervention, most likely had missing participant data;</LI><LI>'withdrew consent', 'lost to follow-up' (LTFU) and 'outcome not assessable' participant categories and any other categories explicitly reported as not being followed-up, which were defined after the initiation of the study intervention, most likely had missing participant data;</LI><LI>'dead', 'experienced adverse events,' 'noncompliant,' and 'discontinued prematurely' (and similarly described) participant categories, less likely had missing participant data.</LI></UL><SUBSECTION><HEADING LEVEL="4">Dealing with participants with missing data in the primary meta-analysis</HEADING><P>In the primary meta-analysis, we used a complete case analysis approach (i.e. we excluded participants considered to have missing data) (<LINK REF="REF-Guyatt-2017" TYPE="REFERENCE">Guyatt 2017</LINK>).</P><P>For categorical data, we used the following calculations for each study arm.</P><UL><LI>Denominator: (number of participants randomized) - (number of participants most likely with missing data, both pre- and postintervention initiation);</LI><LI>Numerator: number of participants with observed events (i.e. participants who experienced at least one event for the outcome of interest during their available follow-up time).</LI></UL><P>For continuous data, we planned to use for each study arm the reported mean and standard deviation (SD) for participants actually followed up by the trial authors.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Assessing the risk of bias associated with participants with missing data</HEADING><P>When the primary meta-analysis of a specific outcome found a statistically significant effect, we conducted sensitivity meta-analyses to assess the risk of bias associated with missing participant data. Those sensitivity meta-analyses used a priori plausible assumptions about the outcomes of participants considered to have missing data. The assumptions we used in the sensitivity meta-analyses were increasingly stringent to progressively challenge the statistical significance of the results of the primary analysis (<LINK REF="REF-Akl-2013" TYPE="REFERENCE">Akl 2013</LINK>; <LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>).</P><P>For categorical data, and for RR showing a reduction in effect (RR &lt; 1), we used the following increasingly stringent but plausible assumptions (<LINK REF="REF-Akl-2013" TYPE="REFERENCE">Akl 2013</LINK>):</P><UL><LI>for the control arm, relative incidence (RI) among those with missing data (LTFU) compared to those with available data (followed up, FU) in the same arm (RI<SUB>LTFU/FU</SUB>) = 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 1.5;</LI></UL><UL><LI>for the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 2;</LI><LI>for the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 3;</LI><LI>for the control arm, RI<SUB>LTFU/FU </SUB>= 1; for the intervention arm, RI<SUB>LTFU/FU </SUB>= 5.</LI></UL><P>For RR showing an increase in effect (RR &gt; 1), we switched the above assumptions between the control and interventions arms (i.e. used RI<SUB>LTFU/FU </SUB>= 1 for the intervention arm).</P><P>Specifically, we used the following calculations for each study arm.</P><UL><LI>Denominator: (number of participants randomized) - (number of participants most likely with missing data, preintervention initiation).</LI><LI>Numerator: (number of participants with observed events) + (number of participants most likely with missing data postintervention initiation, with assumed events).</LI></UL><P>Assumed events were calculated by applying the a priori plausible assumptions to the participants considered most likely with missing data postintervention initiation.</P><P>For continuous data, we planned to use the four strategies suggested by Ebrahim and colleagues (<LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>). The strategies imputed the means for participants with missing data based on the means of participants actually followed up in individual trials included in the systematic review. To impute SD, we used the median SD from the control arms of all included trials (<LINK REF="REF-Ebrahim-2013" TYPE="REFERENCE">Ebrahim 2013</LINK>).</P></SUBSECTION></MISSING_DATA><HETEROGENEITY_ASSESSMENT MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>We assessed heterogeneity between trials by visual inspection of forest plots, estimation of the percentage heterogeneity between trials that could not be ascribed to sampling variation (I<SUP>2</SUP> test; <LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), and by a formal statistical test of the significance of the heterogeneity (<LINK REF="REF-Deeks-2001" TYPE="REFERENCE">Deeks 2001</LINK>). If there was evidence of substantial heterogeneity, we investigated and reported the possible reasons for this (see <LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>).</P></HETEROGENEITY_ASSESSMENT><BIAS_ASSESSMENT MODIFIED="2017-10-22 17:20:26 +0100" MODIFIED_BY="[Empty name]"><P>We assessed selective outcome reporting by trying to identify whether the study was included in a trial registry, whether a protocol was available, and whether the methods section provided a list of outcomes. We compared the list of outcomes from those sources to the outcomes reported in the published paper. We did not create funnel plots due to the low number of included trials for each outcome.</P></BIAS_ASSESSMENT><DATA_SYNTHESIS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>For dichotomous data, we calculated the RR separately for each study. When analyzing data related to participants who were reported as not compliant, we attempted to adhere to the principles of intention-to-treat (ITT) analysis. We approached the issue of noncompliance independently from that of missing data (<LINK REF="REF-Alshurafa-2012" TYPE="REFERENCE">Alshurafa 2012</LINK>). We then pooled the results of the different studies using a random-effects model. We assessed the certainty of evidence at the outcome level using the GRADE approach (<LINK REF="REF-GRADE-handbook" TYPE="REFERENCE">GRADE handbook</LINK>).</P></DATA_SYNTHESIS><SUBGROUP_ANALYSIS MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn"><P>We planned subgroup analyses based on characteristics of participants but did not conduct them as the data were not available.</P></SUBGROUP_ANALYSIS><SENSITIVITY_ANALYSIS MODIFIED="2017-10-24 09:53:45 +0100" MODIFIED_BY="[Empty name]"><P>Unlike the 2014 update of this review, we included in the sensitivity analysis the studies published as abstracts only. As described above, we also planned for sensitivity meta-analyses to assess the risk of bias associated with missing participant data when the primary meta-analysis of a specific outcome found a statistically significant effect.</P></SENSITIVITY_ANALYSIS></DATA_COLLECTION></METHODS><RESULTS MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><STUDY_DESCRIPTION MODIFIED="2018-01-18 15:35:55 +0000" MODIFIED_BY="Gail Quinn"><SEARCH_RESULTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>The 14 January 2018 search strategy identified 7387 unique citations. <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> shows the study flow. The title and abstract screening identified 150 citations as potentially eligible for this review. We included 13 eligible RCTs published as full reports (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>; <LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>; <LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>; <LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>), and two studies published as abstracts (<LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>), and excluded the remaining 134. The January 2018 search identified no new eligible studies. Agreement between review authors for study eligibility was excellent (kappa = 0.94).</P></SEARCH_RESULTS><INCLUDED_STUDIES_DESCR MODIFIED="2018-01-18 15:35:55 +0000" MODIFIED_BY="Gail Quinn"><P>In all 15 included studies, participants with cancer constituted subgroups. Of these 15 studies, three studies reported data for cancer subgroups (<LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>; <LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>), and three studies had follow-up publications reporting cancer subgroup data (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>). For two studies, we obtained cancer subgroup data from the study authors (<LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>). Seven studies did not report cancer subgroup data (<LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>), so we used the data as reported in two published systematic reviews (<LINK REF="REF-Hettiarachchi-1999" TYPE="REFERENCE">Hettiarachchi 1999</LINK>; <LINK REF="REF-Robertson-2017" TYPE="REFERENCE">Robertson 2017</LINK>). We excluded these seven studies from the main analysis and included them in the sensitivity analyses.</P><P>Of the 15 studies, 13 compared LMWH to UFH, one compared fondaparinux to heparin (UFH and LMWH) (<LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>),and one compared dalteparin to tinzaparin (<LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>). None of the studies specified the types of cancer of the participants. In 14/15 studies, the initial parenteral anticoagulation was followed by oral anticoagulation for at least three months. In <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>, the long-term anticoagulation was either SC UFH or oral anticoagulation depending on the usual regimen of the participating center (<LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>).</P><P>Breddin and colleagues recruited 83 people with cancer aged at least 18 years with DVT (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>). Overall, the study enrolled 1137 participants. Participants were randomized to receive IV UFH for five to seven days or SC reviparin twice a day for five to seven days or once a day for a mean (SD) of 28 ± 2 days. All the participants received a vitamin K antagonist (VKA) until the end of the 90-day observation period. The primary efficacy outcome was a change in the venographically determined thrombus size. Assessed outcomes were recurrence of DVT or PE. Participants were followed up for 90 days. The author reported 91% follow-up.</P><P>Buller and colleagues recruited 232 people with cancer, aged at least 18 years, with proximal or distal DVT, PE, or both (<LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>). Participants were randomized to receive weight-based SC reviparin twice daily at home or IV UFH (target activated partial thromboplastin time (aPTT) 1.5 to 2.5) in hospital for five days. Oral anticoagulant treatment with a derivative of coumarin was begun concomitantly on the first or second day and continued for 12 weeks. Assessed outcomes were symptomatic recurrent VTE, major bleeding, and death. Participants were followed up for 12 weeks. The study authors reported complete follow-up.</P><P>Duroux and colleagues recruited 18 people with cancer, aged at least 18 years, with proximal DVT but no PE (<LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>). Overall, the study enrolled 170 participants. Participants were randomized to receive nadroparin twice daily for 10 days, or IV UFH (target aPTT 1.5 to 2) for 10 days. After day 10, each center continued its usual anticoagulant regimen either by SC UFH at adjusted dose or by oral anticoagulant for 12 weeks. Assessed outcomes were mortality, recurrent venogram-detected VTE and major bleeding. There was no Information about the follow-up in cancer subgroup reported.</P><P>Hull and colleagues recruited 95 people with cancer, aged at least 18 years, with proximal DVT (<LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>). Overall, the study enrolled 432 participants. Participants were randomized to receive SC tinzaparin once daily or IV UFH (target aPTT 1.5 to 2.5) for six days. All participants received long-term therapy with warfarin for at least three months. Participants assigned to receive IV UFH also received a SC injection of placebo once every 24 hours. Participants assigned to receive SC LMWH also received an IV bolus of placebo and a continuous IV infusion of placebo throughout the initial therapy. Assessed outcomes were recurrent VTE, bleeding complications and participant death. Participants were followed up for three months. The authors reported complete follow-up.</P><P>Koopman and colleagues recruited 70 people with cancer, aged at least 18 years and with a life expectancy of minimum six months, with proximal DVT (<LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>). Overall, the study enrolled 400 participants. Participants were randomized to receive SC nadroparin twice daily at home or IV UFH (target aPTT 1.5 to 2) for five days. In each participant, VKA therapy was begun on the first day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the international normalized ratio (INR) between 2.0 and 3.0. The primary outcome studied was symptomatic recurrent VTE, while the secondary outcome was major bleeding. All participants were contacted daily during the initial treatment and at 4, 12, and 24 weeks. The authors reported complete follow-up.</P><P>Levine and colleagues recruited 103 people with cancer with proximal or distal DVT (<LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>). Overall, the study enrolled 500 participants. Participants were randomized to receive treatment with either SC enoxaparin at home or continuous IV UFH in the hospital for five days. In all participants, warfarin therapy was begun on the second day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were symptomatic recurrent VTE and bleeding during the period of administration of study medication or within 48 hours after its discontinuation. The participants were assessed monthly for three months. The authors reported complete follow-up.</P><P>Lindmarker and colleagues recruited 16 people with cancer, aged at least 18 years, with DVT (<LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>). Overall, the study enrolled 204 participants. Participants were randomized to receive SC fragmin once daily compared to IV UFH (target aPTT 1.5 to 3.0) for five days. In all participants, warfarin therapy was given for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were mortality, recurrent VTE and bleeding. Participants were followed up for six months. The authors reported complete follow-up.</P><P>Lopaciuk and colleagues recruited nine people with cancer with proximal, DVT, or both of the leg (<LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>). Overall, the study enrolled 149 participants. Participants were randomized to receive either fixed dose nadroparin (LMWH) or UFH (doses adjusted according to aPTT) for 10 days. In all participants, VKA therapy was begun on the seventh day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were size of the thrombus pre- and post-treatment and recurrent VTE. Participants were followed up for three months. The authors reported complete follow-up.</P><P>Merli and colleagues recruited 141 people with cancer, aged at least 18 years, with DVT or PE (<LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>). Overall, the study enrolled 204 participants. Participants were randomized to receive SC enoxaparin (1 mg/kg twice daily or 1.5 mg/kg once daily) or IV UFH (target aPTT 55 to 80 seconds) for five days. In all participants, warfarin was started within 72 hours of initial study drug administration to keep INR between 2.0 and 3.0. Assessed outcomes included recurrent DVT or PE. Participants were followed up for three months. There was no information about follow-up in cancer subgroup reported.</P><P>Prandoni and colleagues recruited 33 people with cancer, aged at least 18 years, with proximal DVT (<LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>). Overall, the study enrolled 170 participants. Participants were randomized to receive weight-based SC nadroparin twice daily or IV UFH (target aPTT 1.5 to 2.0) for 10 days. In all participants, coumarin was begun on the seventh day after commencing initial therapy and continued for at least three months. The dose of coumarin was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes included symptomatic recurrent DVT or PE. Participants were followed up for six months. The authors reported complete follow-up.</P><P>Prandoni and colleagues recruited 156 people with cancer, aged at least 18 years and with a life expectancy of minimum three months, with DVT, PE, or both (<LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>). Overall, the study enrolled 720 participants. Participants were randomized to receive nadroparin twice daily or SC UFH twice daily (target aPTT 50 to 90 seconds) for five days. In all participants, VKA therapy was begun on the first or second day after commencing initial therapy and continued for 12 weeks. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. The primary endpoint was the incidence of symptomatic recurrent VTE during the three-month study period. A secondary outcome was the incidence of major bleeding during the initial LMWH treatment and additional 48 hours. During the initial treatment with the study drugs, participants were examined daily. Follow-up visits were scheduled after one and three months. The authors report complete follow-up.</P><P>Simonneau recruited nine people with cancer, aged at least 18 years, with proximal DVT (<LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>). Overall, the study enrolled 134 participants. Participants were randomized to receive SC enoxaparin twice daily or IV UFH for 10 days (target aPTT 1.5 to 2.5). In all participants, VKA therapy was begun on the 10th day after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Outcomes assessed were mortality, recurrent symptomatic VTE, and bleeding. Participants were followed up for three months. The authors reported complete follow-up.</P><P>Simonneau and colleagues recruited 60 people with cancer, aged at least 18 years and life expectancy of minimum three months, with clinically suspected PE (<LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>). Overall, the study enrolled 612 participants. Participants were randomized to receive SC tinzaparin once daily or IV UFH (target aPTT 2 to 3) for five days. In all participants, VKA therapy was begun on the first three days after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Outcomes assessed were mortality, recurrent symptomatic VTE, and major bleeding. Participants were followed up for 90 days. The authors reported complete follow-up.</P><P>Van Doormaal and colleagues recruited 477 people with cancer, aged at least 18 years, with acute symptomatic DVT without PE (subgroup analysis of MATISSE study) (<LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>). Participants were randomized to receive SC fondaparinux once daily, or enoxaparin twice daily, or UFH (target aPTT 1.5 to 2.5). In all participants, VKA therapy was begun as soon as possible but not later than 72 hours after commencing initial therapy and continued for at least three months. The dose of VKA was adjusted to maintain the INR between 2.0 and 3.0. Assessed outcomes were mortality, symptomatic recurrent VTE, and bleeding. Participants were followed up for 90 days. The authors reported complete follow-up.</P><P>Wells and colleagues recruited 113 people with cancer, aged at least 18 years, with upper or lower extremity DVT (<LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>). Overall, the study enrolled 505 participants. Participants were randomized to receive SC tinzaparin once daily or SC dalteparin once daily on an outpatient basis. In all participants, warfarin therapy was begun within 24 hours of the first dose of LMWH and continued for three months. Assessed outcomes were mortality, symptomatic recurrent VTE, and major and minor bleeding. Participants were followed up for three months. The authors reported complete follow-up.</P></INCLUDED_STUDIES_DESCR><EXCLUDED_STUDIES_DESCR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Of the 134 excluded studies, in 11 studies people with cancer constituted study subgroups but their outcome data were not available (<LINK REF="STD-Albada-1989" TYPE="STUDY">Albada 1989</LINK>; <LINK REF="STD-Belcaro-1999" TYPE="STUDY">Belcaro 1999</LINK>; <LINK REF="STD-Bratt-1990" TYPE="STUDY">Bratt 1990</LINK>; <LINK REF="STD-Buller-2004" TYPE="STUDY">Buller 2004</LINK>; <LINK REF="STD-Fiessinger-1996" TYPE="STUDY">Fiessinger 1996</LINK>; <LINK REF="STD-Harenberg-1990" TYPE="STUDY">Harenberg 1990</LINK>; <LINK REF="STD-Harenberg--2000" TYPE="STUDY">Harenberg 2000</LINK>; <LINK REF="STD-Holm-1986" TYPE="STUDY">Holm 1986</LINK>; <LINK REF="STD-Hull-2000" TYPE="STUDY">Hull 2000</LINK>; <LINK REF="STD-Luomanmaki-1996" TYPE="STUDY">Luomanmaki 1996</LINK>; <LINK REF="STD-Riess-2003" TYPE="STUDY">Riess 2003</LINK>). We excluded the remaining 123 studies for the following reasons: not population of interest: participants without VTE (74 studies), no participants with cancer (three studies); not intervention of interest: secondary treatment (17 studies), different long-term management (one study); not design of interest: review (11 studies), case report or series (four studies), letter to the editor or editorial (four studies), cohort study (three studies), retrospective study (two studies), not randomized (one study), survey (one study); and not outcome of interest (three studies).</P></EXCLUDED_STUDIES_DESCR></STUDY_DESCRIPTION><STUDY_QUALITY MODIFIED="2018-01-18 15:36:09 +0000" MODIFIED_BY="Gail Quinn"><P>The judgments for the risk of bias are summarized in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P><ALLOCATION MODIFIED="2018-01-15 13:11:58 +0000" MODIFIED_BY="[Empty name]"><P>We judged allocation to be adequately concealed in 13 of the 15 studies (<LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>; <LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>; <LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>; <LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>). Two studies did not report on allocation concealment (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>).</P></ALLOCATION><BLINDING MODIFIED="2018-01-18 15:36:09 +0000" MODIFIED_BY="Gail Quinn"><SUBSECTION><HEADING LEVEL="4">Blinding of participants and personnel (performance bias)</HEADING><P>We judged participants and personnel to be definitely blinded in three of the 15 studies (<LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>; <LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>), and definitely not blinded in 12 studies (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>; <LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Blinding of outcome assessment (detection bias)</HEADING><P>We judged outcome assessors to be definitely blinded in 14 studies (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>; <LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>; <LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>; <LINK REF="STD-Wells-2005" TYPE="STUDY">Wells 2005</LINK>) and probably not blinded in one study (<LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>).</P></SUBSECTION></BLINDING><EXCLUSIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>All but three studies (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>) reported complete follow-up.</P><P>Breddin and colleagues reported an approximate 91% follow-up in the cancer subgroup (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>).</P><P>For the other two studies, we analyzed the available data assuming that any possibly missing data were missing at random (<LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>).</P></EXCLUSIONS><SELECTIVE_REPORTING MODIFIED="2017-10-22 16:32:19 +0100" MODIFIED_BY="[Empty name]"><P>The outcomes listed in the methods section were reported in the results section for all 15 studies.</P><P>We did not suspect selective reporting of outcomes for any of the studies. The cancer subgroup data were missing for seven studies.</P></SELECTIVE_REPORTING><OTHER_BIAS_SOURCES MODIFIED="2017-10-23 20:15:54 +0100" MODIFIED_BY="[Empty name]"><P>None found.</P></OTHER_BIAS_SOURCES></STUDY_QUALITY><INTERVENTION_EFFECTS MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><SUBSECTION><HEADING LEVEL="3">Low molecular weight heparin versus unfractionated heparin</HEADING><SUBSECTION><HEADING LEVEL="4">Mortality</HEADING><P>Meta-analysis of the five RCTs, including 418 participants found that LMWH compared to UFH likely decreased mortality at three months (RR 0.66, 95% CI 0.40 to 1.10; risk difference (RD) 57 fewer per 1000, 95% CI 101 fewer to 17 more; moderate certainty evidence) (see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Hull-1992" TYPE="STUDY">Hull 1992</LINK>; <LINK REF="STD-Prandoni-1992" TYPE="STUDY">Prandoni 1992</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>; <LINK REF="STD-Simonneau-1993" TYPE="STUDY">Simonneau 1993</LINK>). The I<SUP>2</SUP> value showed no heterogeneity (I<SUP>2</SUP> = 0%). We did not create funnel plots due to the low number of included trials for the outcome of mortality. The certainty of evidence for mortality was moderate due to imprecision (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> includes the Evidence Profile (a more detailed version of the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). These results did not change in a meta-analysis including the studies that did not report data for the cancer subgroup (<LINK REF="STD-Buller-1997-_x0028_COLOMBUS_x0029_" TYPE="STUDY">Buller 1997 (COLOMBUS)</LINK>; <LINK REF="STD-Duroux-1991" TYPE="STUDY">Duroux 1991</LINK>; <LINK REF="STD-Koopman-1996" TYPE="STUDY">Koopman 1996</LINK>; <LINK REF="STD-Levine-1996" TYPE="STUDY">Levine 1996</LINK>; <LINK REF="STD-Simonneau-1997-_x0028_THESEE_x0029_" TYPE="STUDY">Simonneau 1997 (THESEE)</LINK>), and the studies published as abstracts (<LINK REF="STD-Lindmarker-1994" TYPE="STUDY">Lindmarker 1994</LINK>; <LINK REF="STD-Lopaciuk-1992" TYPE="STUDY">Lopaciuk 1992</LINK>) (RR 0.75, 95% CI 0.56 to 1.02).</P></SUBSECTION><SUBSECTION><HEADING LEVEL="4">Recurrent venous thromboembolism</HEADING><P>There were no data available for DVT or PE events separately. Meta-analysis of three RCTs including 422 participants comparing LMWH to UFH did not rule out a clinically significant increase or decrease in VTE (RR 0.69, 95% CI 0.27 to 1.76; RD 30 fewer per 1000, 95% CI 70 fewer to 73 more; moderate certainty evidence) (<LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK>; <LINK REF="STD-Merli-2001" TYPE="STUDY">Merli 2001</LINK>; <LINK REF="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TYPE="STUDY">Prandoni 2004 (GALILEI)</LINK>). The I<SUP>2</SUP> value indicated moderate heterogeneity (I<SUP>2 </SUP>= 46%) (see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The certainty of evidence for recurrent VTE was moderate due to imprecision (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> includes the Evidence Profile (a more detailed version of the <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P><P>There were no data available for bleeding outcomes, postphlebitic syndrome, quality of life, or thrombocytopenia.</P></SUBSECTION></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Fondaparinux versus heparin</HEADING><P>One study comparing fondaparinux with heparin (UFH and LMWH) did not show or exclude a beneficial or detrimental effect of fondaparinux on mortality at three months (RR 1.25, 95% CI 0.86 to 1.81; RD 43 more per 1000, 95% CI 24 fewer to 139 more, moderate certainty evidence), recurrent VTE (RR 0.93, 95% CI 0.56 to 1.54; RD 8 fewer per 1000, 95% CI 52 fewer to 63 more, moderate certainty evidence), major bleeding (RR 0.82, 95% CI 0.40 to 1.66; RD 12 fewer per 1000, 95% CI 40 fewer to 44 more, moderate certainty evidence), or minor bleeding (RR 1.53, 95% CI 0.88 to 2.66; RD 42 more per 1000, 95% CI from 10 fewer to 132 more, moderate certainty evidence) (<LINK REF="STD-van-Doormaal-2009" TYPE="STUDY">van Doormaal 2009</LINK>). The certainty of evidence was moderate for mortality, major bleeding, minor bleeding, and recurrent VTE due to imprecision (see Summary of findings table 2). <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> includes the Evidence Profile (a more detailed version of the Summary of findings table 2).</P><P>There were no data available for postphlebitic syndrome, quality of life, thrombocytopenia.</P></SUBSECTION><SUBSECTION><HEADING LEVEL="3">Dalteparin versus tinzaparin</HEADING><P>One study comparing dalteparin with tinzaparin did not show or exclude a beneficial or detrimental effect of dalteparin on mortality (RR 0.86, 95% CI 0.43 to 1.73; RD 33 fewer per 1000, 95% CI 135 fewer to 173 more; low certainty evidence), VTE recurrence (RR 0.44, 95% CI 0.09 to 2.16; RD 47 fewer per 1000, 95% CI 77 fewer to 98 more; low certainty evidence), major bleeding (RR 2.19, 95% CI 0.20 to 23.42; RD 20 more per 1000, 95% CI 14 fewer to 380 more; low certainty evidence), or minor bleeding (RR 0.82, 95% CI 0.30 to 2.21; RD 24 fewer per 1000, 95% CI 95 fewer to 164 more; low certainty evidence). The certainty of evidence was low for all tested outcomes, due to imprecision (see <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK> includes the Evidence Profile (a more detailed version of the <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>).</P><P>There were no data available for postphlebitic syndrome, quality of life, or thrombocytopenia.</P></SUBSECTION></INTERVENTION_EFFECTS></RESULTS><DISCUSSION MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><SUMMARY_OF_RESULTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>LMWH appeared to have a small effect on mortality compared to UFH in the initial treatment of VTE in people with cancer. The review did not prove or exclude a clinically important effect of fondaparinux compared to any heparin, on mortality, recurrent VTE, or major or minor bleeding. The available evidence did not show a differential effect between dalteparin and tinzaparin for all tested outcomes.</P></SUMMARY_OF_RESULTS><APPLICABILITY_OF_FINDINGS MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><P>The completeness of the data was a major concern in this systematic review. First, of a total of 26 potentially eligible studies, we did not include 11 because the study authors did not report the required subgroup data for people with cancer. These 11 studies would have contributed 340 additional participants to the meta-analysis (1615 are currently included). If the treatment effect from those studies was different from the reported effect, their exclusion from the meta-analysis could have biased our results. Moreover, only three of the included studies reported cancer subgroup data for VTE recurrence and none reported cancer subgroup data for the bleeding outcomes.</P></APPLICABILITY_OF_FINDINGS><QUALITY_OF_EVIDENCE MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><P>For the LMWH versus UFH comparison, the certainty of evidence for all tested outcomes was moderate due to imprecision. For the fondaparinux versus heparin comparison, the certainty of evidence was moderate for all tested outcomes due to imprecision. For the dalteparin versus tinzaparin comparison, the certainty of evidence was low for all tested outcomes due to imprecision.</P></QUALITY_OF_EVIDENCE><POTENTIAL_BIASES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Our systematic approach to searching for studies, selecting studies, and extracting data should have minimized the likelihood of missing relevant studies. The inclusion of different types of cancer in the same study precluded us from conducting the subgroup analyses to explore effect modifiers such as type and stage of cancer. A potential bias of our review might be the limitation of the electronic search strategy to people with cancer, while the data needed for this review came from studies not restricted to this subgroup.</P></POTENTIAL_BIASES><AGREEMENT MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Four previous systematic reviews compared the effects of LMWH and UFH on mortality in people with cancer and with VTE (<LINK REF="REF-Erkens-2010" TYPE="REFERENCE">Erkens 2010</LINK>; <LINK REF="STD-Gould-1999" TYPE="STUDY">Gould 1999</LINK>; <LINK REF="REF-Hettiarachchi-1999" TYPE="REFERENCE">Hettiarachchi 1999</LINK>; <LINK REF="REF-Robertson-2017" TYPE="REFERENCE">Robertson 2017</LINK>). We limited our comparison to the newest systematic review.</P><P>Erkens and colleagues conducted in a Cochrane Review comparing fixed-dose LMWH versus UFH for treatment of acute VTE (<LINK REF="REF-Erkens-2010" TYPE="REFERENCE">Erkens 2010</LINK>). In a subgroup analysis of people with cancer, they included six studies and 446 participants. The meta-analysis found a significant reduction in mortality in the LMWH group compared to the UFH group at three months of follow-up (OR 0.53, 95% CI 0.33 to 0.85). Erkens and colleagues did not include data from <LINK REF="STD-Breddin-2001" TYPE="STUDY">Breddin 2001</LINK> for the outcome of mortality, and that explains the difference between our results.</P></AGREEMENT></DISCUSSION><CONCLUSIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><IMPLICATIONS_PRACTICE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Low molecular weight heparin (LMWH) is possibly superior to unfractionated heparin (UFH) in reducing mortality in the initial treatment of venous thromboembolism (VTE) in people with cancer. The confidence in this effect is reduced by both the risk of bias in included studies and the likelihood of publication bias. However, there are additional advantages of LMWH related to subcutaneous administration and outpatient management (<LINK REF="REF-O_x0027_Brien-1999" TYPE="REFERENCE">O'Brien 1999</LINK>; <LINK REF="REF-Othieno-2007" TYPE="REFERENCE">Othieno 2007</LINK>).</P><P>The decision for a person with cancer with VTE to start heparin therapy should balance the benefits and harms, and should integrate the person's values and preferences (<LINK REF="REF-Haynes-2002" TYPE="REFERENCE">Haynes 2002</LINK>).</P></IMPLICATIONS_PRACTICE><IMPLICATIONS_RESEARCH MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>There is a need to conduct trials comparing anticoagulants in the initial treatment of VTE that are restricted to people with cancer. Researchers should consider making the raw data of randomized controlled trials available for individual participant data meta-analysis. In addition, as recognized by Cochrane, addressing all important outcomes including harm is of great importance in making evidence-based healthcare decisions.</P></IMPLICATIONS_RESEARCH></CONCLUSIONS></BODY><ACKNOWLEDGEMENTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>We thank Dr Merli, Dr Prandoni, Dr Siragusa, and Dr Wells for providing us with data. We thank Ms Ann Grifasi for her administrative support. We thank Dr Sameer Gunukula, Dr Paola Muti, Dr Ignacio Neumann, and Dr Srinivasa Rao Vasireddi for their contributions to previous versions of this systematic review.</P><P>We also thank Dr Assem Khamis for his help with conducting the sensitivity analysis.</P><P>We thank Jo Morrison, Co-ordinating Editor for the Cochrane Gynaecological Neuro-oncology and Orphan Cancers Group. We also thank Gail Quinn, Managing Editor of the Cochrane Gynaecological Neuro-oncology and Orphan Cancers Group for her exceptional support. We thank Joanne Platt, the Information Specialist of the Cochrane Gynaecological Neuro-oncology and Orphan Cancers Group, for setting up and managing the monthly alerts.</P><P>This project was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure Funding. The views and opinions expressed therein are those of the review authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service, or the Department of Health.</P></ACKNOWLEDGEMENTS><CONFLICT_OF_INTEREST MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>HJS: no personal payments from for-profit sponsors related to the subject matter since 2014.</P><P>EAA served on the executive committee the ACCP Antithrombotic Therapy Guidelines published in 2016.</P><P>All other review authors declare no conflicts of interests.</P></CONFLICT_OF_INTEREST><CONTRIBUTIONS MODIFIED="2018-01-17 12:22:39 +0000" MODIFIED_BY="Gail Quinn"><P>MBH: screening, full-text retrieval, data extraction, manuscript drafting.<BR/>LAK: searching for trials, screening, data extraction, data analysis, manuscript drafting, review co-ordination.<BR/>IGT: screening, full-text retrieval, data extraction, manuscript drafting.<BR/>CM: screening, full-text retrieval, data extraction.<BR/>VY: screening, full-text retrieval, data extraction.<BR/>IT: screening, full-text retrieval, data extraction.<BR/>FS: screening, full-text retrieval, data extraction.<BR/>MB: screening, full-text retrieval, data extraction.<BR/>HJS: protocol development, data interpretation, methodological expertise.<BR/>EAA: protocol development, data analysis, manuscript drafting, methodological expertise, review co-ordination.</P></CONTRIBUTIONS><PRO_REV_DIFF MODIFIED="2017-09-26 08:53:13 +0100" MODIFIED_BY="[Empty name]"/><PUBLIC_NOTES/></MAIN_TEXT><STUDIES_AND_REFERENCES MODIFIED="2018-01-22 10:30:37 +0000" MODIFIED_BY="Gail Quinn">
<STUDIES MODIFIED="2018-01-22 10:22:29 +0000" MODIFIED_BY="Gail Quinn">
<INCLUDED_STUDIES MODIFIED="2018-01-15 13:11:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Breddin-2001" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Breddin 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV, Cortes Investigators</AU>
<TI>Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>9</NO>
<PG>626-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626189"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626188"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_" MODIFIED="2018-01-08 16:34:58 +0000" MODIFIED_BY="Anne Lawson" NAME="Buller 1997 (COLOMBUS)" YEAR="1997">
<REFERENCE MODIFIED="2018-01-08 16:34:58 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, Baildon R, et al</AU>
<TI>Low-molecular-weight heparin in the treatment of patients with venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>10</NO>
<PG>657-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500001"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500000"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duroux-1991" MODIFIED="2018-01-08 16:35:03 +0000" MODIFIED_BY="Anne Lawson" NAME="Duroux 1991" YEAR="1991">
<REFERENCE MODIFIED="2018-01-08 16:35:03 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duroux P, Ninet J, Bachet P, Prandoni P, Ruol A, Vigo M, et al</AU>
<TI>A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicenter study</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1991</YR>
<VL>65</VL>
<NO>3</NO>
<PG>251-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626193"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626192"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-1992" MODIFIED="2018-01-08 16:35:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Hull 1992" YEAR="1992">
<REFERENCE MODIFIED="2018-01-08 16:35:11 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al</AU>
<TI>Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>15</NO>
<PG>975-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626197"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626196"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koopman-1996" MODIFIED="2018-01-08 16:35:19 +0000" MODIFIED_BY="Anne Lawson" NAME="Koopman 1996" YEAR="1996">
<REFERENCE MODIFIED="2018-01-08 16:35:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J, et al</AU>
<TI>Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>11</NO>
<PG>682-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626199"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626198"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-1996" MODIFIED="2018-01-08 16:35:26 +0000" MODIFIED_BY="Anne Lawson" NAME="Levine 1996" YEAR="1996">
<REFERENCE MODIFIED="2018-01-08 16:35:26 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al</AU>
<TI>A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<NO>11</NO>
<PG>677-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626201"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626200"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindmarker-1994" MODIFIED="2014-05-21 12:52:21 +0100" MODIFIED_BY="Anne Lawson" NAME="Lindmarker 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-01-04 12:06:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindmarker P, Holstrom M, Granqvist S, Johnsson H, Lockner D</AU>
<TI>Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1994</YR>
<VL>72</VL>
<NO>2</NO>
<PG>186-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626203"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626202"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopaciuk-1992" MODIFIED="2018-01-08 16:35:48 +0000" MODIFIED_BY="Anne Lawson" NAME="Lopaciuk 1992" YEAR="1992">
<REFERENCE MODIFIED="2018-01-08 16:35:48 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Ciesielski L, et al</AU>
<TI>Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1992</YR>
<VL>68</VL>
<NO>1</NO>
<PG>14-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626205"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626204"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merli-2001" NAME="Merli 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merli G, Spiro TE</AU>
<TI>Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>134</VL>
<NO>3</NO>
<PG>191-202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626207"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626206"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prandoni-1992" MODIFIED="2018-01-08 16:35:59 +0000" MODIFIED_BY="Anne Lawson" NAME="Prandoni 1992" YEAR="1992">
<REFERENCE MODIFIED="2018-01-08 16:35:59 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Lensing AW, Büller HR, Carta M, Cogo A, Vigo M, et al</AU>
<TI>Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<NO>8791</NO>
<PG>441-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626209"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626208"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_" MODIFIED="2016-07-21 07:06:13 +0100" MODIFIED_BY="[Empty name]" NAME="Prandoni 2004 (GALILEI)" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Carnovali M, Marchiori A, Galilei Investigators</AU>
<TI>Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>10</NO>
<PG>1077</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500003"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500002"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simonneau-1993" MODIFIED="2018-01-08 16:36:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Simonneau 1993" YEAR="1993">
<REFERENCE MODIFIED="2018-01-08 16:36:11 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simonneau G, Charbonnier B, Decousus H, Planchon B, Ninet J, Sie P, et al</AU>
<TI>Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1993</YR>
<VL>153</VL>
<NO>13</NO>
<PG>1541-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626211"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626210"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simonneau-1997-_x0028_THESEE_x0029_" MODIFIED="2018-01-08 16:36:18 +0000" MODIFIED_BY="Anne Lawson" NAME="Simonneau 1997 (THESEE)" YEAR="1997">
<REFERENCE MODIFIED="2018-01-08 16:36:18 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al</AU>
<TI>A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<NO>10</NO>
<PG>663-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500005"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500004"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Doormaal-2009" MODIFIED="2018-01-15 13:11:58 +0000" MODIFIED_BY="[Empty name]" NAME="van Doormaal 2009" YEAR="2009">
<REFERENCE MODIFIED="2018-01-08 16:36:28 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al</AU>
<TI>Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>867-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500007"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:36:36 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus AG, Lensing AWA, et al</AU>
<TI>Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>101</VL>
<PG>762-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500008"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-08-20 21:15:26 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500006"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wells-2005" MODIFIED="2018-01-08 16:36:43 +0000" MODIFIED_BY="Anne Lawson" NAME="Wells 2005" YEAR="2005">
<REFERENCE MODIFIED="2018-01-08 16:36:43 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wells PS, Anderson DR, Rodger MA, Forgie MA, Florack P, Touchie D, et al</AU>
<TI>A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<PG>733-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626221"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626220"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2018-01-22 10:22:29 +0000" MODIFIED_BY="Gail Quinn">
<STUDY DATA_SOURCE="PUB" ID="STD-Agnelli-1998" MODIFIED="2018-01-08 20:58:22 +0000" MODIFIED_BY="Anne Lawson" NAME="Agnelli 1998" YEAR="1998">
<REFERENCE MODIFIED="2018-01-08 20:58:22 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al</AU>
<TI>Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<PG>80-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500010"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500009"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agnelli-2005" MODIFIED="2018-01-08 16:37:33 +0000" MODIFIED_BY="Anne Lawson" NAME="Agnelli 2005" YEAR="2005">
<REFERENCE MODIFIED="2018-01-08 16:37:33 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M</AU>
<TI>Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high&#8208;risk abdominal surgery</TI>
<SO>British Journal of Surgery</SO>
<YR>2005</YR>
<VL>92</VL>
<NO>10</NO>
<PG>1212-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500012"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500011"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Agnelli-2015-_x0028_AMPLIFY_x0029_" MODIFIED="2018-01-08 16:39:22 +0000" MODIFIED_BY="Anne Lawson" NAME="Agnelli 2015 (AMPLIFY)" YEAR="2015">
<REFERENCE MODIFIED="2018-01-08 16:38:42 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al</AU>
<TI>Apixaban for the treatment of venous thromboembolism in cancer patients: data from the amplify trial</TI>
<SO>Canadian Journal of Cardiology</SO>
<YR>2014</YR>
<VL>30</VL>
<PG>S278</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500014"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:39:22 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, et al</AU>
<TI>Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2015</YR>
<VL>13</VL>
<NO>12</NO>
<PG>2187-91</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500015"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500013"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albada-1989" MODIFIED="2010-11-16 14:42:19 +0000" MODIFIED_BY="[Empty name]" NAME="Albada 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-16 14:42:19 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Albada J, Nieuwenhuis HK, Sixma JJ. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. Circulation. 1989 Oct;80(4):935-40.&lt;/p&gt;" NOTES_MODIFIED="2010-11-16 14:42:19 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albada J, Nieuwenhuis HK, Sixma JJ</AU>
<TI>Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study</TI>
<SO>Circulation</SO>
<YR>1989</YR>
<VL>80</VL>
<NO>4</NO>
<PG>935-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626223"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626222"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alikhan-2003-_x0028_MEDENOX_x0029_" MODIFIED="2018-01-16 09:21:52 +0000" MODIFIED_BY="[Empty name]" NAME="Alikhan 2003 (MEDENOX)" YEAR="2003">
<REFERENCE MODIFIED="2018-01-16 09:21:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al</AU>
<TI>Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study</TI>
<SO>Blood Coagulation and Fibrinolysis</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>4</NO>
<PG>341-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500017"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:40:44 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al</AU>
<TI>A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>341</VL>
<NO>11</NO>
<PG>793-800</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500018"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500016"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altundag-2005" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Altundag 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;&amp;#239;&amp;#187;&amp;#191;Altundag K, Altundag O, Atik MA. Heparin and CXCL12 dimerization. Journal Of Clinical Oncology. 2005 Oct 1;23(28):7248-.&lt;/p&gt;" NOTES_MODIFIED="2014-06-03 09:45:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altundag K, Altundag O, Atik MA</AU>
<TI>Heparin and CXCL12 dimerization</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>28</NO>
<PG>7248</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626225"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626224"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2001" NAME="Anton 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Anton N, Massicotte MP. Venous thromboembolism in pediatrics. Seminars in Vascular Medicine. 2001;1(1):111-22.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton N, Massicotte MP</AU>
<TI>Venous thromboembolism in pediatrics</TI>
<SO>Seminars in Vascular Medicine</SO>
<YR>2001</YR>
<VL>1</VL>
<NO>1</NO>
<PG>111-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626227"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626226"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auer-2011" MODIFIED="2018-01-16 09:22:07 +0000" MODIFIED_BY="[Empty name]" NAME="Auer 2011" YEAR="2011">
<REFERENCE MODIFIED="2018-01-16 09:22:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D, et al</AU>
<TI>The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial</TI>
<SO>Blood Coagulation and Fibrinolysis</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>8</NO>
<PG>760-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500020"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500019"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bauer-2000" NAME="Bauer 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Bauer KA. Venous thromboembolism in malignancy. Journal of Clinical Oncology. 2000;18(17):3065-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauer KA</AU>
<TI>Venous thromboembolism in malignancy</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>17</NO>
<PG>3065-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626229"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626228"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Belcaro-1999" MODIFIED="2010-11-16 14:42:19 +0000" MODIFIED_BY="[Empty name]" NAME="Belcaro 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-16 14:42:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belcaro G, Nicolaides AN, Cesarone MR, Laurora G, De Sanctis MT, Incandela L</AU>
<TI>Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis</TI>
<SO>Angiology</SO>
<YR>1999</YR>
<VL>50</VL>
<NO>10</NO>
<PG>781-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626231"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626230"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bick-2003" NAME="Bick 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Bick RL. Cancer-associated thrombosis. New England Journal of Medicine. 2003;349(2):109-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bick RL</AU>
<TI>Cancer-associated thrombosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>2</NO>
<PG>109-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626233"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626232"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bigg-1992" MODIFIED="2018-01-08 16:42:04 +0000" MODIFIED_BY="Anne Lawson" NAME="Bigg 1992" YEAR="1992">
<REFERENCE MODIFIED="2018-01-08 16:42:04 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bigg SW, Catalona WJ</AU>
<TI>Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial</TI>
<SO>Urology</SO>
<YR>1992</YR>
<VL>39</VL>
<NO>4</NO>
<PG>309-13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500022"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500021"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Booth-1981" NAME="Booth 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Booth BW, Weiss RB. Venous thrombosis during adjuvant chemotherapy. New England Journal of Medicine. 1981;305(3).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Booth BW, Weiss RB</AU>
<TI>Venous thrombosis during adjuvant chemotherapy</TI>
<SO>New England Journal of Medicine</SO>
<YR>1981</YR>
<VL>305</VL>
<PG>3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626235"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626234"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bratt-1985" MODIFIED="2011-01-04 12:13:36 +0000" MODIFIED_BY="[Empty name]" NAME="Bratt 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-01-04 12:13:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thrombosis &amp;amp; Haemostasis. 1985 Dec 17;54(4):813-7.&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 12:13:36 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D</AU>
<TI>A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1985</YR>
<VL>54</VL>
<NO>4</NO>
<PG>813-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626237"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626236"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bratt-1990" MODIFIED="2011-01-04 12:14:01 +0000" MODIFIED_BY="[Empty name]" NAME="Bratt 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-01-04 12:14:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thrombosis &amp;amp; Haemostasis. 1990 Dec 28;64(4):506-10.&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 12:14:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bratt G, Aberg W, Johansson M, Tornebohm E, Granqvist S, Lockner D</AU>
<TI>Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT)</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1990</YR>
<VL>64</VL>
<NO>4</NO>
<PG>506-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626239"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626238"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1969" NAME="Brooks 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Brooks MB. Heparin in the treatment of hemorrhagic diathesis associated with prostatic carcinoma. Journal of Urology. 1969 Aug;102(2):240-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks MB</AU>
<TI>Heparin in the treatment of hemorrhagic diathesis associated with prostatic carcinoma</TI>
<SO>Journal of Urology</SO>
<YR>1969</YR>
<VL>102</VL>
<NO>2</NO>
<PG>240-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626241"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626240"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buller-2004" MODIFIED="2018-01-08 16:50:29 +0000" MODIFIED_BY="Anne Lawson" NAME="Buller 2004" YEAR="2004">
<REFERENCE MODIFIED="2018-01-08 16:50:29 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.[see comment]. Annals of Internal Medicine. 2004 Jun 1;140(11):867-73.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 16:50:29 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al</AU>
<TI>Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<NO>11</NO>
<PG>867-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626243"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626242"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cahan-2000" MODIFIED="2018-01-08 16:51:19 +0000" MODIFIED_BY="Anne Lawson" NAME="Cahan 2000" YEAR="2000">
<REFERENCE MODIFIED="2018-01-08 16:51:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cahan MA, Hanna DJ, Wiley LA, Cox DK, Killewich LA</AU>
<TI>External pneumatic compression and fibrinolysis in abdominal surgery</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>3</NO>
<PG>537-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500024"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500023"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ciftci-2012" MODIFIED="2018-01-08 21:00:08 +0000" MODIFIED_BY="Anne Lawson" NAME="Ciftci 2012" YEAR="2012">
<REFERENCE MODIFIED="2018-01-08 21:00:08 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ciftci A, Altiay G</AU>
<TI>The effect of warfarin on survival in patients with lung cancer</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>7</NO>
<PG>S122</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500026"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500025"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke_x002d_Pearson-1993" MODIFIED="2018-01-08 16:52:50 +0000" MODIFIED_BY="Anne Lawson" NAME="Clarke-Pearson 1993" YEAR="1993">
<REFERENCE MODIFIED="2018-01-08 16:52:50 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE</AU>
<TI>A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1993</YR>
<VL>168</VL>
<NO>4</NO>
<PG>1146-54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500028"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500027"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1997" MODIFIED="2018-01-08 16:53:17 +0000" MODIFIED_BY="Anne Lawson" NAME="Cohen 1997" YEAR="1997">
<REFERENCE MODIFIED="2018-01-08 16:53:02 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AT, Wagner MB, Mohamed MS</AU>
<TI>Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis</TI>
<SO>American Journal of Surgery</SO>
<YR>1997</YR>
<VL>174</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500030"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:53:17 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Das SK, Maher KT, et al</AU>
<TI>Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<NO>8840</NO>
<PG>259-65</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500031"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500029"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2006" MODIFIED="2018-01-08 21:00:23 +0000" MODIFIED_BY="Anne Lawson" NAME="Cohen 2006" YEAR="2006">
<REFERENCE MODIFIED="2018-01-08 21:00:23 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al</AU>
<TI>Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7537</NO>
<PG>325-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500033"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500032"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2007-_x0028_PREVENT_x0029_" MODIFIED="2018-01-08 16:55:52 +0000" MODIFIED_BY="Anne Lawson" NAME="Cohen 2007 (PREVENT)" YEAR="2007">
<REFERENCE MODIFIED="2018-01-08 16:54:52 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al</AU>
<TI>Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7537</NO>
<PG>325-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500035"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:55:26 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AT, Turpie AG, Leizorovicz A, Olsson CG, Vaitkus PT, Goldhaber SZ</AU>
<TI>Thromboprophylaxis with dalteparin in medical patients: which patients benefit?</TI>
<SO>Vascular Medicine</SO>
<YR>2007</YR>
<VL>12</VL>
<NO>2</NO>
<PG>123-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500036"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:55:52 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group</AU>
<TI>Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>110</VL>
<NO>7</NO>
<PG>874-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500037"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500034"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Couban-2005" MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" NAME="Couban 2005" YEAR="2003">
<REFERENCE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Anderson D., Goodyear M., Burnell M., Dolan S., Wasi P., Barnes D., Macleod D., Burton E., Andreou P., &amp; Couban S</AU>
<TI>A randomized double-blind placebo controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer</TI>
<SO>Journal of thrombosis and haemostasis</SO>
<YR>2003</YR>
<PG>Abstract no: P198</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500039"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 16:57:52 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al</AU>
<TI>Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter&#8211;associated thrombosis in patients with cancer</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4063-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500040"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Couban S., Goodyear M, Burnell M., Dolan S., Wasi P., Macleod D, Burton E., Andreou P., Anderson D</AU>
<TI>A randomized double-blind placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>11</NO>
<PG>703</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500041"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500038"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickinson-1998" MODIFIED="2018-01-16 08:54:04 +0000" MODIFIED_BY="[Empty name]" NAME="Dickinson 1998" YEAR="1998">
<REFERENCE MODIFIED="2018-01-16 08:54:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dickinson LD, Miller LD, Patel CP, and Gupta SK</AU>
<TI>Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors</TI>
<SO>Neurosurgery</SO>
<YR>1998</YR>
<VL>43</VL>
<NO>5</NO>
<PG>1074-81</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500043"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500042"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolovich-2004" NAME="Dolovich 2004" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Archives of Internal Medicine. 2000 Jan 24;160(2):181-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G</AU>
<TI>A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>2</NO>
<PG>181-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626245"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626244"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Douketis-2000" NAME="Douketis 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Archives of Internal Medicine. 2000 Dec 11-25;160(22):3431-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS</AU>
<TI>Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>22</NO>
<PG>3431-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626247"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626246"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eikelboom-1998" MODIFIED="2014-05-21 12:56:04 +0100" MODIFIED_BY="Anne Lawson" NAME="Eikelboom 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Eikelboom JW, Baker RI. Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma. American Journal of Hematology. 1998 Nov;59(3):260-1.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eikelboom JW, Baker RI</AU>
<TI>Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma</TI>
<SO>American Journal of Hematology</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>3</NO>
<PG>260-1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626249"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626248"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elly-1969" NAME="Elly 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Elly GL. Heparin therapy for bleeding associated with hemangioma. Surgery. 1969 Jun;65(6):894-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elly GL</AU>
<TI>Heparin therapy for bleeding associated with hemangioma</TI>
<SO>Surgery</SO>
<YR>1969</YR>
<VL>65</VL>
<NO>6</NO>
<PG>894-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626251"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626250"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fiessinger-1996" MODIFIED="2018-01-09 10:28:30 +0000" MODIFIED_BY="Anne Lawson" NAME="Fiessinger 1996" YEAR="1996">
<REFERENCE MODIFIED="2018-01-09 10:28:30 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thrombosis &amp;amp; Haemostasis. 1996 Aug;76(2):195-9.&lt;/p&gt;" NOTES_MODIFIED="2018-01-09 10:28:30 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, et al</AU>
<TI>Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1996</YR>
<VL>76</VL>
<NO>2</NO>
<PG>195-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626253"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626252"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldhaber-2002" MODIFIED="2018-01-08 21:02:30 +0000" MODIFIED_BY="Anne Lawson" NAME="Goldhaber 2002" YEAR="2002">
<REFERENCE MODIFIED="2018-01-08 21:02:30 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM</AU>
<TI>Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis</TI>
<SO>Chest</SO>
<YR>2002</YR>
<VL>122</VL>
<NO>6</NO>
<PG>1933-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500045"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500044"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gould-1999" NAME="Gould 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Annals of Internal Medicine. 1999 May 18;130(10):800-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM</AU>
<TI>Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1999</YR>
<VL>130</VL>
<NO>10</NO>
<PG>800-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626255"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626254"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-1992" NAME="Green 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet. 1992 Jun 13;339(8807):1476.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green D, Hull RD, Brant R, Pineo GF</AU>
<TI>Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>339</VL>
<NO>8807</NO>
<PG>1476</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626257"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626256"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haage-2002" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Haage 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Haage P, Krings T, Schmitz-Rode T. Nontraumatic vascular emergencies: Imaging and intervention in acute occlusion. European Radiology. 2002;12(11):2627-43.&lt;/p&gt;" NOTES_MODIFIED="2014-06-03 09:45:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haage P, Krings T, Schmitz-Rode T</AU>
<TI>Nontraumatic vascular emergencies: imaging and intervention in acute occlusion</TI>
<SO>European Radiology</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>11</NO>
<PG>2627-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626259"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626258"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas-2011" MODIFIED="2018-01-08 22:17:59 +0000" MODIFIED_BY="Anne Lawson" NAME="Haas 2011" YEAR="2011">
<REFERENCE MODIFIED="2018-01-08 17:05:42 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, et al</AU>
<TI>CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2011</YR>
<VL>105</VL>
<NO>6</NO>
<PG>981-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500047"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 22:17:59 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas S, Schellong SM, Tebbe U, Gerlach H-E, Bauersachs R, Abletshauser C, et al</AU>
<TI>CERTIFY: certoparin versus UFH to prevent venous thromboembolic events in the patients with cancer</TI>
<SO>Hämostaseologie</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>1</NO>
<PG>A10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500048"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:07:00 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Haas S, Schellong SM, Tebbe U, Gerlach HE, Bauersachs R, Melzer N, et al</AU>
<TI>Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer-a subgroup analysis of CERTIFY</TI>
<SO>BMC Cancer</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>1</NO>
<PG>1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500049"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500046"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Handeland-1990" NAME="Handeland 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Handeland GF</AU>
<TI>Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1990</YR>
<VL>39</VL>
<NO>2</NO>
<PG>107-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626261"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626260"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harenberg-1990" MODIFIED="2018-01-08 17:07:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Harenberg 1990" YEAR="1990">
<REFERENCE MODIFIED="2018-01-08 17:07:11 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle CE, Mall K, et al. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis. Haemostasis. 1990;20 Suppl 1:205-19.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 17:07:11 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harenberg J, Huck K, Bratsch H, Stehle G, Dempfle CE, Mall K, et al</AU>
<TI>Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis</TI>
<SO>Haemostasis</SO>
<YR>1990</YR>
<VL>20 Suppl 1</VL>
<PG>205-19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626263"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626262"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harenberg-1996" MODIFIED="2018-01-08 17:07:56 +0000" MODIFIED_BY="Anne Lawson" NAME="Harenberg 1996" YEAR="1996">
<REFERENCE MODIFIED="2018-01-08 17:07:27 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Harenberg J, Roebruck P, Heene DL</AU>
<TI>Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients</TI>
<SO>Pathophysiology of Haemostasis and Thrombosis</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>3</NO>
<PG>127-39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500051"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:07:56 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harenberg J, Roebruck P, Stehle G, Habscheid W, Biegholdt M, Heene DL</AU>
<TI>Heparin Study in Internal Medicine (HESIM): design and preliminary results</TI>
<SO>Thrombosis Research</SO>
<YR>1992</YR>
<VL>68</VL>
<NO>1</NO>
<PG>33-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500052"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500050"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harenberg--2000" MODIFIED="2011-01-04 12:14:46 +0000" MODIFIED_BY="[Empty name]" NAME="Harenberg  2000" YEAR="2000">
<REFERENCE MODIFIED="2011-01-04 12:14:46 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thrombosis &amp;amp; Haemostasis. 2000 May;83(5):652-6.&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 12:14:46 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Buller HR</AU>
<TI>Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2000</YR>
<VL>83</VL>
<NO>5</NO>
<PG>652-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626265"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626264"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hata-2016" MODIFIED="2018-01-08 17:08:36 +0000" MODIFIED_BY="Anne Lawson" NAME="Hata 2016" YEAR="2016">
<REFERENCE MODIFIED="2018-01-08 17:08:36 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hata K, Kimura T, Tsuzuki S, Ishii G, Kido M, Yamamoto T, et al</AU>
<TI>Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: a prospective randomized clinical trial</TI>
<SO>International Journal of Urology</SO>
<YR>2016</YR>
<VL>23</VL>
<NO>11</NO>
<PG>923-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500054"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500053"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hettiarachchi-1998" NAME="Hettiarachchi 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Hettiarachchi RJ, Prins MH, Lensing AW, Buller HR. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism.[see comment]. Current Opinion in Pulmonary Medicine. 1998 Jul;4(4):220-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hettiarachchi RJ, Prins MH, Lensing AW, Buller HR</AU>
<TI>Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism</TI>
<SO>Current Opinion in Pulmonary Medicine</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>4</NO>
<PG>220-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626267"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626266"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holm-1986" MODIFIED="2018-01-08 17:08:48 +0000" MODIFIED_BY="Anne Lawson" NAME="Holm 1986" YEAR="1986">
<REFERENCE MODIFIED="2018-01-08 17:08:48 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis. 1986;16 Suppl 2:30-7.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 17:08:48 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holm HA, Ly B, Handeland GF, Abildgaard U, Arnesen KE, Gottschalk P, et al</AU>
<TI>Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin</TI>
<SO>Haemostasis</SO>
<YR>1986</YR>
<VL>16 Suppl 2</VL>
<PG>30-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626269"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626268"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holmstrom-1999" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Holmstrom 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NOTES="&lt;p&gt;Holmstrom M, Aberg W, Lockner D, Paul C. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: A retrospective analysis. Thrombosis &amp;amp; Haemostasis. 1222;82(4):1222-6.&lt;/p&gt;" NOTES_MODIFIED="2014-06-03 09:45:04 +0100" NOTES_MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holmstrom M, Aberg W, Lockner D, Paul C</AU>
<TI>Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1999</YR>
<VL>82</VL>
<NO>4</NO>
<PG>1222-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626271"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626270"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2000" MODIFIED="2018-01-08 17:09:01 +0000" MODIFIED_BY="Anne Lawson" NAME="Hull 2000" YEAR="2000">
<REFERENCE MODIFIED="2018-01-08 17:09:01 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.[see comment]. Archives of Internal Medicine. 2000 Jan 24;160(2):229-36.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 17:09:01 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Raskob GE, Brant RF, Pineo GF, Elliott G, Stein PD, et al</AU>
<TI>Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>2</NO>
<PG>229-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626273"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626272"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hull-2006" MODIFIED="2018-01-08 17:09:12 +0000" MODIFIED_BY="Anne Lawson" NAME="Hull 2006" YEAR="2006">
<REFERENCE MODIFIED="2018-01-08 17:09:12 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al; LITE Trial Investigators</AU>
<TI>Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer</TI>
<SO>American Journal of Medicine</SO>
<YR>2006</YR>
<VL>119</VL>
<NO>12</NO>
<PG>1062-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626275"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626274"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jahanzeb-2005" MODIFIED="2011-01-04 11:51:59 +0000" MODIFIED_BY="[Empty name]" NAME="Jahanzeb 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-01-04 11:51:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jahanzeb M, Jahanzeb M</AU>
<TI>Management of deep vein thrombosis in cancer patients</TI>
<SO>Journal of the Nation Comprehensive Cancer Network</SO>
<YR>2005</YR>
<VL>3 Suppl 1</VL>
<PG>50-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626277"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626276"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-2010-_x0028_CANBESURE_x0029_" MODIFIED="2018-01-08 17:10:26 +0000" MODIFIED_BY="Anne Lawson" NAME="Kakkar 2010 (CANBESURE)" YEAR="2010">
<REFERENCE MODIFIED="2018-01-08 17:10:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Balibrea J, Martinez-Gonzalez J, Prandoni P</AU>
<TI>Late breaking clinical trial: a randomised double blind trial to evaluate the efficacy and safety of prolonging the thromboprophylaxis with bemiparin in patients undergoing cancer abdominal or pelvic surgery (the CANBESURE study)</TI>
<SO>International Society on Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>1202</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500056"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:10:26 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P</AU>
<TI>Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2010</YR>
<VL>8</VL>
<NO>6</NO>
<PG>1223-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500057"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500055"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-2014-_x0028_SAVE_x002d_ABDO_x0029_" MODIFIED="2018-01-09 10:29:03 +0000" MODIFIED_BY="Anne Lawson" NAME="Kakkar 2014 (SAVE-ABDO)" YEAR="2014">
<REFERENCE MODIFIED="2018-01-08 17:11:07 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar AK, Agnelli G, Fisher W, George D, Lassen MR, Mismetti P, et al; SAVE-ABDO Investigators</AU>
<TI>Preoperative enoxaparin versus postoperative semuloparin thromboprophylaxis in major abdominal surgery: a randomized controlled trial</TI>
<SO>Annals of Surgery</SO>
<YR>2014</YR>
<VL>259</VL>
<NO>6</NO>
<PG>1073-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500059"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-09 10:29:03 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar AK, Agnelli G, Fisher WD, George D, Mouret P, Lassen MR, et al</AU>
<TI>The ultra-low-molecular-weight heparin semuloparin for prevention of venous thromboembolism in patients undergoing major abdominal surgery</TI>
<SO>Blood</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>21</NO>
<PG>188</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500060"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500058"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khorana-2017-_x0028_PHACS_x0029_" MODIFIED="2018-01-08 17:12:43 +0000" MODIFIED_BY="Anne Lawson" NAME="Khorana 2017 (PHACS)" YEAR="2015">
<REFERENCE MODIFIED="2018-01-08 17:12:08 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T, et al</AU>
<TI>Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial</TI>
<SO>Blood</SO>
<YR>2015</YR>
<VL>126</VL>
<NO>23</NO>
<PG>427</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500062"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:12:43 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="UNPUBLISHED">
<AU>Khorana AA, Francis CW, Kuderer N, Carrier M, Ortel TL, Wun T, et al</AU>
<TI>Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial</TI>
<SO>Thrombosis Research</SO>
<YR>2017</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500063"/><IDENTIFIER TYPE="DOI" VALUE="http://dx.doi.org/10.1016/j.thromres.2017.01.009"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500061"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koppenhagen-1992" MODIFIED="2018-01-08 17:12:58 +0000" MODIFIED_BY="Anne Lawson" NAME="Koppenhagen 1992" YEAR="1992">
<REFERENCE MODIFIED="2018-01-08 17:12:58 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koppenhagen K, Adolf J, Matthes M, Tröster E, Roder JD, Hass S, et al</AU>
<TI>Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>6</NO>
<PG>627-30</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500065"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500064"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larocca-2012" MODIFIED="2018-01-08 17:13:05 +0000" MODIFIED_BY="Anne Lawson" NAME="Larocca 2012" YEAR="2012">
<REFERENCE MODIFIED="2018-01-08 17:13:05 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larocca A, Cavallo F, Bringhen S, Raimondo FD, Falanga A, Evangelista A, et al</AU>
<TI>Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide</TI>
<SO>Blood</SO>
<YR>2012</YR>
<VL>119</VL>
<PG>933-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500067"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500066"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2015-_x0028_CATCH_x0029_" MODIFIED="2018-01-09 10:29:38 +0000" MODIFIED_BY="Anne Lawson" NAME="Lee 2015 (CATCH)" YEAR="2013">
<REFERENCE MODIFIED="2018-01-08 17:13:28 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauersachs R, Lee AYY, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, et al</AU>
<TI>Long-term tinzaparin versus warfarin for treatment of venous thromboembolism (VTE) in cancer patients - analysis of renal impairment (RI) in the catch study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2015</YR>
<VL>13</VL>
<PG>76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500069"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:13:44 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bauersachs R</AU>
<TI>Catch-a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients</TI>
<SO>Hematology Reports</SO>
<YR>2011</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>13</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500070"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:14:04 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al</AU>
<TI>Characteristics and risk factors of major and clinically relevant non-major bleeding in cancer patients receiving anticoagulant treatment for acute venous thromboembolism-the CATCH study</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2015</YR>
<VL>13</VL>
<PG>182-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500071"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:14:20 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khorana AA, Bauersachs R, Kamphuisen PW, Meyer G, Janas MS, Jarner MF, et al</AU>
<TI>Clinical predictors of recurrent venous thromboembolism (VTE) in cancer patients from a randomized trial of long-term tinzaparin versus warfarin for treatment: the CATCH study</TI>
<SO>Journal of Clinical Oncology Conference</SO>
<YR>2015</YR>
<VL>33</VL>
<NO>15 Suppl</NO>
<PG>9621</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500072"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, Khorana AA</AU>
<TI>CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients</TI>
<SO>BMC cancer</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>284</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500073"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:14:27 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al</AU>
<TI>CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. PROTOCOL</TI>
<SO>BMC Cancer</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>1</NO>
<PG>284</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500074"/><IDENTIFIER TYPE="OTHER" VALUE="NCT01130025"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-09 10:29:38 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, et al</AU>
<TI>CATCH: a randomized trial comparing tinzaparin versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients. ASCO Annual Meeting</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2012</YR>
<VL>Suppl</VL>
<PG>TPS9149</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500075"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:15:03 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF</AU>
<TI>Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial</TI>
<SO>JAMA</SO>
<YR>2015</YR>
<VL>314</VL>
<PG>677</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500076"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:15:34 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al</AU>
<TI>A randomized trial of long-term tinzaparin, a low molecular weight heparin (LMWH), versus warfarin for treatment of acute venous thromboembolism (VTE) in cancer patients - the CATCH study</TI>
<SO>Blood</SO>
<YR>2014</YR>
<VL>124</VL>
<PG>21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500077"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500068"/><IDENTIFIER TYPE="CTG" VALUE="NCT01130025"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leizorovicz-1994" NAME="Leizorovicz 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leizorovicz A, Simonneau G, Decousus H, Boissel JP</AU>
<TI>Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6950</NO>
<PG>299-304</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626279"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626278"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2001" MODIFIED="2011-01-04 11:52:41 +0000" MODIFIED_BY="[Empty name]" NAME="Levine 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-01-04 11:52:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Levine MN. Management of thromboembolic disease in cancer patients. Haemostasis. 2001;31 Suppl 1:68-9.&lt;/p&gt;" NOTES_MODIFIED="2011-01-04 11:52:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine MN</AU>
<TI>Management of thromboembolic disease in cancer patients</TI>
<SO>Haemostasis</SO>
<YR>2001</YR>
<VL>31 Suppl 1</VL>
<PG>68-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626281"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626280"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luomanmaki-1996" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Luomanmaki 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loumanmaki K, Grankvist S, Hallert C, Jauro I, Ketola K, Kim HC</AU>
<TI>A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1996</YR>
<VL>240</VL>
<NO>2</NO>
<PG>85-92</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626283"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626282"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Macbeth-2016-_x0028_FRAGMATIC_x0029_" MODIFIED="2018-01-08 17:18:35 +0000" MODIFIED_BY="Anne Lawson" NAME="Macbeth 2016 (FRAGMATIC)" YEAR="2016">
<REFERENCE MODIFIED="2018-01-08 17:16:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS</AU>
<TI>FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer</TI>
<SO>BMC Cancer</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500079"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:16:50 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, et al</AU>
<TI>Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2016</YR>
<VL>34</VL>
<NO>5</NO>
<PG>488-94</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500080"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:18:17 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Macbeth F, Noble S, Griffiths G, Chowdhury R, Rolfe C, Hood K, et al</AU>
<TI>Preliminary results from the Fragmatic Trial: a randomised phase III clinical trial investigating the effect of Fragmin (R) added to standard therapy in patients with lung cancer</TI>
<SO>Journal of Thoracic Oncology</SO>
<YR>2013</YR>
<VL>8</VL>
<PG>S243</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500081"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:18:35 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Noble S, Robbins A, Alikhan R, Hood K, Macbeth F</AU>
<TI>Prediction of venous thromboembolism in lung cancer patients receiving chemotherapy</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2015</YR>
<VL>13</VL>
<PG>143</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500082"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin_x002d_Carbonero-2002" MODIFIED="2014-05-19 21:18:16 +0100" MODIFIED_BY="Anne Lawson" NAME="Martin-Carbonero 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;Martin-Carbonero L, Salgado X, Pedrajas JM, Armengol JG, Jimenez Rodriguez-Madridejos R, Fernandez-Cruz A. [Short-term and long-term evolution of deep vein thrombosis treated by a health care unit]. Revista Clinica Espanola. 2002 Aug;202(8):430-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin-Carbonero L, Salgado X, Pedrajas JM, Armengol JG, Jimenez Rodriguez-Madridejos R, Fernandez-Cruz A</AU>
<TI>Short-term and long-term evolution of deep vein thrombosis treated by a health care unit</TI>
<SO>Revista Clinica Espanola</SO>
<YR>2002</YR>
<VL>202</VL>
<NO>8</NO>
<PG>430-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626285"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626284"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maxwell-2001" MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" NAME="Maxwell 2001" YEAR="2001">
<REFERENCE MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL</AU>
<TI>Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial</TI>
<SO>American College of Obstetricians and Gynecologists</SO>
<YR>2001</YR>
<VL>98</VL>
<NO>6</NO>
<PG>989-95</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500084"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500083"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazilu-2014-_x0028_OVIDIUS_x0029_" MODIFIED="2018-01-08 21:08:09 +0000" MODIFIED_BY="Anne Lawson" NAME="Mazilu 2014 (OVIDIUS)" YEAR="2014">
<REFERENCE MODIFIED="2018-01-08 21:08:09 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazilu L, Parepa IR, Suceveanu AI, Suceveanu A, Baz R, Catrinoiu D</AU>
<TI>Venous thromboembolism: secondary prevention with dabigatran vs. acenocumarol in patients with paraneoplastic deep vein thrombosis. Results from a small prospective study in Romania</TI>
<SO>Cardiovascular Research</SO>
<YR>2014</YR>
<VL>103</VL>
<NO>Suppl 1</NO>
<PG>S39</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500086"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500085"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menzoian-1983" MODIFIED="2018-01-08 17:19:30 +0000" MODIFIED_BY="Anne Lawson" NAME="Menzoian 1983" YEAR="1983">
<REFERENCE MODIFIED="2018-01-08 17:19:30 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Menzoian JO, Sequeira JC, Doyle JE, et al. Therapeutic and clinical course of deep vein thrombosis. American Journal of Surgery. 1983;146(5):581-5.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 17:19:30 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menzoian JO, Sequeira JC, Doyle JE, Cantelmo NL, Nowak M, Tracey K, et al</AU>
<TI>Therapeutic and clinical course of deep vein thrombosis</TI>
<SO>American Journal of Surgery</SO>
<YR>1983</YR>
<VL>146</VL>
<NO>5</NO>
<PG>581-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626287"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626286"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murakami-2002" MODIFIED="2018-01-08 17:20:05 +0000" MODIFIED_BY="Anne Lawson" NAME="Murakami 2002" YEAR="2002">
<REFERENCE MODIFIED="2018-01-08 17:20:05 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murakami M, Wiley LA, Cindrick-Pounds L, Hunter GC, Uchida T, Killewich LA</AU>
<TI>External pneumatic compression does not increase urokinase plasminogen activator after abdominal surgery</TI>
<SO>Journal of Vascular Surgery</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>5</NO>
<PG>917-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500088"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500087"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagata-2015" MODIFIED="2018-01-08 17:20:18 +0000" MODIFIED_BY="Anne Lawson" NAME="Nagata 2015" YEAR="2015">
<REFERENCE MODIFIED="2018-01-08 17:20:18 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagata C, Tanabe H, Takakura S, Narui C, Saito M, Yanaihara N, et al</AU>
<TI>Randomized controlled trial of enoxaparin versus intermittent pneumatic compression for venous thromboembolism prevention in Japanese surgical patients with gynecologic malignancy</TI>
<SO>Journal of Obstetrics and Gynaecology Research</SO>
<YR>2015</YR>
<VL>41</VL>
<NO>9</NO>
<PG>1440-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500090"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500089"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naschitz-1994" NAME="Naschitz 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naschitz JE</AU>
<TI>Thromboembolism in cancer: changing trends</TI>
<SO>Radiology</SO>
<YR>1994</YR>
<VL>19</VL>
<PG>2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626289"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626288"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nurmohamed-1996" MODIFIED="2018-01-22 10:22:29 +0000" MODIFIED_BY="Gail Quinn" NAME="Nurmohamed 1996" YEAR="1996">
<REFERENCE MODIFIED="2018-01-22 10:22:29 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, et al</AU>
<TI>Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery</TI>
<SO>Thrombosis Haemostasis</SO>
<YR>1996</YR>
<VL>75</VL>
<PG>233-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500092"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500091"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palumbo-2011" MODIFIED="2018-01-08 22:20:21 +0000" MODIFIED_BY="Anne Lawson" NAME="Palumbo 2011" YEAR="2011">
<REFERENCE MODIFIED="2018-01-08 17:21:39 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavo M, Palumbo A, Bringhen S, Di Raimondo F, Patriarca F, Rossi D, et al</AU>
<TI>Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated upfront with thalidomide-containing regimens</TI>
<SO>Haematologica</SO>
<YR>2010</YR>
<VL>95</VL>
<PG>391</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500094"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:21:56 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, et al</AU>
<TI>A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens</TI>
<SO>Blood</SO>
<YR>2008</YR>
<VL>112</VL>
<NO>11</NO>
<PG>3017</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500095"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:23:10 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cavo M, Palumbo A, Bringhen S, Falcone A, Musto P, Ciceri F, et al</AU>
<TI>A phase III study of enoxaparin versus low-dose warfarin versus aspirin as thromboprophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide-containing regimens</TI>
<SO>Haematologica</SO>
<YR>2009</YR>
<VL>94</VL>
<PG>s4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500096"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 22:20:21 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Magarotto V, Brioli A, Patriarca F, Rossi D, Petrucci MT, Nozzoli C, et al</AU>
<TI>Enoxaparin, aspirin, or warfarin for the thromboprophylaxis in newly diagnosed myeloma patients receiving thalidomide: a randomized controlled trial</TI>
<SO>XI Congress of the Italian Society of Experimental Hematology</SO>
<YR>2010</YR>
<VL>95</VL>
<PG>S1-S162</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500097"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:23:36 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palumbo A, Cavo M, Bringhen S, Zaccaria A, Spadano A, Palmieri S, et al</AU>
<TI>Enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens: a randomized, controlled trial [Abstract No. 0910]</TI>
<SO>Haematologica</SO>
<YR>2008</YR>
<VL>93</VL>
<PG>362</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500098"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 22:16:29 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al</AU>
<TI>Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2011</YR>
<VL>29</VL>
<PG>986-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500099"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500093"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pelzer-2015-_x0028_CONKO_x002d_004_x0029_" MODIFIED="2018-01-16 09:14:21 +0000" MODIFIED_BY="[Empty name]" NAME="Pelzer 2015 (CONKO-004)" YEAR="2009">
<REFERENCE MODIFIED="2018-01-16 09:14:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, Hahnfeld S, Müller J., Stieler B., and Dörken H</AU>
<TI>A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy - first results of the CONKO 004 trial</TI>
<SO>Onkologie - DGHO meeting</SO>
<YR>October 2009</YR>
<VL>580</VL>
<PG>Abstract</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500101"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:25:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelzer U, Hilbig A, Stieler J, Roll L, Riess H, Dorken B, et al</AU>
<TI>A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT - CONKO 004)</TI>
<SO>Onkologie</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>Suppl 3</NO>
<PG>54</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500102"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:25:28 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelzer U, Hilbig A, Stieler J, Roll L, Stauch M, Opitz B, et al</AU>
<TI>A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT-CONKO 004)</TI>
<SO>ASCO Annual Meeting Proceedings</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>18</NO>
<PG>4110</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500103"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:25:39 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pelzer U, Hilbig A, Stieler JM, Bahra M, Sinn M, Gebauer B, et al</AU>
<TI>Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial</TI>
<SO>BMC cancer</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500104"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:26:15 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pelzer U, Oettle H, Stauch M, Opitz B, Stieler J, Scholten T, et al</AU>
<TI>Prospective, randomized open trial of enoxaparin in patients with advanced pancreatic cancer undergoing first-line chemotherapy</TI>
<SO>XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 July 6-12; Geneva, Switzerland</SO>
<YR>2007</YR>
<PG>P-T-488</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500105"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:27:25 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al</AU>
<TI>Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2015</YR>
<VL>33</VL>
<NO>18</NO>
<PG>2028-34</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500106"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:27:42 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riess H, Pelzer U, Deutschinoff G, Opitz B, Stauch M, Reitzig P, et al</AU>
<TI>A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): results of the CONKO 004 trial</TI>
<SO>ASCO Annual Meeting Proceedings</SO>
<YR>2009</YR>
<VL>27</VL>
<NO>18S</NO>
<PG>LBA4506</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500107"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-09 10:30:44 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riess H, Pelzer U, Hilbig A, Stieler J, Opitz B, Scholten T, et al</AU>
<TI>Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy</TI>
<SO>BMC Cancer</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>361</PG>
<CY>NOTE: WE USED THIS PROTOCOL TO VERIFY THE RESULTS SECTION</CY>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500108"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:28:22 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riess H, Pelzer U, Opitz B, Stauch M, Reitzig P, Hahnfeld S, et al</AU>
<TI>A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial</TI>
<SO>Journal of Clinical Oncology Conference</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>15 Suppl</NO>
<PG>4033</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500109"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 17:28:44 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riess HB, Pelzer U, Opitz B, Hilbig A, Strauch M, Hahnfeld S, et al</AU>
<TI>Late breaking clinical trial: a prospective, randomized trial of chemotherapy with and without the low molecular weight heparin (LMWH) enoxaparin in advanced pancreatic cancer patients</TI>
<SO>International Society on Thrombosis and Haemostasis</SO>
<YR>2009</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>1-1204</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500110"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500100"/><IDENTIFIER TYPE="ISRCTN" VALUE="02140505"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prandoni-1988" MODIFIED="2018-01-08 17:28:51 +0000" MODIFIED_BY="Anne Lawson" NAME="Prandoni 1988" YEAR="1988">
<REFERENCE MODIFIED="2018-01-08 17:28:51 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Vigo M, Tropeano PF, Carletti E, Corbetti F, Antonello G, et al</AU>
<TI>Treatment of venous thromboembolic disease using low molecular weight CY216 heparin in patients with high risk of hemorrhage</TI>
<SO>Annali Italiani di Medicina Interna</SO>
<YR>1988</YR>
<VL>3</VL>
<NO>3</NO>
<PG>213-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626291"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626290"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prandoni-1990" MODIFIED="2011-01-04 11:53:43 +0000" MODIFIED_BY="[Empty name]" NAME="Prandoni 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-01-04 11:53:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Vigo M, Cattelan AM, Ruol A</AU>
<TI>Treatment of deep venous thrombosis by fixed doses of a low-molecular-weight heparin (CY216)</TI>
<SO>Haemostasis</SO>
<YR>1990</YR>
<VL>20 Suppl 1</VL>
<PG>220-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626293"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626292"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prandoni-2005" NAME="Prandoni 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood. 2005 Dec 15;106(13):4027-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P</AU>
<TI>How I treat venous thromboembolism in patients with cancer</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>13</NO>
<PG>4027-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626295"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626294"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prins-2014-_x0028_EINSTEIN_x0029_" MODIFIED="2018-01-08 21:09:16 +0000" MODIFIED_BY="Anne Lawson" NAME="Prins 2014 (EINSTEIN)" YEAR="2014">
<REFERENCE MODIFIED="2018-01-08 21:09:16 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al</AU>
<TI>Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials</TI>
<SO>Lancet Haematology</SO>
<YR>2014</YR>
<VL>1</VL>
<NO>1</NO>
<PG>e37-e46</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500112"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500111"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raskob-2016-_x0028_HOKUSAI_x0029_" MODIFIED="2018-01-08 21:09:23 +0000" MODIFIED_BY="Anne Lawson" NAME="Raskob 2016 (HOKUSAI)" YEAR="2016">
<REFERENCE MODIFIED="2018-01-08 21:09:23 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, et al</AU>
<TI>Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial</TI>
<SO>Lancet Haematology</SO>
<YR>2016</YR>
<VL>3</VL>
<NO>8</NO>
<PG>e379-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500114"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500113"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riess-2003" MODIFIED="2018-01-08 17:30:28 +0000" MODIFIED_BY="Anne Lawson" NAME="Riess 2003" YEAR="2003">
<REFERENCE MODIFIED="2018-01-08 17:30:28 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, et al. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.[see comment]. Thrombosis &amp;amp; Haemostasis. 2003 Aug;90(2):252-9.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 17:30:28 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, et al</AU>
<TI>Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>90</VL>
<NO>2</NO>
<PG>252-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626297"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626296"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakon-2010" MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" NAME="Sakon 2010" YEAR="2010">
<REFERENCE MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakon M, Kobayashi T, Shimazui T</AU>
<TI>Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study</TI>
<SO>Thrombosis Research</SO>
<YR>2010</YR>
<VL>125</VL>
<NO>3</NO>
<PG>e65-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500116"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500115"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sakuragi-2003" MODIFIED="2018-01-08 17:30:56 +0000" MODIFIED_BY="Anne Lawson" NAME="Sakuragi 2003" YEAR="2003">
<REFERENCE MODIFIED="2018-01-08 17:30:56 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Sakuragi T, Sakao Y, Furukawa K, Rititake K, Ohtsubo S, Okazaki Y, et al. Successful management of acute pulmonary embolism after surgery for lung cancer. European Journal Of Cardio-Thoracic Surgery. 2003 Oct;24(4):580-7.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 17:30:56 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sakuragi T, Sakao Y, Furukawa K, Rititake K, Ohtsubo S, Okazaki Y, et al</AU>
<TI>Successful management of acute pulmonary embolism after surgery for lung cancer</TI>
<SO>European Journal of Cardio-thoracic Surgery</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>4</NO>
<PG>580-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626299"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626298"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-2003" MODIFIED="2018-01-08 17:31:02 +0000" MODIFIED_BY="Anne Lawson" NAME="Schulman 2003" YEAR="2003">
<REFERENCE MODIFIED="2018-01-08 17:31:02 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H, Investigators TI, et al</AU>
<TI>Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>18</NO>
<PG>1713-21</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500118"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500117"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-2013-_x0028_RE_x002d_MEDY_x0029_" MODIFIED="2018-01-08 21:10:02 +0000" MODIFIED_BY="Anne Lawson" NAME="Schulman 2013 (RE-MEDY)" YEAR="2013">
<REFERENCE MODIFIED="2018-01-08 21:10:02 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al</AU>
<TI>Extended use of dabigatran, warfarin, or placebo in venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>2013</YR>
<VL>368</VL>
<NO>8</NO>
<PG>709-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500120"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500119"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulman-2015-_x0028_RECOVER_x0029_" MODIFIED="2018-01-08 21:10:13 +0000" MODIFIED_BY="Anne Lawson" NAME="Schulman 2015 (RECOVER)" YEAR="2015">
<REFERENCE MODIFIED="2018-01-08 21:10:13 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulman S, Goldhaber SZ, Kearon C, Kakkar AK, Schellong S, Eriksson H, et al</AU>
<TI>Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>2015</YR>
<VL>114</VL>
<NO>1</NO>
<PG>150-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500122"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500121"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siragusa-2005" MODIFIED="2018-01-08 18:05:34 +0000" MODIFIED_BY="Anne Lawson" NAME="Siragusa 2005" YEAR="2005">
<REFERENCE MODIFIED="2018-01-08 18:05:34 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siragusa S, Arcara C, Malato A, Anastasio R, Valerio MR, Fulfaro F, et al</AU>
<TI>Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16 Suppl 4</VL>
<PG>136-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626301"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626300"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2014" MODIFIED="2018-01-08 21:10:25 +0000" MODIFIED_BY="Anne Lawson" NAME="Song 2014" YEAR="2014">
<REFERENCE MODIFIED="2018-01-08 21:10:25 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song KY, Yoo HM, Kim EY, Kim JI, Yim HW, Jeon HM, et al</AU>
<TI>Optimal prophylactic method of venous thromboembolism for gastrectomy in Korean patients: an interim analysis of prospective randomized trial</TI>
<SO>Annals of Surgical Oncology</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>13</NO>
<PG>4232-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500124"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500123"/><IDENTIFIER TYPE="CTG" VALUE="NCT01448746"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turchetti-2003" MODIFIED="2018-01-08 18:06:21 +0000" MODIFIED_BY="Anne Lawson" NAME="Turchetti 2003" YEAR="2003">
<REFERENCE MODIFIED="2018-01-08 18:06:21 +0000" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Turchetti V, Bellini MA, Richichi MG, Boschi L, Postorino G, Naddeo S, et al. Venous thrombosis in the elderly: Pathogenesis, diagnosis, treatment and follow-up. [Italian]. Giornale di Gerontologia. 2003;51(4):212-8.&lt;/p&gt;" NOTES_MODIFIED="2018-01-08 18:06:21 +0000" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turchetti V, Bellini MA, Richichi MG, Boschi L, Postorino G, Naddeo S, et al</AU>
<TI>Venous thrombosis in the elderly: pathogenesis, diagnosis, treatment and follow-up</TI>
<SO>Giornale di Gerontologia</SO>
<YR>2003</YR>
<VL>51</VL>
<NO>4</NO>
<PG>212-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626303"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626302"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vadhan_x002d_Raj-2013" MODIFIED="2018-01-08 18:06:51 +0000" MODIFIED_BY="Anne Lawson" NAME="Vadhan-Raj 2013" YEAR="2013">
<REFERENCE MODIFIED="2018-01-08 18:06:51 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vadhan-Raj S, Zhou X, Varadhachary GR, Milind J, Fogelman D, Shroff R, et al</AU>
<TI>Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE</TI>
<SO>Blood</SO>
<YR>2013</YR>
<VL>122</VL>
<NO>21</NO>
<PG>580</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500126"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500125"/><IDENTIFIER TYPE="CTG" VALUE="NCT00966277"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vedovati-2014" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NAME="Vedovati 2014" YEAR="2014">
<REFERENCE MODIFIED="2018-01-08 18:07:25 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becattini C, Rondelli F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al</AU>
<TI>Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer</TI>
<SO>Haematologica</SO>
<YR>2015</YR>
<VL>100</VL>
<NO>1</NO>
<PG>e35-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500128"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becattini C, Rondelli F, Vedovati MC, Camporese G, Giustozzi M, Boncompagni M, et al</AU>
<TI>Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer</TI>
<SO>Haematologica</SO>
<YR>2015</YR>
<VL>100</VL>
<PG>e35-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500129"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 22:22:39 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Becattini C, Vedovati MC, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al</AU>
<TI>One week vs. four week heparin prophylaxis after laparoscopic surgery for colorectal cancer. The Pro-lapspilot feasibility study</TI>
<SO>International Society on Thrombosis and Haemostasis</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>Suppl 3</NO>
<PG>ATT05</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500130"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 18:30:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al</AU>
<TI>A randomized study on 1 vs. 4 weeks prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2013</YR>
<VL>11</VL>
<PG>214</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500131"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 18:29:47 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vedovati MC, Becattini C, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al</AU>
<TI>A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer</TI>
<SO>Annals of Surgery</SO>
<YR>2014</YR>
<VL>259</VL>
<NO>4</NO>
<PG>665-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500132"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500127"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verso-2008" MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" NAME="Verso 2008" YEAR="2008">
<REFERENCE MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Agnelli G, Verso M, Bertoglio S, Ageno W, Bazzan M, Parise P, et al</AU>
<TI>A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>734S</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500134"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2017-09-12 06:04:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al</AU>
<TI>Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>18</NO>
<PG>4057-62</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500135"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 18:31:14 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Verso M, Agnelli G, Kamphuisen PW, Ageno W, Bazzan M, Lazzaro A, et al</AU>
<TI>Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients</TI>
<SO>Internal and Emergency Medicine</SO>
<YR>2008</YR>
<VL>3</VL>
<NO>2</NO>
<PG>117-22</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500136"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Verso M., Agnelli G., Bertoglio S., Di Somma C., Paoletti F., Ageno W., Bazzan M., Parise P., Quintavalla R., Naglieri E., Santoro A., Imberti D. and Sorarù M</AU>
<TI>A double-blind placebo-controlled randomized study on the efficacy and safety of enoxaparin for the prevention of upper limb deep vein thrombosis in cancer patients with central vein catheter</TI>
<SO>2003</SO>
<YR>Journal of thrombosis and haemostasis</YR>
<VL>1</VL>
<PG>P0825</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500137"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500133"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ward-1998" MODIFIED="2018-01-16 09:18:41 +0000" MODIFIED_BY="[Empty name]" NAME="Ward 1998" YEAR="1998">
<REFERENCE MODIFIED="2018-01-16 09:18:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ward B, Pradhan S</AU>
<TI>Comparison of low molecular weight heparin (Fragmin) with sodium heparin for prophylaxis against postoperative thrombosis in women undergoing major gynaecological surgery</TI>
<SO>Australian and New Zealand Journal of Obstetrics and Gynaecology</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>1</NO>
<PG>91-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500139"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500138"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warkentin-1995" NAME="Warkentin 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warkentin T</AU>
<TI>Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>332</VL>
<PG>1330-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626305"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626304"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wester-1996" MODIFIED="2018-01-08 18:41:22 +0000" MODIFIED_BY="Anne Lawson" NAME="Wester 1996" YEAR="1996">
<REFERENCE MODIFIED="2018-01-08 18:39:54 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wester JP, de Valk HW, Nieuwenhuis HK, Brouwer CB, van der Graaf Y, Meuwissen OJ, et al</AU>
<TI>Risk factors for bleeding during treatment of acute venous thromboembolism</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1996</YR>
<VL>76</VL>
<NO>5</NO>
<PG>682-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500141"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 18:41:22 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, et al</AU>
<TI>Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism: a randomized controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1995</YR>
<VL>123</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500142"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500140"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-2003" NAME="Wong 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Wong JEL. Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE. Cancer Treatment Reviews. 2003 Jun;29:11-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong JEL</AU>
<TI>Are patients with cancer receiving adequate treatment for thrombosis? Results from FRONTLINE</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2003</YR>
<VL>29</VL>
<PG>11-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2626307"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2626306"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2014" MODIFIED="2018-01-08 18:44:13 +0000" MODIFIED_BY="Anne Lawson" NAME="Zheng 2014" YEAR="2014">
<REFERENCE MODIFIED="2018-01-08 18:44:13 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng H, Gao Y, Yan X, Gao M, Gao W</AU>
<TI>Prophylactic use of low molecular weight heparin in combination with graduated compression stockings in post-operative patients with gynecologic cancer</TI>
<SO>Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]</SO>
<YR>2014</YR>
<VL>36</VL>
<NO>1</NO>
<PG>39-42</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500144"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500143"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zwicker-2013-_x0028_MICRO-TEC_x0029_" MODIFIED="2018-01-08 21:11:26 +0000" MODIFIED_BY="Anne Lawson" NAME="Zwicker 2013 (MICRO TEC)" YEAR="2013">
<REFERENCE MODIFIED="2018-01-08 21:11:26 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zwicker J, Liebman HA, Bauer KA, Caughey T, Rosovsky R, Mantha S, et al</AU>
<TI>A randomized-controlled phase II trial of primary thromboprophylaxis with enoxaparin in cancer patients with elevated tissue factor bearing microparticles (the Microtec study)</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2013</YR>
<VL>11</VL>
<PG>6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500146"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2018-01-08 21:11:13 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, et al</AU>
<TI>Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor&#8208;bearing microparticles: a randomized-controlled phase II trial (the Microtec study)</TI>
<SO>British Journal of Haematology</SO>
<YR>2013</YR>
<VL>160</VL>
<NO>4</NO>
<PG>530-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="7500147"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="7500145"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-16 14:42:19 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2017-09-26 09:08:23 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2018-01-22 10:12:42 +0000" MODIFIED_BY="Gail Quinn">
<ADDITIONAL_REFERENCES MODIFIED="2018-01-22 10:12:42 +0000" MODIFIED_BY="Gail Quinn">
<REFERENCE ID="REF-Akl-2013" MODIFIED="2018-01-08 18:48:14 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2013" TYPE="JOURNAL_ARTICLE">
<AU>Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al</AU>
<TI>Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers</TI>
<SO>PloS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e57132</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akl-2016" MODIFIED="2018-01-08 18:48:23 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2016" TYPE="JOURNAL_ARTICLE">
<AU>Akl EA, Kahale LA, Ebrahim S, Alonso-Coello P, Schünemann HJ, Guyatt GH</AU>
<TI>Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2016</YR>
<VL>76</VL>
<PG>147-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alshurafa-2012" MODIFIED="2018-01-08 18:48:34 +0000" MODIFIED_BY="Anne Lawson" NAME="Alshurafa 2012" TYPE="JOURNAL_ARTICLE">
<AU>Alshurafa M, Briel M, Akl EA, Haines T, Moayyedi P, Gentles SJ, et al</AU>
<TI>Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature</TI>
<SO>PloS One</SO>
<YR>2012</YR>
<VL>7</VL>
<NO>11</NO>
<PG>e49163</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2001" MODIFIED="2018-01-08 18:50:15 +0000" MODIFIED_BY="Anne Lawson" NAME="Deeks 2001" TYPE="BOOK_SECTION">
<AU>Deeks JJ, Altman DG, Bradburn MJ</AU>
<TI>Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis</TI>
<SO>Systematic Reviews in Health Care: Meta-Analysis in Context</SO>
<YR>2001</YR>
<EN>2nd</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Publication Group</PB>
<CY>London (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ebrahim-2013" MODIFIED="2017-09-07 10:51:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ebrahim 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ebrahim S, Akl EA, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, et al</AU>
<TI>Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>9</NO>
<PG>1014-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erkens-2010" MODIFIED="2018-01-08 18:50:31 +0000" MODIFIED_BY="Anne Lawson" NAME="Erkens 2010" TYPE="COCHRANE_REVIEW">
<AU>Erkens PMG, Prins MH</AU>
<TI>Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2017-09-11 10:04:50 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-09-11 10:04:50 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001100.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gallus-1997" MODIFIED="2011-01-04 11:58:11 +0000" MODIFIED_BY="[Empty name]" NAME="Gallus 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gallus AS</AU>
<TI>Prevention of post-operative deep leg vein thrombosis in patients with cancer</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>1</NO>
<PG>126-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GRADE-handbook" MODIFIED="2018-01-08 18:59:53 +0000" MODIFIED_BY="Anne Lawson" NAME="GRADE handbook" TYPE="OTHER">
<AU>Schünemann H, Bro&#380;ek J, Guyatt G, Oxman A</AU>
<TI>GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. Updated October 2013</TI>
<SO>gdt.guidelinedevelopment.org/app/handbook/handbook.htmlG</SO>
<YR>(accessed prior to 8 January 2018)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2017" MODIFIED="2018-01-08 19:00:45 +0000" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2017" TYPE="OTHER">
<AU>Guyatt GH, Ebrahim S, Alonso-Coello P, Johnston BC, Mathioudakis AG, Briel M, et al</AU>
<TI>GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2017</YR>
<VL>87</VL>
<PG>14-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haynes-2002" MODIFIED="2017-10-04 13:46:54 +0100" MODIFIED_BY="[Empty name]" NAME="Haynes 2002" TYPE="JOURNAL_ARTICLE">
<AU>Haynes RB, Devereaux PJ, Guyatt GH</AU>
<TI>Clinical expertise in the era of evidence-based medicine and patient choice</TI>
<SO>Vox Sanguinis</SO>
<YR>2002</YR>
<VL>83</VL>
<NO>Suppl 1</NO>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heit-2000" MODIFIED="2018-01-08 19:00:58 +0000" MODIFIED_BY="Anne Lawson" NAME="Heit 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd</AU>
<TI>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<NO>6</NO>
<PG>809-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hettiarachchi-1999" MODIFIED="2011-01-04 11:58:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hettiarachchi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hettiarachchi RJ, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Buller HR</AU>
<TI>Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1999</YR>
<VL>82</VL>
<PG>947-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-01-04 11:59:02 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2018-01-08 18:49:59 +0000" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editor(s)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011</TI>
<SO>Available from handbook.cochrane.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-1993" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Hirsh 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J</AU>
<TI>Low molecular weight heparin</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1993</YR>
<VL>70</VL>
<NO>1</NO>
<PG>204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirsh-2008" MODIFIED="2011-01-04 12:01:04 +0000" MODIFIED_BY="[Empty name]" NAME="Hirsh 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI</AU>
<TI>Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)</TI>
<SO>Chest</SO>
<YR>2008</YR>
<VL>133 Suppl</VL>
<PG>141-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hutten-2000" MODIFIED="2010-11-16 14:52:40 +0000" MODIFIED_BY="[Empty name]" NAME="Hutten 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR</AU>
<TI>Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>17</NO>
<PG>3078-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kakkar-1970" MODIFIED="2010-11-16 14:52:43 +0000" MODIFIED_BY="[Empty name]" NAME="Kakkar 1970" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB</AU>
<TI>Deep vein thrombosis of the leg. Is there a "high risk" group?</TI>
<SO>American Journal of Surgery</SO>
<YR>1970</YR>
<VL>120</VL>
<NO>4</NO>
<PG>527-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levitan-1999" MODIFIED="2014-06-03 09:45:04 +0100" MODIFIED_BY="Gail Quinn" NAME="Levitan 1999" TYPE="JOURNAL_ARTICLE">
<AU>Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R</AU>
<TI>Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data</TI>
<SO>Medicine</SO>
<YR>1999</YR>
<VL>78</VL>
<NO>5</NO>
<PG>285-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-1999" MODIFIED="2011-01-04 12:03:50 +0000" MODIFIED_BY="[Empty name]" NAME="O'Brien 1999" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, Gent M</AU>
<TI>Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1999</YR>
<VL>159</VL>
<NO>19</NO>
<PG>2298-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Othieno-2007" MODIFIED="2010-11-16 19:04:22 +0000" MODIFIED_BY="[Empty name]" NAME="Othieno 2007" TYPE="COCHRANE_REVIEW">
<AU>Othieno R, Abu Affan M, Okpo E</AU>
<TI>Home versus in-patient treatment for deep vein thrombosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-11-16 19:04:22 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2010-11-16 19:04:22 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003076.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prandoni-2002" MODIFIED="2018-01-08 19:02:29 +0000" MODIFIED_BY="Anne Lawson" NAME="Prandoni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al</AU>
<TI>Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<NO>10</NO>
<PG>3484-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robertson-2017" MODIFIED="2018-01-22 10:12:42 +0000" MODIFIED_BY="Gail Quinn" NAME="Robertson 2017" TYPE="COCHRANE_REVIEW">
<AU>Robertson L, Jones LE</AU>
<TI>Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2017</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2018-01-16 10:30:11 +0000" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2018-01-16 10:30:11 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001100.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sorensen-2000" MODIFIED="2018-01-08 21:13:51 +0000" MODIFIED_BY="Anne Lawson" NAME="Sorensen 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA</AU>
<TI>Prognosis of cancers associated with venous thromboembolism</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>25</NO>
<PG>1846-50</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2018-01-08 19:09:28 +0000" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-Akl-2008a" MODIFIED="2018-01-08 19:04:21 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2008a" TYPE="COCHRANE_REVIEW">
<AU>Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Schünemann H</AU>
<TI>Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2017-10-07 07:38:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-07 07:38:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006649.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Akl-2008b" MODIFIED="2018-01-08 19:05:01 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2008b" TYPE="JOURNAL_ARTICLE">
<AU>Akl EA, Barba M, Muti P, Rohilla S, Schünemann H, Sperati F, et al</AU>
<TI>Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cancer</SO>
<YR>2008</YR>
<VL>113</VL>
<NO>7</NO>
<PG>1685-94</PG>
<IDENTIFIERS MODIFIED="2017-10-07 07:37:19 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-07 07:37:19 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006649"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Akl-2011a" MODIFIED="2018-01-08 19:09:28 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2011a" TYPE="COCHRANE_REVIEW">
<AU>Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, et al</AU>
<TI>Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2017-10-07 07:39:18 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-07 07:39:18 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006649.pub3"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Akl-2011b" MODIFIED="2018-01-08 19:09:26 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2011b" TYPE="COCHRANE_REVIEW">
<AU>Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, et al</AU>
<TI>Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2017-10-07 07:40:49 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-07 07:40:49 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006649.pub4"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Akl-2011c" MODIFIED="2018-01-08 19:09:22 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2011c" TYPE="COCHRANE_REVIEW">
<AU>Akl EA, Vasireddi SR, Gunukula S, Barba M, Sperati F, Terrenato I, et al</AU>
<TI>Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2017-10-07 07:41:59 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-07 07:41:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006649.pub5"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Akl-2014" MODIFIED="2018-01-08 19:08:48 +0000" MODIFIED_BY="Anne Lawson" NAME="Akl 2014" TYPE="COCHRANE_REVIEW">
<AU>Akl EA, Kahale LA, Neumann I, Barba M, Sperati F, Terrenato I, et al</AU>
<TI>Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2017-10-07 07:42:48 +0100" MODIFIED_BY="[Empty name]"><IDENTIFIER MODIFIED="2017-10-07 07:42:48 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006649.pub6"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES><CHARACTERISTICS_OF_STUDIES MODIFIED="2018-01-22 10:14:13 +0000" MODIFIED_BY="Gail Quinn"><CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2018-01-22 10:14:13 +0000" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Breddin-2001"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled open-label trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>137 (12%) people with cancer with DVT but not PE (study subgroup); minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: reviparin weight-based SC twice daily.</P><P>Control: UFH IV (continuous infusion of 1250 IU/hour) x 5-7 days.</P><P>Vitamin K antagonist (target INR &gt; 2) started on day 1 x 90 days.</P><P>A third group received reviparin SC once daily x 28 days and vitamin K antagonist on days 21-90.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 90 days.</P><UL><LI>Mortality.</LI><LI>Symptomatic DVT or PE (unclear whether asymptomatic events included).</LI><LI>Major bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE:</B> venography or scintigraphy if DVT or PE suspected.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Knoll, Germany.</LI><LI>Ethical approval: "The protocol was approved by the local institutional review boards and was conducted in accordance with national and international regulations."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: not reported.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial, subgroup of a large study.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>232 people with cancer with proximal or distal DVT, PE, or both; minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: reviparin weight-based SC twice daily at home.</P><P>Control: UFH IV (target aPTT 1.5-2.5) in hospital x 5 days.</P><P>Coumarin derivative (target INR &gt; 2) started on 1st or 2nd day x 12 weeks.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 12 weeks.</P><UL><LI>Death</LI><LI>Symptomatic DVT.</LI><LI>PE.</LI><LI>Major bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>not reported.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: participants could be treated at home, but the decision to do so was left to the treating physician.</LI><LI>Funding: Knoll, AG.</LI><LI>Ethical approval: "The study protocol was approved by the institutional review boards of all the clinical centers."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: not reported.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Duroux-1991"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>18 people with cancer with proximal DVT but no PE; minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: CY216 (Fraxiparin (nadroparin)) 255 antiXa U/kg twice daily x 10 days.</P><P>Control: UFH IV (target aPTT 1.5-2) x 10 days.</P><P>After day 10, each center continued its usual anticoagulant regimen either by SC UFH at adjusted doses or by oral anticoagulants x 12 weeks.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 12 weeks.</P><UL><LI>Mortality.</LI><LI>Recurrent VTE.</LI><LI>Major bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT: </B>venography surveillance for DVT conducted at day 0 and day 10.</P><P><B>Screening and diagnostic testing for PE: </B>lung scan by injecting IV with the participant in the supine position microspheres labelled with technetium 99 m albumin.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Sanofi-Choay.</LI><LI>Ethical approval: not reported.</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: "An intention-to-treat analysis including patients with premature cessation of treatment but in whom there was a D10 venogram was also undertaken."</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Hull-1992"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>95 people with cancer with proximal DVT (study subgroup); minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: tinzaparin 175 antiXa U/kg SC once daily.</P><P>Control: UFH IV (target aPTT 1.5-2.5) x 6 days</P><P>Warfarin (target INR 2-3) started on day 2 for 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 3 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic VTE.</LI><LI>Major bleeding.</LI><LI>Minor bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>impedance plethysmography, venography, perfusion lung scan.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: inpatient.</LI><LI>Funding: Heart and Stroke Foundation of Alberta and Novo Nordisk.</LI><LI>Ethical approval: "The protocol was approved by the institutional review board at each center."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: all participants randomized were included in the analyses of outcomes.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Koopman-1996"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>70 people with cancer with proximal DVT without PE (study subgroup); minimum age 18 years; minimum life expectancy 6 months.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: nadroparin weight-based SC twice daily at home.</P><P>Control: UFH IV (target aPTT 1.5-2) x 5 days.</P><P>Oral anticoagulation (target INR 2-3) started x 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 6 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent VTE.</LI><LI>Major bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>venography, pulmonary angiography, perfusion lung scan.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: standard heparin was administered at the hospital and participants receiving LMWH were allowed to be treated at home.</LI><LI>Funding: Sanofi Winthrop.</LI><LI>Ethical approval: "The study protocol was approved by the institutional review boards at all the participating institutions."</LI><LI>Conflict of interest: "Dr. Büller is an Established Investigator of the Dutch Heart Foundation."</LI><LI>ITT analysis: analyses were performed on an ITT basis.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Levine-1996"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>103 people with cancer with proximal or distal DVT without PE (study subgroup).</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: enoxaparin 1 mg/kg SC twice daily at home.</P><P>Control: UFH IV (target aPTT 60-85 s) x 5 days.</P><P>Warfarin (target INR 2-3) started on evening of 2nd day for at least 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 90 days.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent VTE.</LI><LI>Major bleeding.</LI><LI>Minor bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>impedance plethysmography, duplex ultrasonography, venography.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: LMWH given as outpatient (mean (± SD) hospital stay 1.1 ± 2.9 days); UFH given as inpatient (mean (± SD) hospital stay 2.2 ± 3.8 days).</LI><LI>Funding: not reported.</LI><LI>Ethical approval: "The study protocol was reviewed and approved by the institutional review boards of the participating centers."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: not reported.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lindmarker-1994"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>16 people with cancer with DVT (below the inguinal ligament) but no PE (study subgroup); minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: dalteparin 200 IU/kg SC once daily.</P><P>Control: UFH IV (target aPTT 1.5-3) x 5 days.</P><P>Warfarin (target INR 2-3) x 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 6 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic PE.</LI><LI>Bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE:</B> not reported.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Pharmacia AB.</LI><LI>Ethical approval: not reported.</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: not used.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lopaciuk-1992"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>9 people with cancer with proximal or calf DVT without PE (study subgroup).</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: nadroparin 92 antiXa U/kg twice daily.</P><P>Control: UFH 1st dose IV, subsequent dose SC twice daily (target aPTT 1.5-2.5) x 10 days.</P><P>Acenocoumarol (target INR 2-3) started the 7th day x at least 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 3 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic PE.</LI><LI>Recurrent DVT.</LI><LI>Bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE:</B> not reported.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Sanofi.</LI><LI>Ethical approval: not reported.</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: not reported.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Merli-2001"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>141 people with cancer with DVT or PE (study subgroup); minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: enoxaparin 1 mg/kg SC twice daily or 1.5 mg/kg SC once daily.</P><P>Control: UFH IV (target aPTT 55-80 s) x 5 days.</P><P>Warfarin (target INR 2-3) started within 72 hours x 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 3 months.</P><UL><LI>Mortality.</LI><LI>Recurrent DVT or PE.</LI><LI>Major bleed.</LI><LI>Minor bleed.</LI></UL><P><B>Screening and diagnostic testing for DVT: </B>venography, ultrasonography, or both.</P><P><B>Screening and diagnostic testing for PE: </B>lung perfusion scanning, pulmonary angiography, or both.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Aventis.</LI><LI>Ethical approval: "approved by the institutional review board or ethics committees at each location."</LI><LI>Conflict of interest: Aventis Pharmaceuticals Participants Study Co-ordinators: Kimberly Miller, BS, RN; Ghislaine Pisapia; Annette Stevenson, MS; Patrick Valode. Data Management: Todd Koser, Patrick Poinot. Biostatistics: Marie-Josée Cossec-Vion; Eric Genevois, PhD; Alain Vasseur. Project Director: Theodore E Spiro, MD.</LI><LI>ITT analysis: "The efficacy analysis was performed on two study samples: all treated patients, who received at least one dose of study medication, and evaluable patients, which excluded all patients who met at least one of the criteria for non evaluability."</LI><LI>Comment: first analysis was ITT.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Prandoni-1992"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>33 people with cancer with proximal DVT (study subgroup); minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: Fraxiparin (nadroparin) weight -based SC twice daily.</P><P>Control: UFH IV (target aPTT 1.5-2.0) x 10 days.</P><P>Coumarin (target INR 2-3) started on day 7 for at least 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 6 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent DVT.</LI><LI>Symptomatic PE.</LI><LI>Major bleeding.</LI><LI>Minor bleeding</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>contrast venography, perfusion lung scanning, and chest radiography.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: not reported.</LI><LI>Ethical approval: "The study protocol was approved by the institutional review board."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: was used.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>156 people with cancer (study subgroup) with DVT of lower extremities, PE, or both; minimum age 18 years; minimum life expectancy 3 months.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: nadroparin 80 U/kg twice daily.</P><P>Control: UFH 1st dose weight adjusted IV, subsequent doses SC twice daily (target aPTT 50-90 s) x 5 days.</P><P>Warfarin (target INR 2-3) started the first 2 days x 12 weeks.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 3 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent VTE.</LI><LI>Major bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT: </B>venogram, compression ultrasound.</P><P><B>Screening and diagnostic testing for PE: </B>pulmonary angiography or computed tomographic scan.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Gentium SpA, Como, Italy.</LI><LI>Ethical approval: "The study was approved by the ethical board of all participating centers."</LI><LI>Conflict of interest: "The Writing Committee for this article has no relevant financial interest in this article."</LI><LI>ITT analysis: "analyses were performed on an intention-to-treat basis."</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Simonneau-1993"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.<BR/></P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>9 people with cancer with proximal DVT (study subgroup); minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: enoxaparin 1 mg/kg SC twice daily.</P><P>Control: UFH IV (target aPTT 1.5-2.5) x 10 days.</P><P>Oral anticoagulation (target INR 2-3) started on day 10 for at least 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 3 months.</P><UL><LI>Mortality.</LI><LI>Recurrent symptomatic VTE.</LI><LI>Major bleeding.</LI><LI>Minor bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT: </B>venography.</P><P><B>Screening and diagnostic testing for PE: </B>perfusion lung scan.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: not reported.</LI><LI>Ethical approval: "The protocol was approved by the ethical committee of Grenoble (France) University."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: not reported.</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>60 people with cancer with PE (study subgroup); minimum age 18 years; minimum life expectancy 3 months.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: tinzaparin 175 antiXa U/kg SC once daily.</P><P>Control: UFH IV (target aPTT 2-3) x 5 days.</P><P>Oral anticoagulation (target INR 2-3) started on 1st to 3rd day x at least 3 months.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 90 days.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent VTE.</LI><LI>Major bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT: </B>ultrasonography or venography.</P><P><B>Screening and diagnostic testing for PE: </B>ventilation-perfusion scanning or angiography.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: not reported.</LI><LI>Funding: Leo Pharmaceuticals.</LI><LI>Ethical approval: "The study protocol was approved by the institutional review boards of all the participating centers."</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: "The primary analysis was performed on an intention to treat basis."</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-van-Doormaal-2009"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>477 people with cancer with DVT; minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: fondaparinux SC once daily in fixed dose (5 mg if participants weighed &lt; 50 kg, 7.5 mg if they weighed 50-100 kg, or 10 mg if they weighed &gt; 100 kg) and twice daily SC injections of placebo that appeared identical to enoxaparin.</P><P>Control: enoxaparin SC twice daily 1 mg/kg of bodyweight and a once daily SC injection of placebo that appeared identical to fondaparinux or UFH (target aPTT 1.5 to 2.5).</P><P>Vitamin K antagonist therapy was begun as soon as possible but not later than 72 hours after commencing initial therapy.</P><P>Discontinued treatment: not reported for cancer subgroup.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 90 days.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent VTE.</LI><LI>Major bleeding.</LI><LI>Minor bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>not reported.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: drug administered by a home care service for home treatment.</LI><LI>Funding: Sanofi/Organon.</LI><LI>Ethical approval: Matisse clinical trial.</LI><LI>Conflict of interest: not reported.</LI><LI>ITT analysis: "The analyses were calculated in the intention to treat populations."</LI></UL></CHAR_NOTES></INCLUDED_CHAR><INCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Wells-2005"><CHAR_METHODS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Randomized controlled trial, single blind.</P></CHAR_METHODS><CHAR_PARTICIPANTS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>113 people with cancer with upper or lower extremity DVT; minimum age 18 years.</P></CHAR_PARTICIPANTS><CHAR_INTERVENTIONS MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Intervention: tinzaparin SC 175 IU/kg once daily.</P><P>Control: dalteparin SC 200 IU/kg once daily.</P><P>Discontinued treatment: 0 participants.</P></CHAR_INTERVENTIONS><CHAR_OUTCOMES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Duration of follow-up: 3 months.</P><UL><LI>Mortality.</LI><LI>Symptomatic recurrent VTE.</LI><LI>Major bleeding.</LI><LI>Minor bleeding.</LI></UL><P><B>Screening and diagnostic testing for DVT/PE: </B>not reported.</P></CHAR_OUTCOMES><CHAR_NOTES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><UL><LI>Setting: participants had received therapy on outpatient basis.</LI><LI>Funding: Canada Research Chair from the Canadian Research Chair Program, Ottawa, Ontario (Dr PS Wells); a research scholarship from Dalhousie University, Halifax, Nova Scotia (Dr Anderson); an internal scholarship from the Department of Medicine, University of Western Ontario, London (Dr Kovacs); and the Maureen Andrew New Investigator Award from the Heart and Stroke Foundation of Ontario, London (Dr Rodger).</LI><LI>Ethical approval: not reported.</LI><LI>Conflict of interest: "Financial Disclosure: None."</LI><LI>ITT analysis: "The primary analysis was intention to treat."</LI></UL></CHAR_NOTES></INCLUDED_CHAR><FOOTNOTES><P>antiXa: anti-factor Xa; aPTT: activated partial thromboplastin time; DVT: deep venous thrombosis; INR: international normalized ratio; ITT: intention to treat; IU: international units; IV: intravenous; LMWH: low molecular weight heparin; mg: milligram; MPD: missing participant data; PE: pulmonary embolism; s: second; SC: subcutaneous; SD: standard deviation; U: unit; UFH: unfractionated heparin; VTE: venous thromboembolism.</P></FOOTNOTES></CHARACTERISTICS_OF_INCLUDED_STUDIES><CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" SORT_BY="STUDY"><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Agnelli-1998"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Agnelli-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Agnelli-2015-_x0028_AMPLIFY_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment); included 2 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Albada-1989"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Alikhan-2003-_x0028_MEDENOX_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Altundag-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Letter to editor.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Anton-2001"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Auer-2011"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bauer-2000"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Editorial.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Belcaro-1999"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bick-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bigg-1992"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Booth-1981"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Case report.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bratt-1985"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>No relevant clinical outcomes.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Bratt-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Brooks-1969"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Case report.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Buller-2004"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Cahan-2000"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Ciftci-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (ambulatory people with cancer without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Clarke_x002d_Pearson-1993"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Cohen-1997"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Cohen-2006"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Cohen-2007-_x0028_PREVENT_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE) included 3 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Couban-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 3 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Dickinson-1998"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Dolovich-2004"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Douketis-2000"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Cohort study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Eikelboom-1998"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Case series.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Elly-1969"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Case report.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Fiessinger-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Goldhaber-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Gould-1999"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Green-1992"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Letter to editor.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Haage-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Haas-2011"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 3 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Handeland-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>No people with cancer in the study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Harenberg--2000"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Harenberg-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Harenberg-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 2 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Hata-2016"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Hettiarachchi-1998"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Holm-1986"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Holmstrom-1999"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Hull-2000"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Hull-2006"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Jahanzeb-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Kakkar-2010-_x0028_CANBESURE_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 2 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Kakkar-2014-_x0028_SAVE_x002d_ABDO_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 2 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Khorana-2017-_x0028_PHACS_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 2 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Koppenhagen-1992"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Larocca-2012"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Lee-2015-_x0028_CATCH_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment); included 9 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Leizorovicz-1994"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Levine-2001"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Luomanmaki-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Macbeth-2016-_x0028_FRAGMATIC_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 4 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Martin_x002d_Carbonero-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Cohort study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Maxwell-2001"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Mazilu-2014-_x0028_OVIDIUS_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Menzoian-1983"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Retrospective study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Murakami-2002"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Nagata-2015"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Naschitz-1994"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Nurmohamed-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Palumbo-2011"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 6 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Pelzer-2015-_x0028_CONKO_x002d_004_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 10 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Prandoni-1988"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>No control group.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Prandoni-1990"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>No cancer people in the study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Prandoni-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Review.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Prins-2014-_x0028_EINSTEIN_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Raskob-2016-_x0028_HOKUSAI_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Riess-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Data for cancer subgroup not available.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Sakon-2010"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Sakuragi-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Retrospective study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Schulman-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Schulman-2013-_x0028_RE_x002d_MEDY_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Schulman-2015-_x0028_RECOVER_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the intervention of interest (secondary treatment).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Siragusa-2005"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not randomized.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Song-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Turchetti-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Cohort study.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Vadhan_x002d_Raj-2013"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Vedovati-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 5 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Verso-2008"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); included 4 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Ward-1998"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Warkentin-1995"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>No relevant outcome.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Wester-1996"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>No relevant outcome (cancer subgroup reported without information about number randomized to each study arm).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Wong-2003"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Survey.<BR/></P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Zheng-2014"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE).</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><EXCLUDED_CHAR MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" STUDY_ID="STD-Zwicker-2013-_x0028_MICRO-TEC_x0029_"><CHAR_REASON_FOR_EXCLUSION MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P>Not the population of interest (people without VTE); includes 2 reports.</P></CHAR_REASON_FOR_EXCLUSION></EXCLUDED_CHAR><FOOTNOTES><P>VTE: venous thromboembolism.</P></FOOTNOTES></CHARACTERISTICS_OF_EXCLUDED_STUDIES><CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-16 14:42:19 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_AWAITING_STUDIES><CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2017-09-26 09:08:23 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO"><FOOTNOTES/></CHARACTERISTICS_OF_ONGOING_STUDIES></CHARACTERISTICS_OF_STUDIES><QUALITY_ITEMS MODIFIED="2018-01-22 10:14:13 +0000" MODIFIED_BY="Gail Quinn"><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1"><NAME>Random sequence generation (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Quote: "Patients were randomly assigned to one of three groups, stratified according to site."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Quote: "Randomization was performed with a computer algorithm."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>Quote: "Study was a randomized parallel group trial."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Quote: "A randomized, computer-derived treatment schedule was used to assign the patients to receive intravenous heparin or subcutaneous low molecular-weight heparin."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Quote: "After the patients gave informed consent, randomization (stratified according to center) was achieved by means of a central 24 hour telephone service."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Quote: "Patients were assigned to treatment through randomization over the telephone from a central line."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Quote: "Randomization was organized centrally using sealed envelopes stratified for each center in a block size of 20."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Quote: "Study was a prospective, open, stratified, and randomized multicenter trial with a blind evaluation of phlebographic results."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>Quote: "Patients were randomly assigned."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Quote: "Patients were allocated treatment by a prescribed randomisation schedule."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Quote: "Randomization was performed with a computer algorithm."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>Quote: "The randomization code was drafted by means of a standard random number table randomizing in blocks of four."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Quote: "central randomization was performed."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>Quote: "Randomization was performed in a computer generated blocks, with the block size unknown to the investigators."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Quote: "Patients were randomly assigned by a computerized interactive voice response system."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" NO="2"><NAME>Allocation concealment (selection bias)</NAME><DESCRIPTION><P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Quote: "Randomization was performed with a computer algorithm and the use of a central 24-hour telephone service that recorded information on the patient before the treatment assignment was disclosed."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="UNKNOWN" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>Not reported.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Quote: "Before randomization, patients were stratified into groups according to a randomized, computer-derived treatment schedule was used to assign the patients to receive intravenous heparin or subcutaneous low molecular-weight heparin."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Quote: "After the patients gave informed consent, randomization (stratified according to center) was achieved by means of a central 24 hour telephone service."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Quote: "Patients were assigned to treatment through randomization over the telephone from a central line."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Quote: "Randomization was organized centrally using sealed envelopes stratified for each center in a block size of 20."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-18 15:36:46 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Quote: "they were randomly allocated by using a sealed envelope to either Fraxiparine [nadroparin] or UFH group."</P><P>Comment: no mention of sequential numbering and opacity.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>Quote: "Randomization numbers were affixed to sealed treatment kits that contained study medication and were provided by the study sponsor."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Quote: "Treatment was allocated by the sealed envelop method."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Quote: "Randomization was performed with a computer algorithm and the use of a 24 hour telephone service that recorded patient information before disclosure of the treatment assigned."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>Quote: "The patients' treatment assignments were taken from sealed envelopes."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Quote: "central randomization was performed with the use of a 24 hour computer service."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>Quote: "Randomization assignments were concealed in opaque envelopes. Envelopes were opened sequentially and only after patient consent form was signed."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Quote: "Patients were randomly assigned by a computerized interactive voice response system."</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3"><NAME>Blinding (performance bias and detection bias)</NAME><DESCRIPTION><P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2018-01-22 10:14:13 +0000" MODIFIED_BY="Gail Quinn" NO="13"><NAME>Blinding of participants and personnel (performance bias)</NAME><DESCRIPTION><P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-22 10:14:13 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Open-label trial.</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of co interventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Open-label study.</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>Quote: "Treatment could not be given double-blinded because of the different methods of administration and primarily the need for dose adjustment in the UFH group."</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Double-blind clinical trial.</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Quote: "An unblinded trial."</P><P>Comment: definitely not blinded. Knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Quote: "This was not a double-blind study."</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Not reported.</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Not reported.</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>Not reported.</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Quote: "Because the two regimens were given by different routes and because dose adjustments were necessary in the standard heparin group, we could not use a double blind design."</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Quote: "open multicenter clinical trial."</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>No placebo given.</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="NO" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Quote: "unblinded trial."</P><P>Comment: definitely not blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>Randomization assignments concealed in opaque envelopes. Envelopes opened sequentially and only after the participant consent form was signed. All physicians and nurses who were involved in the participant&#8217;s care were blinded except for the nurse who provided the initial care to the participant. In all cases, 2 prescriptions were written for the participant, and the physician was unaware which drug was ultimately assigned. The nurse who was initially involved with the participant was not involved in follow-up assessment for recurrence or bleeding.</P><P>Comment: definitely blinded; knowledge of the assigned intervention may have led to differential behaviors across intervention groups (e.g. differential dropout, differential cross-over to an alternative intervention, or differential administration of cointerventions).<BR/></P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Quote: "double-blinded, placebo controlled study."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-17" LEVEL="GROUP" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="17"><NAME>Blinding of outcome assessment (detection bias)</NAME><DESCRIPTION><P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P></DESCRIPTION><QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-17.01" NO="1"><NAME>All outcomes</NAME></QUALITY_ITEM_DATA_ENTRY_GROUP><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Quote: "The venograms were assessed by two members of an independent committee who were unaware of the patients' treatment assignments and of whether the venograms were obtained before or after treatment."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Quote: "Information on all suspected outcome events and deaths was reviewed and classified by a central adjudication committee whose members were unaware of the treatment assignments."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>Quote: "Treatment could not be given double-blinded because of the different methods of administration and primarily the need for dose adjustment in the UFH group."</P><P>Comment: probably not blinded; knowledge of the assigned intervention may not have impacted the assessment of the physiological outcomes (mortality, DVT, PE, bleeding, etc.).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Quote: "Central adjudication committee was made by two committee members not involved in the patient's care, and disputes were resolved independently by a third."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Quote: "Documentation of all potential outcome events, including deaths, was submitted to an independent adjudication committee whose members were unaware of the treatment assignments."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Quote: "All reported outcome events were reviewed by a central adjudication committee whose members were unaware of the treatment assignments."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Quote: "All venograms were interpreted by a radiologist who did not know which of the treatments the patient had received or in which order the venogram has been performed."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Quote: "blind evaluation of phlebographic results."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>Quote: "Outcome adjudication committee, which provided blinded outcome assignments for incidence outcomes."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Quote: "All clinical endpoints were reviewed by an adjudication committee from the coordinating center, unaware of treatment allocation or other details of patients."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Quote: "Information on all suspected outcome events and deaths was reviewed and classified by a central adjudication committee blinded to treatment assignment."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>Quote: "Venograms, perfusion lung scans, and pulmonary angiograms were subsequently reviewed by a central independent panel of two consultant specialists unaware of the treatment allocation."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Quote: "All the scans were reviewed independently and scored accordingly to this method by two readers, each unaware of the patient's treatment assignment."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>All physicians and nurses who were involved in the participant's care were blinded except for the nurse who provided the initial care to the participant</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-17.01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Quote: "The study used central adjudication for all clinical outcome events."</P><P>Comment: definitely blinded.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4"><NAME>Incomplete outcome data (attrition bias)</NAME><DESCRIPTION><P>Attrition bias due to amount, nature or handling of incomplete outcome data</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-08-03 18:56:04 +0100" MODIFIED_BY="[Empty name]" NO="5"><NAME>Selective reporting (reporting bias)</NAME><DESCRIPTION><P>Reporting bias due to selective outcome reporting</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-08-03 18:56:04 +0100" MODIFIED_BY="[Empty name]" NO="6"><NAME>Other bias</NAME><DESCRIPTION><P>Bias due to problems not covered elsewhere in the table</P></DESCRIPTION><QUALITY_ITEM_DATA/></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="12"><NAME>Incomplete outcome data addressed?</NAME><DESCRIPTION><P>Were incomplete outcome data adequately addressed?</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Comment: judgment based on comparison between MPD rate (LMWH 11/95 (11.5%); UFH 1/42 (2.4%)) and event rate (mortality: LMWH 14/84 (16.6%); UFH 6/41 (14.6%)).</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>No information about follow-up in cancer subgroup reported.</P><P>Comment: we analyzed the available data assuming that any possibly missing data were missing at random.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>No information about the follow-up in cancer subgroup was reported.</P><P>Comment: we analyzed the available data assuming that any possibly missing data were missing at random.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Complete follow-up.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-15" LEVEL="STUDY" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="15"><NAME>Free of selective reporting?</NAME><DESCRIPTION><P>Are reports of the study free of suggestion of selective outcome reporting?</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in the methods section were reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in methods section are reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Study not registered and no published protocol identified. All relevant outcomes listed in methods section are reported on in the results section.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM><QUALITY_ITEM CORE_ITEM="NO" ID="QIT-16" LEVEL="STUDY" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="16"><NAME>Free of other bias?</NAME><DESCRIPTION><P>Was the study apparently free of other problems that could put it at a high risk of bias?</P></DESCRIPTION><QUALITY_ITEM_DATA><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Breddin-2001"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Buller-1997-_x0028_COLOMBUS_x0029_"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Duroux-1991"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Hull-1992"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Koopman-1996"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Levine-1996"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lindmarker-1994"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Lopaciuk-1992"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Merli-2001"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-1992"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1993"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Simonneau-1997-_x0028_THESEE_x0029_"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-Wells-2005"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY><QUALITY_ITEM_DATA_ENTRY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" RESULT="YES" STUDY_ID="STD-van-Doormaal-2009"><DESCRIPTION><P>Study not reported as stopped early for benefit.</P><P>No other bias suspected.</P></DESCRIPTION></QUALITY_ITEM_DATA_ENTRY></QUALITY_ITEM_DATA></QUALITY_ITEM></QUALITY_ITEMS><SOF_TABLES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><SOF_TABLE ID="SOF-01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1" READONLY="YES"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">LMWH initial treatment compared to UFH initial treatment in people with cancer with VTE</TITLE><TABLE COLS="6" ROWS="10"><TR><TD COLSPAN="6"><P><B>LMWH initial treatment compared to UFH initial treatment in people with cancer with VTE</B></P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P><B>P</B>: people with cancer and a confirmed diagnosis of VTE</P><P><B>S</B>: inpatient/outpatient</P><P><B>I</B>: LMWH initial treatment</P><P><B>C</B>: UFH initial treatment</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>No of participants<BR/>(studies)<BR/></P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Certainty of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Anticipated absolute effects* (95% CI)</P></TH></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk with UFH initial treatment</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk difference with LMWH initial treatment</P></TH></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>Mortality</B><BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>418<BR/>(5 RCTs)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>1</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.66</B><BR/>(0.40 to 1.10)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>168 per 1000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>57 fewer per 1000<BR/>(101 fewer to 17 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>Recurrent VTE</B><BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>422<BR/>(3 RCTs)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/><B>Moderate</B><SUP>2</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.69</B><BR/>(0.27 to 1.76)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>96 per 1000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>30 fewer per 1000<BR/>(70 fewer to 73 more)</P></TD></TR><TR><TD COLSPAN="6"><P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P><P><B>CI:</B> confidence interval; <B>LMWH:</B> low molecular weight heparin; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio; <B>UFH:</B> unfractionated heparin; <B>VTE:</B> venous thromboembolism.</P></TD></TR><TR><TD COLSPAN="6"><P><B>GRADE Working Group grades of evidence</B><BR/><B>High certainty:</B> we are very confident that the true effect lies close to that of the estimate of the effect.<BR/><B>Moderate certainty:</B> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/><B>Low certainty:</B> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<BR/><B>Very low certainty:</B> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.</P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP>95% CI was consistent with the possibility for important benefit (101 per 1000 absolute reduction) and possibility of important harm (17 per 1000 absolute increase), including 59 events in total.</P><P><SUP>2</SUP>95% CI was consistent with the possibility for important benefit (70 per 1000 absolute reduction) and possibility of important harm (73 per 1000 absolute increase), including only 34 events in total.</P></FOOTNOTES></SOF_TABLE><SOF_TABLE ID="SOF-02" MODIFIED="2018-01-15 10:41:31 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES"><TITLE MODIFIED="2018-01-15 10:36:34 +0000" MODIFIED_BY="[Empty name]">Fondaparinux initial treatment compared to Heparin initial treatment in patients with cancer with VTE</TITLE><TABLE COLS="6" ROWS="15"><TR><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P><B>Fondaparinux initial treatment compared to Heparin initial treatment in patients with cancer with VTE </B></P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P><B>P</B>: people with cancer and a confirmed diagnosis of VTE</P><P><B>S</B>: inpatient/outpatient</P><P><B>I</B>: LMWH initial treatment</P><P><B>C</B>: UFH initial treatment</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>No of participants<BR/>(studies)<BR/></P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Certainty of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Anticipated absolute effects<SUP>*</SUP> (95% CI)</P></TH></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk with Heparin initial treatment</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk difference with Fondaparinux initial treatment</P></TH></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Mortality<BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>477<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate <SUP>1</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>RR 1.25<BR/>(0.86 to 1.81)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>172 per 1,000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>43 more per 1,000<BR/>(24 fewer to 139 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Recurrent VTE<BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>477<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate <SUP>2</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>RR 0.93<BR/>(0.56 to 1.54)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>117 per 1,000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>8 fewer per 1,000<BR/>(52 fewer to 63 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Major bleeding<BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>477<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate <SUP>3</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>RR 0.82<BR/>(0.40 to 1.66)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>67 per 1,000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>12 fewer per 1,000<BR/>(40 fewer to 44 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Minor bleeding<BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>477<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate <SUP>4</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>RR 1.53<BR/>(0.88 to 2.66)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>79 per 1,000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>42 more per 1,000<BR/>(10 fewer to 132 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Quality of life - not reported</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>-</P></TD></TR><TR><TD COLSPAN="6"><P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P><P><B>CI:</B> Confidence interval; <B>LMWH:</B> low molecular weight heparin; <B>RCT:</B> randomized controlled trial; <B>RR:</B> Rrisk ratio; <B>OR:</B> Odds ratio;<B>UFH:</B> unfractionated heparin; <B>VTE:</B> venous thromboembolism.</P></TD></TR><TR><TD COLSPAN="6"><P><B>GRADE Working Group grades of evidence</B><BR/><B>High certainty:</B> We are very confident that the true effect lies close to that of the estimate of the effect<BR/><B>Moderate certainty:</B> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<BR/><B>Low certainty:</B> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<BR/><B>Very low certainty:</B> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP> 95% CI is consistent with the possibility for important benefit (24 per 1000 absolute reduction) and possibility of important harm (139 per 1000 absolute increase), including only 92 events in total</P><P><SUP>2</SUP> 95% CI is consistent with the possibility for important benefit (52 per 1000 absolute reduction) and possibility of important harm (63 per 1000 absolute increase), including only 54 events in total</P><P><SUP>3</SUP> 95% CI is consistent with the possibility for important benefit (40 per 1000 absolute reduction) and possibility of important harm (44 per 1000 absolute increase), including only 29 events in total</P><P><SUP>4</SUP> 95% CI is consistent with the possibility for important benefit (10 per 1000 absolute reduction) and possibility of important harm (132 per 1000 absolute increase), including only 48 events in total</P></FOOTNOTES></SOF_TABLE><SOF_TABLE ID="SOF-03" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="3" READONLY="YES"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">Dalteparin compared to tinzaparin in people with cancer with VTE</TITLE><TABLE COLS="6" ROWS="14"><TR><TD COLSPAN="6"><P><B>Dalteparin initial treatment compared to tinzaparin initial treatment in people with cancer with VTE</B></P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="6" ROWSPAN="1" VALIGN="TOP"><P><B>P</B>: people with cancer and a confirmed diagnosis of VTE</P><P><B>S</B>: inpatient/outpatient</P><P><B>I</B>: dalteparin initial treatment</P><P><B>C</B>: tinzaparin initial treatment</P></TD></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Outcomes</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>No of participants<BR/>(studies)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Certainty of the evidence<BR/>(GRADE)</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>Relative effect<BR/>(95% CI)</P></TH><TH ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Anticipated absolute effects* (95% CI)</P></TH></TR><TR><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk with tinzaparin</P></TH><TH ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>Risk difference with dalteparin</P></TH></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>Mortality</B><BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>113<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>1</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.86</B><BR/>(0.43 to 1.73)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>237 per 1000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>33 fewer per 1000<BR/>(135 fewer to 173 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>Recurrent VTE</B><BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>113<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>2</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.44</B><BR/>(0.09 to 2.16)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>85 per 1000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>47 fewer per 1000<BR/>(77 fewer to 98 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>Major bleeding</B><BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>113<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>3</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>RR 2.19</B><BR/>(0.20 to 23.42)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>17 per 1000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>20 more per 1000<BR/>(14 fewer to 380 more)</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>Minor bleeding</B><BR/>follow-up: 3 months</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>113<BR/>(1 RCT)</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/><B>Low</B><SUP>4</SUP></P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="2" VALIGN="TOP"><P><B>RR 0.82</B><BR/>(0.30 to 2.21)</P></TD><TD ALIGN="LEFT" COLSPAN="2" ROWSPAN="1" VALIGN="TOP"><P>Study population</P></TD></TR><TR><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>136 per 1000</P></TD><TD ALIGN="LEFT" COLSPAN="1" ROWSPAN="1" VALIGN="TOP"><P>24 fewer per 1000<BR/>(95 fewer to 164 more)</P></TD></TR><TR><TD COLSPAN="6"><P>*<B>The risk in the intervention group</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).</P><P><B>CI:</B> confidence interval; <B>RCT:</B> randomized controlled trial; <B>RR:</B> risk ratio; <B>VTE:</B> venous thromboembolism.</P></TD></TR><TR><TD COLSPAN="6"><P><B>GRADE Working Group grades of evidence</B><BR/><B>High certainty:</B> we are very confident that the true effect lies close to that of the estimate of the effect.<BR/><B>Moderate certainty:</B> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<BR/><B>Low certainty:</B> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<BR/><B>Very low certainty:</B> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.</P></TD></TR></TABLE><FOOTNOTES><P><SUP>1</SUP>95% CI was consistent with the possibility for important benefit (135 per 1000 absolute reduction) and possibility of important harm (173 per 1000 absolute increase), including 25 events among included participants.</P><P><SUP>2</SUP>95% CI was consistent with the possibility for important benefit (77 per 1000 absolute reduction) and possibility of important harm (98 per 1000 absolute increase), including 7 events among included participants.</P><P><SUP>3</SUP>95% CI was consistent with the possibility for important benefit (14 per 1000 absolute reduction) and possibility of important harm (380 per 1000 absolute increase), including 3 events among included participants.</P><P><SUP>4</SUP>95% CI was consistent with the possibility for important benefit (95 per 1000 absolute reduction) and possibility of important harm (164 per 1000 absolute increase), including 14 events among included participants.</P></FOOTNOTES></SOF_TABLE></SOF_TABLES><ADDITIONAL_TABLES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1"><TITLE>Glossary</TITLE><TABLE COLS="2" ROWS="24"><TR><TH><P>Term</P></TH><TH><P>Definition</P></TH></TR><TR><TD><P>A priori</P></TD><TD><P>Made before or without exam; not supported by factual study.</P></TD></TR><TR><TD><P>Adjuvant therapy</P></TD><TD><P>Assisting in the amelioration or cure of disease.</P></TD></TR><TR><TD><P>Anticoagulation</P></TD><TD><P>Process of hindering the clotting of blood especially by treatment with an anticoagulant.</P></TD></TR><TR><TD><P>Antithrombotic</P></TD><TD><P>Used against or tending to prevent thrombosis (clotting).<BR/></P></TD></TR><TR><TD><P>Coagulation</P></TD><TD><P>Clotting.</P></TD></TR><TR><TD><P>Deep vein thrombosis (DVT)</P></TD><TD><P>Condition marked by the formation of a thrombus within a deep vein (as of the leg or pelvis) that may be asymptomatic or be accompanied by symptoms (as swelling and pain) and that is potentially life threatening if dislodgment of the thrombus results in pulmonary embolism.</P></TD></TR><TR><TD><P>Fondaparinux</P></TD><TD><P>Anticoagulant medication.</P></TD></TR><TR><TD><P>Dalteparin</P></TD><TD><P>Anticoagulant medication.</P></TD></TR><TR><TD><P>Tinzaparin</P></TD><TD><P>Anticoagulant medication.</P></TD></TR><TR><TD><P>Hemostatic system</P></TD><TD><P>System that shortens the clotting time of blood and stops bleeding.</P></TD></TR><TR><TD VALIGN="TOP"><P>Heparin</P></TD><TD><P>Enzyme occurring especially in the liver and lungs that prolongs the clotting time of blood by preventing the formation of fibrin. 2 forms of heparin that are used as anticoagulant medications are: unfractionated heparin (UFH) and low molecular weight heparins (LMWH).</P></TD></TR><TR><TD><P>Heterogeneity</P></TD><TD><P>Quality or state of being heterogeneous, i.e. incongruous. Statistical technique to check whether study results are consistent.</P></TD></TR><TR><TD><P>Hypercoagulable state</P></TD><TD><P>State of excessive affinity to clotting.</P></TD></TR><TR><TD><P>Impedance plethysmography</P></TD><TD><P>Technique that measures the change in blood volume (venous blood volume as well as the pulsation of the arteries) for a specific body segment.</P></TD></TR><TR><TD><P>Kappa statistic</P></TD><TD><P>Measure of degree of nonrandom agreement between observers, measurements of a specific categorical variable, or both.</P></TD></TR><TR><TD><P>Metastasis</P></TD><TD><P>Spread of a cancer cells from the initial or primary site of disease to another part of the body.</P></TD></TR><TR><TD><P>Parenteral nutrition</P></TD><TD><P>Practice of feeding a person intravenously, circumventing the gastrointestinal tract.</P></TD></TR><TR><TD><P>Pulmonary embolism (PE)</P></TD><TD><P>Embolism of a pulmonary artery or 1 of its branches that is produced by foreign matter and most often a blood clot originating in a vein of the leg or pelvis and that is marked by labored breathing, chest pain, fainting, rapid heart rate, cyanosis, shock, and sometimes death.</P></TD></TR><TR><TD><P>Thrombocytopenia</P></TD><TD><P>Persistent decrease in the number of blood platelets that is often associated with hemorrhagic conditions.</P></TD></TR><TR><TD><P>Thrombosis</P></TD><TD><P>Formation or presence of a blood clot within a blood vessel.</P></TD></TR><TR><TD><P>Vitamin K antagonists</P></TD><TD><P>Anticoagulant medications that are used for anticoagulation. Warfarin is a vitamin K antagonist.</P></TD></TR><TR><TD><P>Warfarin</P></TD><TD><P>Anticoagulant medication that is a vitamin K antagonist that is used for anticoagulation.</P></TD></TR><TR><TD><P>Ximelagatran</P></TD><TD><P>Anticoagulant medication.</P></TD></TR></TABLE><FOOTNOTES/></ADDITIONAL_TABLE></ADDITIONAL_TABLES><ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><COMPARISON ID="CMP-001" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1"><NAME>Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH)</NAME><DICH_OUTCOME CHI2="3.1517799468705023" CI_END="1.1018270359752993" CI_START="0.39853598750224273" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6626595851861535" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.042113424627273806" LOG_CI_START="-0.3995324560295529" LOG_EFFECT_SIZE="-0.17870951570113952" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="0.5327544462406776" P_Q="1.0" P_Z="0.11269921969090754" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="228" TOTAL_2="190" WEIGHT="100.00000000000001" Z="1.5861767529583075"><NAME>Mortality (3 months)</NAME><GROUP_LABEL_1>LMWH</GROUP_LABEL_1><GROUP_LABEL_2>UFH</GROUP_LABEL_2><GRAPH_LABEL_1>LMWH</GRAPH_LABEL_1><GRAPH_LABEL_2>UFH</GRAPH_LABEL_2><DICH_DATA CI_END="2.747006276368489" CI_START="0.472175077426207" EFFECT_SIZE="1.1388888888888888" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.43885965169907926" LOG_CI_START="-0.3258969397941828" LOG_EFFECT_SIZE="0.05648135595244821" MODIFIED="2017-09-20 09:44:56 +0100" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.44922180744932355" STUDY_ID="STD-Breddin-2001" TOTAL_1="84" TOTAL_2="41" VAR="0.20180023228803715" WEIGHT="33.35046627978315"/><DICH_DATA CI_END="1.201069368172975" CI_START="0.23618288019102684" EFFECT_SIZE="0.532608695652174" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.07956809095390609" LOG_CI_START="-0.6267515855879893" LOG_EFFECT_SIZE="-0.27359174731704156" ORDER="221" O_E="0.0" SE="0.4148956743394965" STUDY_ID="STD-Hull-1992" TOTAL_1="46" TOTAL_2="49" VAR="0.17213842058562553" WEIGHT="39.0972092068596"/><DICH_DATA CI_END="1.4823184022480005" CI_START="0.02698475573084585" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.17094150019320706" LOG_CI_START="-1.5688815088652448" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2017-09-25 12:43:58 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="1.021980647783726" STUDY_ID="STD-Prandoni-1992" TOTAL_1="15" TOTAL_2="18" VAR="1.0444444444444445" WEIGHT="6.4437432531458825"/><DICH_DATA CI_END="2.5522323347679716" CI_START="0.15629140079649795" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.40692020653615596" LOG_CI_START="-0.8060649163465642" LOG_EFFECT_SIZE="-0.19957235490520417" ORDER="220" O_E="0.0" SE="0.7125134655545053" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TOTAL_1="76" TOTAL_2="80" VAR="0.5076754385964912" WEIGHT="13.256760777674353"/><DICH_DATA CI_END="3.507691973490815" CI_START="0.09308987639525779" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.5450214489794333" LOG_CI_START="-1.0310975463520222" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="227" O_E="0.0" SE="0.9258200997725515" STUDY_ID="STD-Simonneau-1993" TOTAL_1="7" TOTAL_2="2" VAR="0.8571428571428572" WEIGHT="7.851820482537019"/></DICH_OUTCOME><DICH_OUTCOME CHI2="3.704512805476149" CI_END="1.756040674787323" CI_START="0.2707063845274185" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6894718429020612" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="46.01179412732694" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.24453457115499377" LOG_CI_START="-0.5675015014059629" LOG_EFFECT_SIZE="-0.16148346512548453" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="0.15688286349310587" P_Q="1.0" P_Z="0.43566970258296045" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.31409425444431893" TOTALS="YES" TOTAL_1="256" TOTAL_2="166" WEIGHT="100.00000000000001" Z="0.7795263940591036"><NAME>Any recurrent venous thromboembolism (3 months)</NAME><GROUP_LABEL_1>LMWH</GROUP_LABEL_1><GROUP_LABEL_2>UFH</GROUP_LABEL_2><GRAPH_LABEL_1>LMWH</GRAPH_LABEL_1><GRAPH_LABEL_2>UFH</GRAPH_LABEL_2><DICH_DATA CI_END="0.8989654542002397" CI_START="0.08653464993406991" EFFECT_SIZE="0.2789115646258503" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.04625699718610019" LOG_CI_START="-1.062809958870781" LOG_EFFECT_SIZE="-0.5545334780284407" MODIFIED="2017-09-20 09:13:20 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.5971282417118972" STUDY_ID="STD-Breddin-2001" TOTAL_1="84" TOTAL_2="41" VAR="0.3565621370499419" WEIGHT="33.92546275388987"/><DICH_DATA CI_END="4.94647992774476" CI_START="0.3997871398219977" EFFECT_SIZE="1.40625" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.6942962510991907" LOG_CI_START="-0.3981711801883154" LOG_EFFECT_SIZE="0.1480625354554377" ORDER="231" O_E="0.0" SE="0.6417207769392819" STUDY_ID="STD-Merli-2001" TOTAL_1="96" TOTAL_2="45" VAR="0.41180555555555554" WEIGHT="31.34362086456623"/><DICH_DATA CI_END="2.755259004459527" CI_START="0.27927230333877007" EFFECT_SIZE="0.8771929824561403" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.4401624303821527" LOG_CI_START="-0.5539721330550978" LOG_EFFECT_SIZE="-0.05690485133647262" ORDER="230" O_E="0.0" SE="0.5839595636084955" STUDY_ID="STD-Prandoni-2004-_x0028_GALILEI_x0029_" TOTAL_1="76" TOTAL_2="80" VAR="0.3410087719298246" WEIGHT="34.730916381543906"/></DICH_OUTCOME></COMPARISON><COMPARISON ID="CMP-002" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="2"><NAME>Fondaparinux versus heparin (low molecular weight heparin (LMWH) + unfractionated heparin (UFH))</NAME><DICH_OUTCOME CHI2="0.0" CI_END="1.808170606549229" CI_START="0.8629291134258333" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2491289198606272" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.2572394051146326" LOG_CI_START="-0.06402487857497931" LOG_EFFECT_SIZE="0.09660726326982662" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.23849374456848194" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="239" WEIGHT="100.0" Z="1.1787600817573358"><NAME>Mortality (3 months)</NAME><GROUP_LABEL_1>Fondaparinux</GROUP_LABEL_1><GROUP_LABEL_2>Heparin</GROUP_LABEL_2><GRAPH_LABEL_1>Fondaparinux</GRAPH_LABEL_1><GRAPH_LABEL_2>Heparin</GRAPH_LABEL_2><DICH_DATA CI_END="1.808170606549229" CI_START="0.8629291134258333" EFFECT_SIZE="1.2491289198606272" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="41" LOG_CI_END="0.2572394051146326" LOG_CI_START="-0.06402487857497931" LOG_EFFECT_SIZE="0.09660726326982662" MODIFIED="2017-09-07 09:47:58 +0100" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.18871223052313008" STUDY_ID="STD-van-Doormaal-2009" TOTAL_1="238" TOTAL_2="239" VAR="0.03561230594901498" WEIGHT="100.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="1.5415790316534002" CI_START="0.5640358734296914" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9324729891956782" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.18796579447358044" LOG_CI_START="-0.24869327343313152" LOG_EFFECT_SIZE="-0.030363739479775546" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.7851775969620869" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="239" WEIGHT="100.0" Z="0.27257803714742124"><NAME>Recurrent venous thromboembolism (3 months)</NAME><GROUP_LABEL_1>Fondaparinux</GROUP_LABEL_1><GROUP_LABEL_2>Heparin</GROUP_LABEL_2><GRAPH_LABEL_1>Fondaparinux</GRAPH_LABEL_1><GRAPH_LABEL_2>Heparin</GRAPH_LABEL_2><DICH_DATA CI_END="1.5415790316534002" CI_START="0.5640358734296914" EFFECT_SIZE="0.9324729891956782" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="28" LOG_CI_END="0.18796579447358044" LOG_CI_START="-0.24869327343313152" LOG_EFFECT_SIZE="-0.030363739479775546" MODIFIED="2017-09-07 09:48:35 +0100" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.2564956979856489" STUDY_ID="STD-van-Doormaal-2009" TOTAL_1="238" TOTAL_2="239" VAR="0.06579004308514523" WEIGHT="100.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="1.6587135409402909" CI_START="0.4013444272078422" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8159138655462185" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.21977139004432997" LOG_CI_START="-0.3964827629592545" LOG_EFFECT_SIZE="-0.08835568645746229" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5741015467364723" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="239" WEIGHT="100.0" Z="0.5620212454290178"><NAME>Major bleeding (3 months)</NAME><GROUP_LABEL_1>Fondaparinux</GROUP_LABEL_1><GROUP_LABEL_2>Heparin</GROUP_LABEL_2><GRAPH_LABEL_1>Fondaparinux</GRAPH_LABEL_1><GRAPH_LABEL_2>Heparin</GRAPH_LABEL_2><DICH_DATA CI_END="1.6587135409402909" CI_START="0.4013444272078422" EFFECT_SIZE="0.8159138655462185" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.21977139004432997" LOG_CI_START="-0.3964827629592545" LOG_EFFECT_SIZE="-0.08835568645746229" MODIFIED="2017-09-07 09:48:41 +0100" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.3619907399815608" STUDY_ID="STD-van-Doormaal-2009" TOTAL_1="238" TOTAL_2="239" VAR="0.13103729583239795" WEIGHT="100.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="2.6564439541015483" CI_START="0.8843619000898741" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5327288810260946" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.42430065755755825" LOG_CI_START="-0.053369975882052625" LOG_EFFECT_SIZE="0.18546534083775285" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.12801114077092238" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="238" TOTAL_2="239" WEIGHT="100.0" Z="1.5219917783302335"><NAME>Minor bleeding (3 months)</NAME><GROUP_LABEL_1>Fondaparinux</GROUP_LABEL_1><GROUP_LABEL_2>Heparin</GROUP_LABEL_2><GRAPH_LABEL_1>Fondaparinux</GRAPH_LABEL_1><GRAPH_LABEL_2>Heparin</GRAPH_LABEL_2><DICH_DATA CI_END="2.6564439541015483" CI_START="0.8843619000898741" EFFECT_SIZE="1.5327288810260946" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" LOG_CI_END="0.42430065755755825" LOG_CI_START="-0.053369975882052625" LOG_EFFECT_SIZE="0.18546534083775285" MODIFIED="2017-09-07 09:53:16 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.2805860945901973" STUDY_ID="STD-van-Doormaal-2009" TOTAL_1="238" TOTAL_2="239" VAR="0.07872855647737913" WEIGHT="100.0"/></DICH_OUTCOME></COMPARISON><COMPARISON ID="CMP-003" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="3"><NAME>Dalteparin versus tinzaparin</NAME><DICH_OUTCOME CHI2="0.0" CI_END="1.7254834415594316" CI_START="0.42710534518499105" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8584656084656085" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.23691079598110013" LOG_CI_START="-0.3694649933827748" LOG_EFFECT_SIZE="-0.0662770987008373" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.6683238348797078" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="59" WEIGHT="100.0" Z="0.42844958104188585"><NAME>Mortality (3 months)</NAME><GROUP_LABEL_1>Dalteparin</GROUP_LABEL_1><GROUP_LABEL_2>Tinzaparin</GROUP_LABEL_2><GRAPH_LABEL_1>Dalteparin</GRAPH_LABEL_1><GRAPH_LABEL_2>Tinzaparin</GRAPH_LABEL_2><DICH_DATA CI_END="1.7254834415594316" CI_START="0.42710534518499105" EFFECT_SIZE="0.8584656084656085" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.23691079598110013" LOG_CI_START="-0.3694649933827748" LOG_EFFECT_SIZE="-0.0662770987008373" MODIFIED="2017-09-07 07:15:33 +0100" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.3561881402809068" STUDY_ID="STD-Wells-2005" TOTAL_1="54" TOTAL_2="59" VAR="0.12686999127677093" WEIGHT="100.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="2.159772327594963" CI_START="0.08843588247785546" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.437037037037037" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.3344079724099314" LOG_CI_START="-1.0533714861156553" LOG_EFFECT_SIZE="-0.359481756852862" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3099181835542948" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="59" WEIGHT="100.0" Z="1.0153937532399409"><NAME>Recurrent venous thromboembolism (3 months)</NAME><GROUP_LABEL_1>Dalteparin</GROUP_LABEL_1><GROUP_LABEL_2>Tinzaparin</GROUP_LABEL_2><GRAPH_LABEL_1>Dalteparin</GRAPH_LABEL_1><GRAPH_LABEL_2>Tinzaparin</GRAPH_LABEL_2><DICH_DATA CI_END="2.1597723275949634" CI_START="0.08843588247785546" EFFECT_SIZE="0.43703703703703706" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.33440797240993153" LOG_CI_START="-1.0533714861156553" LOG_EFFECT_SIZE="-0.35948175685286193" MODIFIED="2017-09-07 07:16:18 +0100" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.8151885235570412" STUDY_ID="STD-Wells-2005" TOTAL_1="54" TOTAL_2="59" VAR="0.6645323289391086" WEIGHT="100.0"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="23.420392509790652" CI_START="0.2038836151681342" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.185185185185185" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="1.369594169276384" LOG_CI_START="-0.6906176743100704" LOG_EFFECT_SIZE="0.33948824748315687" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.5183193998948572" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="59" WEIGHT="99.99999999999999" Z="0.6459381740892182"><NAME>Major bleeding (3 months)</NAME><GROUP_LABEL_1>Dalteparin</GROUP_LABEL_1><GROUP_LABEL_2>Tinzaparin</GROUP_LABEL_2><GRAPH_LABEL_1>Dalteparin</GRAPH_LABEL_1><GRAPH_LABEL_2>Tinzaparin</GRAPH_LABEL_2><DICH_DATA CI_END="23.42039250979066" CI_START="0.20388361516813425" EFFECT_SIZE="2.185185185185185" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.369594169276384" LOG_CI_START="-0.6906176743100703" LOG_EFFECT_SIZE="0.33948824748315687" MODIFIED="2017-09-07 07:16:34 +0100" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="1.2101786351357837" STUDY_ID="STD-Wells-2005" TOTAL_1="54" TOTAL_2="59" VAR="1.4645323289391086" WEIGHT="99.99999999999999"/></DICH_OUTCOME><DICH_OUTCOME CHI2="0.0" CI_END="2.209859034564156" CI_START="0.30386064768303195" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8194444444444444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.3443645712129422" LOG_CI_START="-0.5173255407911908" LOG_EFFECT_SIZE="-0.08648048478912428" METHOD="MH" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.6940168880168944" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="54" TOTAL_2="59" WEIGHT="100.0" Z="0.39340972628321075"><NAME>Minor bleeding (3 months)</NAME><GROUP_LABEL_1>Dalteparin</GROUP_LABEL_1><GROUP_LABEL_2>Tinzaparin</GROUP_LABEL_2><GRAPH_LABEL_1>Dalteparin</GRAPH_LABEL_1><GRAPH_LABEL_2>Tinzaparin</GRAPH_LABEL_2><DICH_DATA CI_END="2.209859034564156" CI_START="0.30386064768303195" EFFECT_SIZE="0.8194444444444444" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.3443645712129422" LOG_CI_START="-0.5173255407911908" LOG_EFFECT_SIZE="-0.08648048478912428" MODIFIED="2017-09-07 07:16:53 +0100" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.5061610372260742" STUDY_ID="STD-Wells-2005" TOTAL_1="54" TOTAL_2="59" VAR="0.25619899560577525" WEIGHT="100.0"/></DICH_OUTCOME></COMPARISON></ANALYSES_AND_DATA><FIGURES MODIFIED="2018-01-22 10:14:14 +0000" MODIFIED_BY="Gail Quinn"><FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER"><CAPTION><P>Study flow diagram.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2018-01-22 10:14:14 +0000" MODIFIED_BY="Gail Quinn" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT"><CAPTION><P>Risk of bias summary: review authors' judgments about each risk of bias item for each included study.</P></CAPTION><FILE>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</FILE></FIGURE><FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2018-01-22 10:14:14 +0000" MODIFIED_BY="Gail Quinn" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT"><CAPTION><P>Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies.</P></CAPTION><FILE>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</FILE></FIGURE></FIGURES><FEEDBACK MODIFIED="2018-01-17 12:31:49 +0000" MODIFIED_BY="Gail Quinn"/><APPENDICES MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><APPENDIX ID="APP-01" MODIFIED="2018-01-08 19:29:05 +0000" MODIFIED_BY="Anne Lawson" NO="1"><TITLE MODIFIED="2014-05-25 14:32:45 +0100" MODIFIED_BY="Anne Lawson">Full search strategies for the electronic databases - update 2010</TITLE><APPENDIX_BODY MODIFIED="2018-01-08 19:29:05 +0000" MODIFIED_BY="Anne Lawson"><TABLE COLS="2" ROWS="5"><TR><TH><P>Database</P></TH><TH><P>Strategy</P></TH></TR><TR><TD VALIGN="TOP"><P>MEDLINE</P></TD><TD><P>#1 Heparin/<BR/>#2 Heparin.tw<BR/>#3 Heparin, Low-Molecular-Weight/<BR/>#4 (LMWH OR low molecular weight heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran).tw<BR/>#5 1 OR 2 OR 3 OR 4<BR/>#6 Coumarins/<BR/>#7 Warfarin/<BR/>#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA).tw<BR/>#9 6 OR 7 OR 8<BR/>#10 (fondaparinux OR Arixtra).tw<BR/>#11 (ximelagatran OR Exanta).tw</P><P>#12 (Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban).tw.<BR/>#13 5 OR 9 OR 10 OR 11 OR 12<BR/>#14 Neoplasms/<BR/>#15 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor).tw<BR/>#16 14 OR 15<BR/>#17 clinical trial.pt. OR random:.tw. OR tu.xs.<BR/>#18 animals/ NOT human/<BR/>#19 17 NOT 18<BR/>#20 13 AND 16 AND 19<BR/></P></TD></TR><TR><TD VALIGN="TOP"><P>Embase</P></TD><TD><P>#1 Heparin/<BR/>#2 heparin.tw<BR/>#3 Low Molecular Weight Heparin/<BR/>#4 (LMWH OR low molecular weight heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran).tw<BR/>#5 1 OR 2 OR 3 OR 4<BR/>#6 Coumarin derivative/<BR/>#7 Warfarin/<BR/>#8 (warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA).tw<BR/>#9 6 OR 7 OR 8<BR/>#10 fondaparinux/<BR/>#11 (fondaparinux OR Arixtra).tw<BR/>#12 ximelagatran/<BR/>#13 (ximelagatran OR Exanta).tw</P><P>#14 (Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apixaban).tw.<BR/>#15 5 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14<BR/>#16 Neoplasm/<BR/>#17 (malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor).tw<BR/>#18 16 OR 17<BR/>#19 Random:.tw. OR clinical trial:.mp. OR exp health care quality<BR/>#20 animals/ NOT human/<BR/>#21 19 NOT 20<BR/>#22 15 AND 18 AND 21<BR/></P></TD></TR><TR><TD VALIGN="TOP"><P>ISI (International Scientific Information) the Web of Science</P></TD><TD><P>#1 heparin OR low molecular weight heparin OR LMWH OR low-molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran<BR/>#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA<BR/>#3 fondaparinux OR Arixtra<BR/>#4 ximelagatran OR Exanta</P><P>#5 Pradaxa OR Dabigatran OR rivaroxaban OR Xarelto OR apixaban<BR/>#6 1 OR 2 OR 3 OR 4 OR 5<BR/>#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor<BR/>#8 random$ OR placebo$ OR versus OR vs OR double blind OR double-blind OR compar$ OR controlled<BR/>#9 6 AND 7 AND 8<BR/></P></TD></TR><TR><TD VALIGN="TOP"><P>CENTRAL (the Cochrane Library, latest issue)</P></TD><TD><P>#1 heparin OR low molecular weight heparin OR LMWH OR low-molecular-weight-heparin OR nadroparin OR fraxiparin OR enoxaparin OR clexane OR lovenox OR dalteparin OR fragmin OR ardeparin OR normiflo OR tinzaparin OR logiparin OR innohep OR certoparin OR sandoparin OR reviparin OR clivarin OR danaproid OR orgaran<BR/>#2 Coumarins OR Warfarin OR coumadin OR acenocumarol OR phenprocumon OR 4-hydroxicoumarins OR oral anticoagulant OR vitamin K antagonist OR VKA<BR/>#3 fondaparinux OR Arixtra<BR/>#4 ximelagatran OR Exanta<BR/>#5 Pradaxa or Dabigatran or rivaroxaban or Xarelto or apixaban</P><P>#6 1 OR 2 OR 3 OR 4 OR 5<BR/>#7 malignan$ OR neoplasm$ OR cancer OR carcinoma$ OR adenocarcinoma OR tumour OR tumor<BR/>#8 6 AND 7<BR/></P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-02" MODIFIED="2018-01-08 19:29:33 +0000" MODIFIED_BY="Anne Lawson" NO="2"><TITLE MODIFIED="2014-05-25 14:32:34 +0100" MODIFIED_BY="Anne Lawson">Full search strategies for the electronic databases - update 2013</TITLE><APPENDIX_BODY MODIFIED="2018-01-08 19:29:33 +0000" MODIFIED_BY="Anne Lawson"><TABLE COLS="2" ROWS="4"><TR><TH><P>Database</P></TH><TH><P>Strategy</P></TH></TR><TR><TD VALIGN="TOP"><P>MEDLINE</P></TD><TD><P>#1 exp Heparin/</P><P>#2 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum).tw.</P><P>#3 exp Coumarins/</P><P>#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA).tw.</P><P>#5 (fondaparinux or arixtra).tw.</P><P>#6 (ximelagatran or exanta).tw.</P><P>#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban).tw.</P><P>#8 1 or 2 or 3 or 4 or 5 or 6 or 7</P><P>#9 exp Neoplasms/</P><P>#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).tw.</P><P>#11 9 or 10</P><P>#12 8 and 11</P><P>#13 randomized controlled trial.pt.</P><P>#14 controlled clinical trial.pt.</P><P>#15 randomized.ab.</P><P>#16 placebo.ab.</P><P>#17 drug therapy.fs.</P><P>#18 randomly.ab.</P><P>#19 trial.ab.</P><P>#20 groups.ab.</P><P>#21 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20</P><P>#22 12 and 21</P><P>#23 exp animals/ not humans.sh.</P><P>#24 22 not 23</P></TD></TR><TR><TD VALIGN="TOP"><P>Embase</P></TD><TD><P>#1 heparin/</P><P>#2 exp low molecular weight heparin/</P><P>#3 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum).tw.</P><P>#4 exp coumarin derivative/</P><P>#5 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA).tw.</P><P>#6 (fondaparinux or arixtra).tw.</P><P>#7 (ximelagatran or exanta).tw.</P><P>#8 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban).tw.</P><P>#9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8</P><P>#10 exp neoplasm/</P><P>#11 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*).tw.</P><P>#12 10 or 11</P><P>#13 9 and 12</P><P>#14 crossover procedure/</P><P>#15 double-blind procedure/</P><P>#16 randomized controlled trial/</P><P>#17 single-blind procedure/</P><P>#18 random*.mp.</P><P>#19 factorial*.mp.</P><P>#20 (crossover* or cross over* or cross-over*).mp.</P><P>#21 placebo*.mp.</P><P>#22 (double* adj blind*).mp.</P><P>#23 (singl* adj blind*).mp.</P><P>#24 assign*.mp.</P><P>#25 allocat*.mp.</P><P>#26 volunteer*.mp.</P><P>#27 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26</P><P>#28 13 and 27</P><P>#29 (exp animal/ or nonhuman/ or exp animal experiment/) not human/</P><P>#30 28 not 29</P></TD></TR><TR><TD VALIGN="TOP"><P>CENTRAL (the Cochrane Library, latest issue)</P></TD><TD><P>#1 MeSH descriptor: [Heparin] explode all trees</P><P>#2 (LMWH or heparin or nadroparin or fraxiparin or enoxaparin or clexane or lovenox or dalteparin or fragmin or ardeparin or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin or danaproid or orgaran or bemiparin or hibor, badyket, semuloparin, parnaparin, fluxum)</P><P>#3 MeSH descriptor: [Coumarins] explode all trees</P><P>#4 (warfarin or coumadin or acenocumarol or phenprocumon or 4-hydroxicoumarins or oral anticoagulant or vitamin K antagonist or VKA)</P><P>#5 (fondaparinux or arixtra)</P><P>#6 (ximelagatran or exanta)</P><P>#7 (pradaxa or dabigatran or rivaroxaban or xarelto or apixaban or eliquis or edoxaban or lixiana or betrixaban or edoxaban or otamixaban)</P><P>#8 #1 or #2 or #3 or #4 or #5 or #6 or #7</P><P>#9 MeSH descriptor: [Neoplasms] explode all trees</P><P>#10 (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor*)</P><P>#11 #9 or #10</P><P>#12 #8 and #10<BR/></P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-03" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="3"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">Full search strategies for the electronic databases - update 2018</TITLE><APPENDIX_BODY MODIFIED="2018-01-15 09:55:29 +0000" MODIFIED_BY="[Empty name]"><TABLE COLS="2" ROWS="4"><TR><TH><P>Database</P></TH><TH><P>Strategy</P></TH></TR><TR><TD VALIGN="TOP"><P>MEDLINE</P></TD><TD><P><B>RCT</B> <B>search strategy</B>:</P><P>1. exp Anticoagulants/</P><P>2. (LMWH* or heparin* or nadroparin* or frixiparin* or enoxaparin* or clexane or klexane or lovenox or dalteparin or fragmin or ardeparin* or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid or orgaran or antixarin or bemiparin* or hibor or zibor or ivor or badyket or semuloparin or parnaparin or tedelparin or fluxum or lohepa or lowhepa or parvoparin or seleparin* or tedelgliparin or lomoparan or orgaran or sulodexide or zivor or embolex or xaparin or clivarine or fondaparinux or Arixtra or UFH or Hepalean or Calcilean or Calciparine or Liquaemin or Liquemin or Multiparin or Novoheparin or Eparina or Hep-lock or Heparinate or Heparinic acid or Panheprin or Hepalean or Heparin Leo or Heparin Lock).mp.</P><P>3. (FR-860 or FR 860 or FR860 or PK-10,169 or PK 10,169 or PK10,169 or PK-10169 or PK 10169 or PK10169 or EMT-967 or EMT 967 or EMT967 or EMT-966 or EMT 966 or EMT966 or CY 216 or CY-216 or CY216 or LMF CY-216 or LMF CY 216 or LMF CY216).mp.</P><P>4. exp Coumarins/</P><P>5. (4-Hydroxycoumarin* or warfarin* or acenocoumarol or nicoumalone or sinthrome or Sintrom or phenindione or dicoumarol or coumadin or phenprocoumon or phepromaron or ethyl-biscoumacetate or phenindione or Diphenadione or Tioclomarol or Racumi or Marcoumar or Marcumar or Falithrom or Jantoven or vitamin K antagonist* or VKA or fluindione or difenacoum or coumatetralyl).mp.</P><P>6. (Dermatan Sulfate or (Chondroitin Sulfate adj B) or Dermatan Sulfphate or DS 435 or MF-701 or OP-370 or b-Heparin or Mistral or Venorix).mp.</P><P>7. (thrombin adj inhibitor*).mp.</P><P>8. (factor Xa inhibitor* or antithrombin* or anticoagul*).mp.</P><P>9. (rivaroxaban or Xarelto or apixaban or Eliquis or dabigatran etexilate or Edoxaban or Savaysa or Betrixaban or ximelagatran or pradaxa or lixiana or exanta or Darexaban or Otamixaban* or Razaxaban or Bivalirudin or Desirudin or Lepirudin or Melagatran or YM 150 or Iprivask or argatrovan or pradax or BIBR-953 or BIBR-953ZW or BAY 59-7939 or BMS-562247 or DU-176 or DU-176b).mp.</P><P>10. (TSOAC* or NOAC* or DOAC*).ti,ab,kw.</P><P>11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10</P><P>12. exp Neoplasms/</P><P>13. (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor* or glioma* or myeloma* or lymphoma* or leukemia* or leukaemia* or epithelioma* or adenoma*).tw.</P><P>14. 12 or 13</P><P>15. 11 and 14</P><P>16. randomized controlled trial.pt.</P><P>17. controlled clinical trial.pt.</P><P>18. randomized.ab.</P><P>19. placebo.ab.</P><P>20. clinical trials as topic.sh.</P><P>21. randomly.ab.</P><P>22. trial.ti.</P><P>23. 16 or 17 or 18 or 19 or 20 or 21 or 22</P><P>24. (animals not (humans and animals)).sh.</P><P>25. 23 not 24</P><P>26. 15 and 25</P><P/><P><B>Systematic Review search strategy:</B></P><P>1. exp Anticoagulants/</P><P>2. (LMWH* or heparin* or nadroparin* or frixiparin* or enoxaparin* or clexane or klexane or lovenox or dalteparin or fragmin or ardeparin* or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid or orgaran or antixarin or bemiparin* or hibor or zibor or ivor or badyket or semuloparin or parnaparin or tedelparin or fluxum or lohepa or lowhepa or parvoparin or seleparin* or tedelgliparin or lomoparan or orgaran or sulodexide or zivor or embolex or xaparin or clivarine or fondaparinux or Arixtra or UFH or Hepalean or Calcilean or Calciparine or Liquaemin or Liquemin or Multiparin or Novoheparin or Eparina or Hep-lock or Heparinate or Heparinic acid or Panheprin or Hepalean or Heparin Leo or Heparin Lock).mp.</P><P>3. (FR-860 or FR 860 or FR860 or PK-10,169 or PK 10,169 or PK10,169 or PK-10169 or PK 10169 or PK10169 or EMT-967 or EMT 967 or EMT967 or EMT-966 or EMT 966 or EMT966 or CY 216 or CY-216 or CY216 or LMF CY-216 or LMF CY 216 or LMF CY216).mp.</P><P>4. exp Coumarins/</P><P>5. (4-Hydroxycoumarin* or warfarin* or acenocoumarol or nicoumalone or sinthrome or Sintrom or phenindione or dicoumarol or coumadin or phenprocoumon or phepromaron or ethyl-biscoumacetate or phenindione or Diphenadione or Tioclomarol or Racumi or Marcoumar or Marcumar or Falithrom or Jantoven or vitamin K antagonist* or VKA or fluindione or difenacoum or coumatetralyl).mp.</P><P>6. (Dermatan Sulfate or (Chondroitin Sulfate adj B) or Dermatan Sulfphate or DS 435 or MF-701 or OP-370 or b-Heparin or Mistral or Venorix).mp.</P><P>7. (thrombin adj inhibitor*).mp.</P><P>8. (factor Xa inhibitor* or antithrombin* or anticoagul*).mp.</P><P>9. (rivaroxaban or Xarelto or apixaban or Eliquis or dabigatran etexilate or Edoxaban or Savaysa or Betrixaban or ximelagatran or pradaxa or lixiana or exanta or Darexaban or Otamixaban* or Razaxaban or Bivalirudin or Desirudin or Lepirudin or Melagatran or YM 150 or Iprivask or argatrovan or pradax or BIBR-953 or BIBR-953ZW or BAY 59-7939 or BMS-562247 or DU-176 or DU-176b).mp.</P><P>10. (TSOAC* or NOAC* or DOAC*).ti,ab,kw.</P><P>11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10</P><P>12. exp Neoplasms/</P><P>13. (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor* or glioma* or myeloma* or lymphoma* or leukemia* or leukaemia* or epithelioma* or adenoma*).tw.</P><P>14. 12 or 13</P><P>15. 11 and 14</P><P>16. (review or review,tutorial or review, academic).pt.</P><P>17. (medline or medlars or embase or pubmed or cochrane).tw,sh.</P><P>18. (scisearch or psychinfo or psycinfo).tw,sh.</P><P>19. (psychlit or psyclit).tw,sh.</P><P>20. cinahl.tw,sh.</P><P>21. ((hand adj2 search*) or (manual* adj2 search*)).tw,sh.</P><P>22. (electronic database* or bibliographic database* or computeri?ed database* or online database*).tw,sh.</P><P>23. (pooling or pooled or mantel haenszel).tw,sh.</P><P>24. (peto or dersimonian or der simonian or fixed effect).tw,sh.</P><P>25. (retraction of publication or retracted publication).pt.</P><P>26. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25</P><P>27. 16 and 26</P><P>28. meta-analysis.pt.</P><P>29. meta-analysis.sh.</P><P>30. (meta-analys* or meta analys* or metaanalys*).tw,sh.</P><P>31. (systematic* adj5 review*).tw,sh.</P><P>32. (systematic* adj5 overview*).tw,sh.</P><P>33. (quantitativ* adj5 review*).tw,sh.</P><P>34. (quantitativ* adj5 overview*).tw,sh.</P><P>35. (methodologic* adj5 review*).tw,sh.</P><P>36. (methodologic* adj5 overview*).tw,sh.</P><P>37. (integrative research review* or research integration).tw.</P><P>38. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37</P><P>39. 27 or 38</P><P>41. 15 and 39</P></TD></TR><TR><TD VALIGN="TOP"><P>Embase</P></TD><TD><P><B>RCT search strategy:</B></P><P>1. exp anticoagulant agent/</P><P>2. (LMWH* or heparin* or nadroparin* or frixiparin* or enoxaparin* or clexane or klexane or lovenox or dalteparin or fragmin or ardeparin* or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid or orgaran or antixarin or bemiparin* or hibor or zibor or ivor or badyket or semuloparin or parnaparin or tedelparin or fluxum or lohepa or lowhepa or parvoparin or seleparin* or tedelgliparin or lomoparan or orgaran or sulodexide or zivor or embolex or xaparin or clivarine or fondaparinux or Arixtra or UFH or Hepalean or Calcilean or Calciparine or Liquaemin or Liquemin or Multiparin or Novoheparin or Eparina or Hep-lock or Heparinate or Heparinic acid or Panheprin or Hepalean or Heparin Leo or Heparin Lock).mp.</P><P>3. (FR-860 or FR 860 or FR860 or PK-10,169 or PK 10,169 or PK10,169 or PK-10169 or PK 10169 or PK10169 or EMT-967 or EMT 967 or EMT967 or EMT-966 or EMT 966 or EMT966 or CY 216 or CY-216 or CY216 or LMF CY-216 or LMF CY 216 or LMF CY216).mp.</P><P>4. exp coumarin derivative/</P><P>5. (4-Hydroxycoumarin* or warfarin* or acenocoumarol or nicoumalone or sinthrome or Sintrom or phenindione or dicoumarol or coumadin or phenprocoumon or phepromaron or ethyl-biscoumacetate or phenindione or Diphenadione or Tioclomarol or Racumi or Marcoumar or Marcumar or Falithrom or Jantoven or vitamin K antagonist* or VKA or fluindione or difenacoum or coumatetralyl).mp.</P><P>6. (Dermatan Sulfate or (Chondroitin Sulfate adj B) or Dermatan Sulfphate or DS 435 or MF-701 or OP-370 or b-Heparin or Mistral or Venorix).mp.</P><P>7. (thrombin adj inhibitor*).mp.</P><P>8. (factor Xa inhibitor* or antithrombin* or anticoagul*).mp.</P><P>9. (rivaroxaban or Xarelto or apixaban or Eliquis or dabigatran etexilate or Edoxaban or Savaysa or Betrixaban or ximelagatran or pradaxa or lixiana or exanta or Darexaban or Otamixaban* or Razaxaban or Bivalirudin or Desirudin or Lepirudin or Melagatran or YM 150 or Iprivask or argatrovan or pradax or BIBR-953 or BIBR-953ZW or BAY 59-7939 or BMS-562247 or DU-176 or DU-176b).mp.</P><P>10. (TSOAC* or NOAC* or DOAC*).ti,ab,kw.</P><P>11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10</P><P>12. exp neoplasm/</P><P>13. (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor* or glioma* or myeloma* or lymphoma* or leukemia* or leukaemia* or epithelioma* or adenoma*).tw.</P><P>14. 12 or 13</P><P>15. 11 and 14</P><P>16. crossover procedure/</P><P>17. double-blind procedure/</P><P>18. randomized controlled trial/</P><P>19. single-blind procedure/</P><P>20. random*.mp.</P><P>21. factorial*.mp.</P><P>22. (crossover* or cross over* or cross-over*).mp.</P><P>23. placebo*.mp.</P><P>24. (double* adj blind*).mp.</P><P>25. (singl* adj blind*).mp.</P><P>26. assign*.mp.</P><P>27. allocat*.mp.</P><P>28. volunteer*.mp.</P><P>29. 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28</P><P>30. 15 and 29</P><P/><P><B>Systematic Review search strategy:</B></P><P>1. exp anticoagulant agent/</P><P>2. (LMWH* or heparin* or nadroparin* or frixiparin* or enoxaparin* or clexane or klexane or lovenox or dalteparin or fragmin or ardeparin* or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid or orgaran or antixarin or bemiparin* or hibor or zibor or ivor or badyket or semuloparin or parnaparin or tedelparin or fluxum or lohepa or lowhepa or parvoparin or seleparin* or tedelgliparin or lomoparan or orgaran or sulodexide or zivor or embolex or xaparin or clivarine or fondaparinux or Arixtra or UFH or Hepalean or Calcilean or Calciparine or Liquaemin or Liquemin or Multiparin or Novoheparin or Eparina or Hep-lock or Heparinate or Heparinic acid or Panheprin or Hepalean or Heparin Leo or Heparin Lock).mp.</P><P>3. (FR-860 or FR 860 or FR860 or PK-10,169 or PK 10,169 or PK10,169 or PK-10169 or PK 10169 or PK10169 or EMT-967 or EMT 967 or EMT967 or EMT-966 or EMT 966 or EMT966 or CY 216 or CY-216 or CY216 or LMF CY-216 or LMF CY 216 or LMF CY216).mp.</P><P>4. exp coumarin derivative/</P><P>5. (4-Hydroxycoumarin* or warfarin* or acenocoumarol or nicoumalone or sinthrome or Sintrom or phenindione or dicoumarol or coumadin or phenprocoumon or phepromaron or ethyl-biscoumacetate or phenindione or Diphenadione or Tioclomarol or Racumi or Marcoumar or Marcumar or Falithrom or Jantoven or vitamin K antagonist* or VKA or fluindione or difenacoum or coumatetralyl).mp.</P><P>6. (Dermatan Sulfate or (Chondroitin Sulfate adj B) or Dermatan Sulfphate or DS 435 or MF-701 or OP-370 or b-Heparin or Mistral or Venorix).mp.</P><P>7. (thrombin adj inhibitor*).mp.</P><P>8. (factor Xa inhibitor* or antithrombin* or anticoagul*).mp.</P><P>9. (rivaroxaban or Xarelto or apixaban or Eliquis or dabigatran etexilate or Edoxaban or Savaysa or Betrixaban or ximelagatran or pradaxa or lixiana or exanta or Darexaban or Otamixaban* or Razaxaban or Bivalirudin or Desirudin or Lepirudin or Melagatran or YM 150 or Iprivask or argatrovan or pradax or BIBR-953 or BIBR-953ZW or BAY 59-7939 or BMS-562247 or DU-176 or DU-176b).mp.</P><P>10. (TSOAC* or NOAC* or DOAC*).ti,ab,kw.</P><P>11. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10</P><P>12. exp neoplasm/</P><P>13. (malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor* or glioma* or myeloma* or lymphoma* or leukemia* or leukaemia* or epithelioma* or adenoma*).tw.</P><P>14. 12 or 13</P><P>15. 11 and 14</P><P>16. exp review/</P><P>17. (literature adj3 review*).ti,ab.</P><P>18. exp meta analysis/</P><P>19. exp "Systematic Review"/</P><P>20. 16 or 17 or 18 or 19</P><P>21. (medline or medlars or embase or pubmed or cinahl or amed or psychlit or psyclit or psychinfo or psycinfo or scisearch or cochrane).ti,ab.</P><P>22. RETRACTED ARTICLE/</P><P>23. 21 or 22</P><P>24. 20 and 23</P><P>25. (systematic* adj2 (review* or overview)).ti,ab.</P><P>26. (meta?anal* or meta anal* or meta-anal* or metaanal* or metanal*).ti,ab.</P><P>27. 24 or 25 or 26</P><P>28. 15 and 27</P></TD></TR><TR><TD VALIGN="TOP"><P>CENTRAL (the Cochrane Library, latest issue)</P></TD><TD><P>#1 MeSH descriptor: [Anticoagulants] explode all trees</P><P>#2 (LMWH* or heparin* or nadroparin* or frixiparin* or enoxaparin* or clexane or klexane or lovenox or dalteparin or fragmin or ardeparin* or normiflo or tinzaparin or logiparin or innohep or certoparin or sandoparin or reviparin or clivarin* or danaproid or danaparoid or orgaran or antixarin or bemiparin* or hibor or zibor or ivor or badyket or semuloparin or parnaparin or tedelparin or fluxum or lohepa or lowhepa or parvoparin or seleparin* or tedelgliparin or lomoparan or orgaran or sulodexide or zivor or embolex or xaparin or clivarine or fondaparinux or Arixtra or UFH or Hepalean or Calcilean or Calciparine or Liquaemin or Liquemin or Multiparin or Novoheparin or Eparina or Hep-lock or Heparinate or Heparinic acid or Panheprin or Hepalean or Heparin Leo or Heparin Lock)</P><P>#3 FR-860 or FR 860 or FR860 or PK-10,169 or PK 10,169 or PK10,169 or PK-10169 or PK 10169 or PK10169 or EMT-967 or EMT 967 or EMT967 or EMT-966 or EMT 966 or EMT966 or CY 216 or CY-216 or CY216 or LMF CY-216 or LMF CY 216 or LMF CY216</P><P>#4 MeSH descriptor: [Coumarins] explode all trees</P><P>#5 (4-Hydroxycoumarin* or warfarin* or acenocoumarol or nicoumalone or sinthrome or Sintrom or phenindione or dicoumarol or coumadin or phenprocoumon or phepromaron or ethyl-biscoumacetate or phenindione or Diphenadione or Tioclomarol or Racumi or Marcoumar or Marcumar or Falithrom or Jantoven or vitamin K antagonist* or VKA or fluindione or difenacoum or coumatetralyl)</P><P>#6 (Dermatan Sulfate or (Chondroitin Sulfate adj B) or Dermatan Sulfphate or DS 435 or MF-701 or OP-370 or b-Heparin or Mistral or Venorix)</P><P>#7 thrombin near inhibitor*</P><P>#8 factor Xa inhibitor* or antithrombin* or anticoagul*</P><P>#9 rivaroxaban or Xarelto or apixaban or Eliquis or dabigatran etexilate or Edoxaban or Savaysa or Betrixaban or ximelagatran or pradaxa or lixiana or exanta or Darexaban or Otamixaban* or Razaxaban or Bivalirudin or Desirudin or Lepirudin or Melagatran or YM 150 or Iprivask or argatrovan or pradax or BIBR-953 or BIBR-953ZW or BAY 59-7939 or BMS-562247 or DU-176 or DU-176b</P><P>#10 TSOAC* or NOAC* or DOAC*</P><P>#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10</P><P>#12 MeSH descriptor: [Neoplasms] explode all trees</P><P>#13 malignan* or neoplasm* or cancer* or carcinoma* or adenocarcinoma* or tumour* or tumor* or glioma* or myeloma* or lymphoma* or leukemia* or leukaemia* or epithelioma* or adenoma*</P><P>#14 #13 or #14</P><P>#15 #11 and #14</P><P><BR/></P></TD></TR></TABLE></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-04" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="4"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">GRADE Evidence Profile low molecular weight heparin versus unfractionated heparin</TITLE><APPENDIX_BODY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P><B>Question</B>: LMWH initial treatment compared to UFH initial treatment in people with cancer with VTE</P><TABLE COLS="13" ROWS="8"><TR><TH COLSPAN="7" VALIGN="TOP"><P><B>Certainty assessment</B></P></TH><TH COLSPAN="2" VALIGN="TOP"><P><B>No of participants</B></P></TH><TH COLSPAN="2" VALIGN="TOP"><P><B>Effect</B></P></TH><TH ROWSPAN="2" VALIGN="TOP"><P><B>Certainty</B></P></TH><TH ROWSPAN="2" VALIGN="TOP"><P><B>Importance</B></P></TH></TR><TR><TH VALIGN="TOP"><P><B>No of studies</B></P></TH><TH VALIGN="TOP"><P><B>Study design</B></P></TH><TH VALIGN="TOP"><P><B>Risk of bias</B></P></TH><TH VALIGN="TOP"><P><B>Inconsistency</B></P></TH><TH VALIGN="TOP"><P><B>Indirectness</B></P></TH><TH VALIGN="TOP"><P><B>Imprecision</B></P></TH><TH VALIGN="TOP"><P><B>Other considerations</B></P></TH><TH VALIGN="TOP"><P><B>LMWH initial treatment</B></P></TH><TH VALIGN="TOP"><P><B>UFH initial treatment</B></P></TH><TH VALIGN="TOP"><P><B>Relative</B><BR/><B>(95% CI)</B></P></TH><TH VALIGN="TOP"><P><B>Absolute</B><BR/><B>(95% CI)</B></P></TH></TR><TR><TD COLSPAN="13"><P><B>Mortality</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>5</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Serious<SUP>a</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>27/228 (11.8%)</P></TD><TD VALIGN="TOP"><P>32/190 (16.8%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.66</B><BR/>(0.40 to 1.10)</P></TD><TD VALIGN="TOP"><P><B>57 fewer per 1000</B><BR/>(from 17 more to 101 fewer)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Recurrent venous thromboembolism</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>3</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Serious<SUP>b</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>18/256 (7.0%)</P></TD><TD VALIGN="TOP"><P>16/166 (9.6%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.69</B><BR/>(0.27 to 1.76)</P></TD><TD VALIGN="TOP"><P><B>30 fewer per 1000</B><BR/>(from 70 fewer to 73 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Quality of life</B> - not reported</P></TD></TR><TR><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR></TABLE><P><B>CI:</B> confidence interval; <B>LMWH</B><B>: </B>low molecular weight heparin; <B>RR:</B> risk ratio; <B>UFH</B><B>: </B>unfractionated heparin.</P><SUBSECTION><HEADING LEVEL="4">Explanations</HEADING><P><SUP>a</SUP>95% CI was consistent with the possibility for important benefit (101 per 1000 absolute reduction) and possibility of important harm (17 per 1000 absolute increase), including 59 events in total.</P><P><SUP>b</SUP>95% CI was consistent with the possibility for important benefit (70 per 1000 absolute reduction) and possibility of important harm (73 per 1000 absolute increase), including only 34 events in total.</P></SUBSECTION></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-05" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="5"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">GRADE Evidence Profile fondaparinux versus heparin</TITLE><APPENDIX_BODY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P><B>Question</B>: Fondaparinux initial treatment compared to heparin initial treatment in people with cancer with venous thromboembolism (Q15b-Initial)</P><TABLE COLS="13" ROWS="12"><TR><TH COLSPAN="7" VALIGN="TOP"><P><B>Certainty assessment</B></P></TH><TH COLSPAN="2" VALIGN="TOP"><P><B>No of participants</B></P></TH><TH COLSPAN="2" VALIGN="TOP"><P><B>Effect</B></P></TH><TH ROWSPAN="2" VALIGN="TOP"><P><B>Certainty</B></P></TH><TH ROWSPAN="2" VALIGN="TOP"><P><B>Importance</B></P></TH></TR><TR><TH VALIGN="TOP"><P><B>No of studies</B></P></TH><TH VALIGN="TOP"><P><B>Study design</B></P></TH><TH VALIGN="TOP"><P><B>Risk of bias</B></P></TH><TH VALIGN="TOP"><P><B>Inconsistency</B></P></TH><TH VALIGN="TOP"><P><B>Indirectness</B></P></TH><TH VALIGN="TOP"><P><B>Imprecision</B></P></TH><TH VALIGN="TOP"><P><B>Other considerations</B></P></TH><TH VALIGN="TOP"><P><B>Fondaparinux initial treatment </B></P></TH><TH VALIGN="TOP"><P><B>Heparin initial treatment</B></P></TH><TH VALIGN="TOP"><P><B>Relative</B><BR/><B>(95% CI)</B></P></TH><TH VALIGN="TOP"><P><B>Absolute</B><BR/><B>(95% CI)</B></P></TH></TR><TR><TD COLSPAN="13"><P><B>Mortality</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Serious<SUP>a</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>51/238 (21.4%)</P></TD><TD VALIGN="TOP"><P>41/239 (17.2%)</P></TD><TD VALIGN="TOP"><P><B>RR 1.25</B><BR/>(0.86 to 1.81)</P></TD><TD VALIGN="TOP"><P><B>43 more per 1000</B><BR/>(from 24 fewer to 139 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Recurrent venous thromboembolism</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Serious<SUP>b</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>26/238 (10.9%)</P></TD><TD VALIGN="TOP"><P>28/239 (11.7%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.93</B><BR/>(0.56 to 1.54)</P></TD><TD VALIGN="TOP"><P><B>8 fewer per 1000</B><BR/>(from 52 fewer to 63 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Major bleeding</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Serious<SUP>c</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>13/238 (5.5%)</P></TD><TD VALIGN="TOP"><P>16/239 (6.7%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.82</B><BR/>(0.40 to 1.66)</P></TD><TD VALIGN="TOP"><P><B>12 fewer per 1000</B><BR/>(from 40 fewer to 44 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Minor bleeding</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Serious<SUP>d</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>29/238 (12.2%)</P></TD><TD VALIGN="TOP"><P>19/239 (7.9%)</P></TD><TD VALIGN="TOP"><P><B>RR 1.53</B><BR/>(0.88 to 2.66)</P></TD><TD VALIGN="TOP"><P><B>42 more per 1000</B><BR/>(from 10 fewer to 132 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8853;&#8861;<BR/>Moderate</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Quality of life</B> - not reported</P></TD></TR><TR><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>-</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR></TABLE><P><B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P><SUBSECTION><HEADING LEVEL="4">Explanations</HEADING><P><SUP>a</SUP>95% CI was consistent with the possibility for important benefit (24 per 1000 absolute reduction) and possibility of important harm (139 per 1000 absolute increase), including only 92 events in total.</P><P><SUP>b</SUP>95% CI was consistent with the possibility for important benefit (52 per 1000 absolute reduction) and possibility of important harm (63 per 1000 absolute increase), including only 54 events in total.</P><P><SUP>c</SUP>95% CI was consistent with the possibility for important benefit (40 per 1000 absolute reduction) and possibility of important harm (44 per 1000 absolute increase), including only 29 events in total.</P><P><SUP>d</SUP>95% CI was consistent with the possibility for important benefit (10 per 1000 absolute reduction) and possibility of important harm (132 per 1000 absolute increase), including only 48 events in total.</P></SUBSECTION></APPENDIX_BODY></APPENDIX><APPENDIX ID="APP-06" MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn" NO="6"><TITLE MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn">GRADE Evidence profile dalteparin versus tinzaparin</TITLE><APPENDIX_BODY MODIFIED="2018-01-17 12:17:48 +0000" MODIFIED_BY="Gail Quinn"><P><B>Question</B>: Dalteparin initial treatment compared to tinzaparin initial treatment in people with cancer with venous thromboembolism</P><TABLE COLS="13" ROWS="10"><TR><TH COLSPAN="7" VALIGN="TOP"><P><B>Quality assessment</B></P></TH><TH COLSPAN="2" VALIGN="TOP"><P><B>No</B><B> of participants</B></P></TH><TH COLSPAN="2" VALIGN="TOP"><P><B>Effect</B></P></TH><TH ROWSPAN="2" VALIGN="TOP"><P><B>Quality</B></P></TH><TH ROWSPAN="2" VALIGN="TOP"><P><B>Importance</B></P></TH></TR><TR><TH VALIGN="TOP"><P><B>No of studies</B></P></TH><TH VALIGN="TOP"><P><B>Study design</B></P></TH><TH VALIGN="TOP"><P><B>Risk of bias</B></P></TH><TH VALIGN="TOP"><P><B>Inconsistency</B></P></TH><TH VALIGN="TOP"><P><B>Indirectness</B></P></TH><TH VALIGN="TOP"><P><B>Imprecision</B></P></TH><TH VALIGN="TOP"><P><B>Other considerations</B></P></TH><TH VALIGN="TOP"><P><B>Dalteparin</B></P></TH><TH VALIGN="TOP"><P><B>Tinzaparin</B></P></TH><TH VALIGN="TOP"><P><B>Relative</B><BR/><B>(95% CI)</B></P></TH><TH VALIGN="TOP"><P><B>Absolute</B><BR/><B>(95% CI)</B></P></TH></TR><TR><TD COLSPAN="13"><P><B>Mortality</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Very serious<SUP>a</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>11/54 (20.4%)</P></TD><TD VALIGN="TOP"><P>14/59 (23.7%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.86</B><BR/>(0.43 to 1.73)</P></TD><TD VALIGN="TOP"><P><B>33 fewer per 1000</B><BR/>(from 135 fewer to 173 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Recurrent venous thromboembolism</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Very serious<SUP>b</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>2/54 (3.7%)</P></TD><TD VALIGN="TOP"><P>5/59 (8.5%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.44</B><BR/>(0.09 to 2.16)</P></TD><TD VALIGN="TOP"><P><B>47 fewer per 1000</B><BR/>(from 77 fewer to 98 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Major bleeding</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Very serious<SUP>c</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>2/54 (3.7%)</P></TD><TD VALIGN="TOP"><P>1/59 (1.7%)</P></TD><TD VALIGN="TOP"><P><B>RR 2.19</B><BR/>(0.20 to 23.42)</P></TD><TD VALIGN="TOP"><P><B>20 more per 1000</B><BR/>(from 14 fewer to 380 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR><TR><TD COLSPAN="13"><P><B>Minor bleeding</B> (follow-up: 3 months)</P></TD></TR><TR><TD VALIGN="TOP"><P>1</P></TD><TD VALIGN="TOP"><P>Randomised trials</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Not serious</P></TD><TD VALIGN="TOP"><P>Very serious<SUP>d</SUP></P></TD><TD VALIGN="TOP"><P>None</P></TD><TD VALIGN="TOP"><P>6/54 (11.1%)</P></TD><TD VALIGN="TOP"><P>8/59 (13.6%)</P></TD><TD VALIGN="TOP"><P><B>RR 0.82</B><BR/>(0.30 to 2.21)</P></TD><TD VALIGN="TOP"><P><B>24 fewer per 1000</B><BR/>(from 95 fewer to 164 more)</P></TD><TD VALIGN="TOP"><P>&#8853;&#8853;&#8861;&#8861;<BR/>LOW</P></TD><TD VALIGN="TOP"><P>Critical</P></TD></TR></TABLE><P><B>CI:</B> confidence interval; <B>RR:</B> risk ratio.</P><SUBSECTION><HEADING LEVEL="4">Explanations</HEADING><P><SUP>a</SUP>95% CI is consistent with the possibility for important benefit (135 per 1000 absolute reduction) and possibility of important harm (173 per 1000 absolute increase), including 25 events among included participants.</P><P><SUP>b</SUP>95% CI is consistent with the possibility for important benefit (77 per 1000 absolute reduction) and possibility of important harm (98 per 1000 absolute increase), including 7 events among included participants.</P><P><SUP>c</SUP>95% CI is consistent with the possibility for important benefit (14 per 1000 absolute reduction) and possibility of important harm (380 per 1000 absolute increase), including 3 events among included participants.</P><P><SUP>d</SUP>95% CI is consistent with the possibility for important benefit (95 per 1000 absolute reduction) and possibility of important harm (164 per 1000 absolute increase), including 14 events among included participants</P></SUBSECTION></APPENDIX_BODY></APPENDIX></APPENDICES><EXTENSIONS><EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART"><ALIAS ALIAS_ID="1"><FLOWCHARTBOX TEXT="&lt;p&gt;8 RCTs included in quantitative synthesis (meta-analysis)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="125"><FLOWCHARTBOX TEXT="&lt;p&gt;16 reports of 15 RCTs included in qualitative synthesis&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;150 full-text articles assessed for eligibility&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;7387 records screened&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"><FLOWCHARTBOX TEXT="&lt;p&gt;7387 records after duplicates removed&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;"><FLOWCHARTBOX TEXT="&lt;p&gt;15440 records identified through database searching&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/><FLOWCHARTBOX TEXT="&lt;p&gt;81 additional records identified through other sources&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;7237 records excluded&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/></FLOWCHARTBOX><OUT TEXT="&lt;p&gt;134 full-text articles of 88 RCTs excluded, with reasons:&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;not population of interest: patients without VTE (n = 74);&lt;/li&gt;&lt;li&gt;not intervention of interest: Secondary treatment (n = 17);&lt;/li&gt;&lt;li&gt;no outcome data for cancer subgroups (n = 11);&lt;/li&gt;&lt;li&gt;reviews (n = 11);&lt;/li&gt;&lt;li&gt;cohort studies (n = 3);&lt;/li&gt;&lt;li&gt;letter to the editor or editorials (n = 4);&lt;/li&gt;&lt;li&gt;case report or series (n = 4);&lt;/li&gt;&lt;li&gt;no relevant outcome (n = 3);&lt;/li&gt;&lt;li&gt;retrospective study (n = 2);&lt;/li&gt;&lt;li&gt;not randomized (n = 1);&lt;/li&gt;&lt;li&gt;different long-term management (n = 1);&lt;/li&gt;&lt;li&gt;survey (n = 1);&lt;/li&gt;&lt;li&gt;no patient with cancer included (n = 3).&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="236"/></FLOWCHARTBOX></FLOWCHARTBOX></FLOWCHARTBOX></ALIAS></EXTENSION></EXTENSIONS></COCHRANE_REVIEW>